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General introduction
1GENERAL INTRODUCTION
The human body consists of a collection of tissues and organs, each with its own unique 
composition of different cell types and extracellular matrices. To maintain integrity of all 
of these tissues and organ systems it is vital that potential threats from both the outside, 
in the form of foreign substances and infectious micro-organisms and from the inside, like 
(pre-)malignant cells, are recognized and neutralized. This work is done by a specialized 
and highly diverse organ system called the immune system.
The immune system consists of a cellular compartment of leucocytes circulating in the 
peripheral blood and a set of solid tissues called the primary (bone marrow and thymus) 
and secondary (spleen, lymph nodes and mucosal associated lymphoid tissue) lymphoid 
organs, that facilitate the generation, differentiation and maturation of the immune cells 
(Figure 1a). The large number of different cell types and tissues, each with its own function, 
makes the immune system a highly dynamic system that requires strict regulation. The cells 
of the immune system arise from hematopoietic stem cells in the bone marrow and are 
divided into the myeloid lineage and the lymphoid lineage. Precursor cells of the myeloid 
lineage can develop into erythrocytes, monocytes, granulocytes and thrombocytes.1 The 
common lymphoid progenitors give rise to B lymphocytes (B cells), T lymphocytes (T cells), 
natural killer cells (NK cells) and dendritic cells.2 Erythrocytes and thrombocytes are not 
part of the immune-system. The others cells together are the leucocytes, or white blood 
cells (WBCs) which are divided into the innate (granulocytes, macrophages, monocytes, 
dendritic cells and NK cells) and the adaptive system (T cells and B cells). Innate immune cells 
recognize pathogens using germ-line encoded receptors for conserved molecular patterns 
which are specific for microorganisms.3, 4 Its response is fast, not antigen specific and does 
not require prior sensitization; then, innate cells do not form immunological memory. The 
adaptive immune system is complementing the innate system in many ways: pathogens 
are recognized by antigen-specific, somatically generated receptors that can be adapted 
to increase specificity, but require a few days to be generated. Additionally, the adaptive 
system can form an immunological memory and thus protect from recurrent infections.5, 6 
Together, these two cellular systems form a solid defense to pathogens. 
If one of the components of the immune system is lacking or unable to fulfil its function 
due to an inborn defect, this is called a primary immunodeficiency (PID).7-9 A large group 
of PIDs comprises the Primary Antibody Deficiencies (PAD), which are caused by reduced 
or absent production of antibodies (also referred to as immunoglobulin (Ig)) by the B cells. 
Defects in any stage of B cell development, differentiation, activation and maturation can 
lead to PAD.10-13 This thesis will focus on defects at different stages of B cell development 
and how those can lead to PAD. In relation to that, it is essential to study normal precursor 
B cell development in bone marrow, B cell receptor repertoire formation, B-cell receptor 
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mediated signaling and B cell intrinsic signaling in response to stimulation. To this extent, 
different techniques can be employed, many of which have been improved or even 
newly developed within the past few years. We aimed to make optimal use of available 
techniques and set-up our own assays to study B cell development and its defects in the 
context of PAD.   
NORMAL B CELL PRECURSOR DEVELOPMENT IN HUMAN BONE MARROW
From stem cell to B cell
The B cells arise from multipotent hematopoietic stem cells that reside in the bone 
marrow.14 These cells are long lived and self-renewing, and have the capacity to give rise 
to pluripotent hematopoietic progenitor cells. Because of their self-renewing capacity, the 
stem cells can provide a life-long supply of pluripotent progenitor cells, which in turn can 
give rise to different cell types within a specific cell lineage. In this way, pluripotent cells are 
formed that give rise to the myeloid lineage and the lymphoid lineage. It is important to keep 
in mind that this process is most studied in mice, and although most processes and factors 
have the same function in human bone marrow, some might have different importance and 
effects.15, 16 Upon further differentiation into their lineage, cells become more committed 
to their specific fate. This is regulated by of combinations of transcription factors that at 
the same time promote one lineage and suppress others.17 However, experiments in mice 
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Figure 1. 
Systematic overview of the immune system. A. The primary and secondary lymphoid organs 
B. Overview of the hematopoietic cells divided into the myeloid lineage and the lymphoid lineage
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1have shown plasticity and dedifferentiation upon transcriptional reprogramming.
18, 19 One 
of the key transcription factors which is vital for hematopoiesis is PU.1 (Figure 2) which 
has a broad, but graded expression pattern.20 Different PU.1 expression levels have a 
critical role in defining differentiation of different lineages; an artificial moderate PU.1 level 
promotes B cell development ,21 while loss of PU.1 in mice prevents development of all 
lymphoid cells.22 Another broadly expressed factor is the zinc finger transcription factor 
IKAROS,23 which expression is required for the progression into lymphoid lineages24 and 
which is involved in transcriptional control of the rearrangement of IgH and IgL loci during 
later stages of B cell development.25 While PU.1 and Ikaros promote a lymphoid fate, the 
myeloid differentiation is being inhibited by the expression of E2A and IL7R.18, 26, 27 This 
transcriptional program forms the common lymphoid progenitor (CLP), in which induction 
of recombination activating genes 1 and 2 (RAG1 and RAG2)28 restricts the cell further to 
either a T or a B cell faith.29, 30 In mice, expression of Ly6D marks the branching of T and B 
cells, with Ly6D+ cells being called: B cell biased lymphoid progenitors,31 in which the B 
cell specific transcription factor network is initiated. Key players in this network are Early 
B-cell factor 1 (Ebf1), essential for B cell specification and commitment30, 32 and paired box 
protein 5 (PAX5), completing commitment to the B cell lineage.33, 34 PAX5 is a critical B cell 
lineage commitment factor that induces the expression of multiple B cell specific markers 
such as CD79a (also known as Igα), which can be detected in the cytoplasm of pro-B cells, 
and CD19, which is first expressed in the pre-B stage.18 These cells however, have been 
Pro-B Pre-BI Pre-BII Immature Mature
IgM IgM
IgDcyIgu
DH-JH VH-DJH rearrangement
rearrangementVκ-Jκ
Vλ-Jλ rearrangement
cyCD79a+
CD19+
CD34-
CD10+
CD20-/+
cyCD79a+
CD19+
CD34+
CD10+
CD20-
cyCD79a+
CD19-
CD34+
CD10dim/+
CD20-
cyCD79a+
CD19+
CD34-
CD10+
CD20+
cyCD79a+
CD19+
CD34-
CD10-
CD20++
TdT
RAG
2nd wave
B-lymphoid
progenitor
Ebf1
PAX5
RAG
TdT
RAG
TdT
RAG
lymphoid
progenitor
PU.1
Ikaros
E2A
ILR7
cyCD79a-
CD19-
CD22+
CD34+
Peripheral
blood
Checkpoint 1
functional IgH
Checkpoint 2
functional IgL
autoreactivity
RAG
T cell NK cell 
Figure 2.  
B cell precursor differentiation stages in the human bone marrow. Important transcriptionfactors are indicated 
in the cell nuclei at individual differentiation stages. The bottom panel indicated the immunphenotype per 
differentiation stage.
Part 1
14
shown to retain some plasticity in mice.35 If Pax5 was deleted after the first B cell stages 
in conditional knock-out mice, those cells dedifferentiated and committed to the T-cell 
lineage.36 This indicates the dual role of transcription factors like PAX5: supporting the one 
lineage, while suppressing another one. Once committed to the B-cell lineage, the goal 
of the B cell precursor (BCP) is to form a functional B cell receptor, a process that started 
already with the induction of RAG1 and RAG2 at the common lymphoid progenitor stage. 
Further progression in development and differentiation is for a large part regulated by and 
dependent on how well the cell succeeds to form a B cell receptor.
Structure of the B-cell receptor
The B-cell receptor (BR) of Immunoglobulin (IG) consists of two heavy chains (IGH) 
and two light chains, either IGκ or IGλ.(Figure 3) All chains have a variable and a constant 
domain. The variable domain of the IGH is encoded by a combination of one V, one D 
and one J gene, the variable domain of the IGκ or IGλ in encoded by a combination of 
one V and one J gene. The variable region is important for antigen recognition. It consists 
of complementary determining regions (CDRs), which bind the antigen, and frame-work 
regions (FRs), which are needed for proper folding and configuration of the protein. IGH 
also comprises a constant region, for which 9 genes are available on the IGH locus (Cμ, Cδ, 
Cγ3, Cγ1, Cα1, Cγ2, Cγ4, Cε and Cα2). Different constant regions have different effector 
functions. 
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Figure 3.  
Structure of the B cell receptor (BR). The left panel is a schematic representation of the BR, consisting of two heavy 
and two light chains and accompanied by CD79a and CD79b upon expression on the plasma membrane. The 
right panel is a schematic representation of the process of V(D)J-recombination.
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1V(D)J recombination 
The V, D, and J genes need to be combined to form a functional BR (Figure 3). This 
process of VDJ-recombination takes place in the early B cell development in bone marrow. 
Ordering of the recombination process is controlled by multiple mechanisms, amongst 
which a specific transcriptional network,37 localization in the nucleus38 and epigenetics 
that control the accessibility of the chromatin.39, 40 During the pro-B cell stage first DH-JH 
incomplete rearrangements of both the IGH loci takes place.41, 42 The lymphocyte specific 
RAG1 and RAG2 recognize the recombination signal sequences (RSSs) that are flanking 
the coding regions and induce single strand nicks between the coding segment and the 
RSS. This results in a hairpin structure on the coding end and a blunt end at the RSS-end.43 
Since this happens at both the D and the J genes, all genes in between are cut out and 
ligated into signal joints. The resulting DNA double strand breaks are recognized by the 
non-homologous end joining machinery. The DNA-dependent protein kinase (DNA-PK) 
complex is recruited to the DNA end, to protect it from exonuclease activities.44 Next, 
Artemis is recruited to this complex and phosphorylated so it will open the hairpin of the 
coding ends.45 At this point nucleotides can be removed by exonuclease activity and the 
protein deoxynucleotidyl transferase (TdT) can add non-templated nucleotides.46 These 
deletions and random nucleotides create junctional diversity. Finally, both ends are ligated 
by a protein complex consisting of DNA ligaseIV (LIG4), XRCC4 and XRCC4-like factor 
(XLF).44 In the preB-I stage, one allele performs VH-DJH recombination in the same way as 
was done for the DH-JH recombination. When this results in an unproductive sequence, 
the second allele is rearranged.40, 47 After formation of a VDJ-exon, this is transcribed and 
spliced to the Cμ exon. The resulting heavy chain can be expressed as pre-BR together with 
the surrogate light chain. After recombination of a functional IGH, RAG is re-expressed 
and the light chain V and J segments are rearranged.48, 49 Besides different combinations 
of V and J, the light chain can either be formed from the kappa or lambda gene, resulting 
in many different light chains that can be formed. The multitude of VDJ-combination and 
IGH-IGL combinations, create an enormous diversity in different BR molecules that can 
potentially be formed.50 This is referred to as the BR-repertoire of the naive B cells.
Checkpoints in precursor B-cell development
In addition to producing a functional BR, committed B cells need to go through multiple 
rounds of proliferative expansion, to form the large pool of B cells that is required for good 
humoral immunity. These two processes must be tightly regulated to prevent genomic 
instability, which can lead to malignancies. Furthermore, only cells with a functional, non-
autoreactive BR must proliferate to ensure a proper function of B cells at the phase of 
antigenic selection. Once recombination of the heavy chain is successful, a cytoplasmic 
form of the BR heavy chain can be expressed and detected.51 This heavy chain can pair with 
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a surrogate light chain (composed of the λ-like and VpreB proteins) and be expressed on 
the surface in a complex together with Igα (also known as CD79a) and Igβ (also known as 
CD79b)52 that form a heterodimer. The expressed pre-BR provides a docking site for Lyn and 
Syk (Figure 4), two kinases that can recruit and activate SLP-65 (also known as B cell linker 
(BLNK)) and BTK, which in turn activates PLCγ2 by phosphorylation. It is important to note 
that this process and most importantly the function of BTK and IL7R-mediated signaling, 
is different in mice and man. In humans, deficiency in BTK results in a lack of peripheral B 
cells, whereas BTK-KO, even though there is an impairment in pre-B-cell development, do 
have peripheral B cells.53 Although different proteins expressed on bone marrow stromal 
cells have been proposed to serve as a ligand,54, 55 establishment of a feeder-cell free in vitro 
system in which human stem cells can be differentiated into functional B cells, has shown 
pre-BR signaling without a ligand is possible.56 Successful signaling via this cascade induces 
allelic exclusion of the second IGH allele,47 it induces proliferation via the MAPK pathway57 
and it represses RAG expression58 to prevent DNA double strand breaks occurring during 
proliferation. After a couple of rounds of cell division, the IgK-locus is activated and RAG 
protein expression is upregulated to induce VJ-rearrangement of the BR light chain.39, 48 Not 
all cells succeed to signal via expression of a pre-BR, either because they did not rearrange a 
functional heavy chain, or their heavy chain was not able to pair with a light chain, or other 
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Figure 4.  
Pre-BR signaling via multiple intracellular signaling molecules in BCP in human bone marrow.
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1components of the signaling cascade are missing.
59, 60 Without signaling via this cascade, 
cells will die. Thus, the cells that have rearranged a functional heavy chain that can pair 
with the surrogate light chain and can that be expressed to induce pre-BR signaling are 
positively selected for at this pre-BR checkpoint (Figure 2).61
A second checkpoint in precursor B cell development takes place during the immature 
B-cell stage (Figure 2), when cells have recombined a functional light chain and can 
express a BR in the form of IgM on their surface.29 Cells that express a functional light chain 
that is able to pair with the cells’ heavy chain and can be expressed on the surface, down 
regulate RAG1 and RAG2 expression and stop light chain rearrangement.49 However, if 
the expressed surface-IgM signals above a certain threshold (because the BR responds to 
membrane bound or soluble auto-antigens), this might be indicative of auto reactivity. 
Then, negative selection of cells that experience high BR mediated signaling is initiated. 
Experiments with transgenic autoreactive mouse models indicated that high-affinity 
interactions lead to elimination of the cells (clonal deletion),62 and low-affinity interactions 
and soluble antigens result in anergy of the cells or in receptor editing.63-65 During the 
latter process the light chain loci are further rearranged under continuous RAG expression, 
continuing with the second Kappa allele or the Lambda alleles until a functional light chain 
is formed, that together with the heavy chain does not result in an autoreactive BR.
NORMAL B CELL DEVELOPMENT IN THE HUMAN PERIPHERAL BLOOD AND 
SECONDARY LYMPHOID ORGANS
After formation of a functional, non-autonomously signaling, non-autoreactive BR that 
can be expressed on the cell surface, the B cell is ready to egress from the bone marrow 
to the peripheral blood. The B cell is now considered mature, however, since it has not 
encountered antigen yet, it is still called naive. Further maturation of the B cell, from this 
stage onwards, will be antigen dependent (Figure 5).
The peripheral blood
The earliest stage of B cell development in peripheral blood is the transitional B cell, 
that has just exited the bone marrow. These are B cells that express IgM and IgD on their 
surface, but still have some phenotypic markers that indicate their recent exit from the 
bone marrow, like increased expression of CD38 and high expression of CD24.66 Some 
additionally consider low expression of CD21 and increased expression of CD10 to define 
these cells phenotypically.67, 68 The CD10+ CD21lo fraction has been suggested to represent 
regulatory B cells67 a cell type that is found and studied in mice.69 After the transitional 
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stage, expression of CD21 is high on the B cells, although a small proportion of CD21lo 
peripheral B cells can be found in healthy controls. Their biological role has been much 
disputed, and high numbers of CD19hiCD21lo cells are found in a variety of diseases 
including systemic lupus erythematosous,70 HIV,71 hepatitis C,72 Downs’ syndrome,73 and 
CVID.74 Recently Keller et al. have shown, that high SYK expression is a common feature 
of CD21lo B cells independent of the underlying disorder.75 In addition, Unger et al. found 
a possible relation between IFN-γ related auto-immunity in CVID and a high number of 
CD21lo cells,76 indicating a common mechanism by which these cells arise in patients. 
However, in healthy B cell development most B cells in the peripheral blood gain 
CD21 at the naive B cell stage. Naive B cells are defined by their expression of IgD and the 
lack of CD27 on their surface.77 They patrol the peripheral blood and lymphoid organs in 
search for the antigen that specifically binds to their BR. After recognizing and binding 
antigen, the naive B cell moves to the follicles of one of the secondary lymphoid organs 
for further maturation. Here they will gain their effector function, either becoming 
an antigen secreting plasma cell or a memory B cell.78 In the mucosal associated tissue 
(MALT), mainly IgA-secreting plasma blasts can be formed, which produce IgA that can 
be excreted, for example into the lumen of the small bowel.79 Memory cells enter the 
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B cell differentiation in the peripheral blood and secondary lymphoid organs.
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1bloodstream again after maturation in the lymph node or spleen, they express only one of 
the immunoglobulin isotypes, IgM, IgA, IgG, or IgE. Many of these cells additionally express 
CD27, which was considered to be the hallmark of memory B cells.80 However, over the 
past years, several studies have shown the presence of CD27- memory B cells, which have 
an activated phenotype and carry molecular signs of antigen experience.81, 82 Also plasma 
cells can be detected in the peripheral blood, those are characterized by high expression 
of CD38 and CD27 and a reduced expression of CD19 and CD20. Plasma cells are formed 
in the secondary lymphoid tissues and from there move via the peripheral blood to the 
bone marrow, where they can live in their niche for years,83 while secreting antibodies that 
circulate in the peripheral blood.
The lymph node
Once a naive B cell has encountered an antigen that binds specifically to its BR, the cell 
moves to the follicles of secondary lymphoid organs for further maturation to increase 
affinity of the BR for the specific antigen. Depending on the type of antigen, affinity 
maturation takes place in the lymph node (T cell dependent antigens) or the spleen (T-cell 
independent antigens). In order to facilitate the complex process of affinity maturation, 
specialized structures called germinal centers (GCs), arise in the lymph nodes upon 
immunization. Germinal centers consist of a light zone, where selection takes place, and 
the dark zone, where the B cells undergo clonal expansion, Ig-class switch recombination 
(CSR) and somatic hypermutation (SHM).84 In the light zone the antigenic signal is 
maintained by antigen presenting follicular dendritic cells (fDCs).85 The B cell is further 
stimulated by CD4+ T cells via interactions such as CD40-CD40ligand interaction (Figure 5)86 
and production of IL-2187 and other cytokines. Especially the stimulation via IL-21, induces 
CSR in in vitro cultures, promoting naive B cells to switch to IgG1 and IgG3.
88 In patients with 
defects in IL21-IL21R signaling, plasma blast formation and CSR are defect.89 Vice versa, 
the B cell can stimulate and feedback to the CD4+ T cell via ICOS-ICOSL interaction and by 
MHC-II-TR interaction. In the dark zone the positively selected B cells undergo extensive 
proliferation,90 to form a large pool of B cells with specificity for the same antigen. Gitlin 
et al. showed that the affinity for the antibody determined the level of proliferation;91 cells 
with the highest affinity selectively expand.92 Affinity is further increased by CSR and SHM. 
Both these processes are controlled by the key regulator Activation Induced Deaminase 
(AID).93 During CSR, the constant region of the IgH is replaced by another isotype. This is 
essential since the different isotypes have different properties, such as affinity, half-life, 
ability to dimerize, ability to bind to Fc receptors and activate the complement system. SHM 
takes place at the variable region of the IgH and IgL chains. Single nucleotide mutations 
are induced by AID in both the CDR and the FR of the Ig. Since these mutations can either 
enhance or reduce affinity, B cells move back to the light zone to again be selected by the 
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fDCs and T cells. To ensure only the most specific B cells are selected and expanded, cells go 
through multiple rounds of cycling between the light and dark zone. Imaging studies have 
confirmed this bi-directionally movement of the cells.94 Eventually the B cells will migrate 
back into the peripheral blood as highly specific memory B cells or plasma cells.
The spleen
Some naive B cells mature further in the spleen. Blood is filtered by the spleen, and 
blood borne antigens are filtered, concentrated and captured by macrophages and 
dendritic cells.95 In B cell follicles in the splenic marginal zone, the fDCs present antigen 
to the maturing B cells, but this time without T-cell help.96 Specific lipid or carbohydrate 
structures of blood-borne antigens evoke this response97 and B cells are additionally 
activated via Toll like receptors or via extensive cross-linking of the BR due to the repetitive 
nature of the antigens. This route of affinity maturation can lead to the formation of natural 
effector cells, which are still IgD+, but have a memory and effector function after maturation 
in the spleen. A similar T-cell independent response can also take place in mucosa 
associated lymphoid tissue (MALT) which is found for example around the bronchi, and 
in the intestinal wall.81 In all these tissues, B cell follicles can be formed that histologically 
highly resemble the GC. Affinity maturation is supported by binding of soluble BAFF and 
APRIL to TACI98, 99 to promote B cell survival.
SIGNALING IN B-CELL DEVELOPMENT
B-cell receptor mediated signaling
The receptors from every individual B cell will recognize one specific epitope of an 
antigen. Once this antigen in encountered, the receptor starts signaling, enabling the B cell 
to respond to the antigen. Upon antigen binding, tyrosine residues in CD79a and CD79b 
are phosphorylated by Lyn and Syk, two Src family kinases. This results in recruitment 
of different kinases, like the previously discussed BTK, and adaptor proteins such as 
SLP-65 (or BLNK). In a positive feedback loop, amplified by the tyrosine kinases Lyn and 
Syk, BR complexes aggregate into microclusters.100 The CD19-complex or B cell receptor 
co-complex (BR-co complex) amplifies this signal and promotes the formation of the 
microclusters.101 The signal is propagated via multiple pathways. Through phospholipase 
C-γ2 (PLC- γ2) and BTK calcium (Ca2+) influx is initiated and signaling via DAG results in 
activation of protein kinase C. Additionally PI3K-AKT signaling is initiated, which will be 
discussed in more detail later. This results in many different signals, that promote survival, 
proliferation and migration of the B cell to secondary lymphoid tissue, to undergo further 
maturation into an antibody producing plasma cell or a memory B cell. Dependent on the 
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1presence or absence of other signals via co-stimulatory receptors, cytokine receptors and 
survival signals (such as BAFF, and APRIL), cells will have a specific response to antigenic 
stimulation.
The B-cell co-receptor complex 
The BR-co complex amplifies signals through the B cell receptor thereby lowering 
the threshold for antigenic signaling. The complex consists of CD19, CD21, CD81 and 
CD225 (Figure 6). CD19 is a transmembrane protein that has an extracellular domain 
and a cytoplasmic tail that harbors multiple tyrosine kinase residues. It is a member of 
the immunoglobulin superfamily and it is expressed on all B cell stages except for pro-B 
cells in bone marrow and long lived plasma cells.101 The long cytoplasmic tail enables 
recruitment of tyrosine kinases and signaling via PI3K.102 Dependence on CD19 mediated 
signaling was shown in the mid-nineties by studies in mice,103 and later by the description 
of CD19 deficient patients.104-106 CD81 is a tetraspanin, a transmembrane protein which is 
critically important for the expression of CD19 on the plasma membrane.107, 108 The third 
member of the BR-co receptor complex is CD21, also known as complement receptor 2 
(CR2) or EBV receptor.109-111 This protein is expressed on B cells after the transitional stage 
and follicular dendritic cells.112 In humans, this is a 145kDA protein that consists of 15 short 
consensus repeats, a transmembrane domain ad a short cytoplasmic tail.113 CD21 binds 
C3d-opsonized immune complexes and hereby enables responses to low dose antigens. In 
mice, it is encoded by the Cr2 locus, which also encodes the complement receptor 1 (CR1) 
otherwise known as CD35. Results from mice have shown that CD21/CD35 knock-out leads 
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Figure 6. 
Dual receptor signaling via the BR and the CD19-complex. The BR recognized epitopes of the antigen, while the 
CD21-molecule functions as a receptor for complement factor C3d, together initiating dual receptor signaling.
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to decreased specific antigenic responses and increased susceptibility to auto-immune 
diseases.114, 115 The last member of the BR co-complex is CD225, also named Interferon-
induced transmembrane protein 1 (IFITM1), is supposed to have a function in antiviral 
immunity, however, its function within the BR co-complex in unknown.
Signaling via the PI3K- AKT pathway
Phosphoinositide 3-kinases (PI3Ks) are expressed in all mammalian cell types.116 PI3K 
signaling contributes to many cellular processes like cell cycle progression, cells growth, 
survival and migration and intracellular transport.117 PI3Ks can be divided into Classes 
(based on their lipid substrate and structural features) and isoforms. In mammals, class I 
is the most studied and understood isoform. All proteins in this class are heterodimers, 
consisting of a regulatory and a catalytic subunit. The regulatory subunit provides 
stabilization, inactivation of kinase activity in the basal state and recruitment to pTyrosine 
residues for the catalytic subunit and is therefore highly important in the regulation of 
signaling and activity of total heterodimer.118 Class I PI3Ks can be activated via Ras and other 
small-GTPases118 or via G-protein coupled receptors119, 120 and tyrosine kinase-associated 
receptors.121 As a result of these multiple options for activation, PI3K signaling is often 
found to integrate multiple signals; for example linking BR-signaling with TLR signaling on 
B cells, to integrate adaptive and innate immune responses122 and integrating BR signals 
and BAFF-R signals to promote mature B cell survival.123 
Upon activation, PI3Ks generate PtdIns(3,4,5)P3 (PIP3) lipids by phosphorylation of 
PtdIns(3,4)P2 or PtdIns(4,5)P2 (PIP2). Its antagonist is the phosphatase and tensin homolog 
deleted on chromosome 10 (PTEN), which is often found inactivated in malignant cells. 
Proteins recruited to the membrane though PIP3, are referred to as PI3K-effectors.124, 125 
One of those effector is AKT, which is activated by phosphorylation via phosphoinositide-
dependent kinase 1 (PDK1). Via multiple pathways AKT is important for diverse cellular 
processes,126 including cell growth and metabolism via the mTOR1 signaling cascade127-129 
and regulation of transcription via the Forkhead Box Subgroup O (FoxO) transcription 
factors.130, 131 PTEN and PI3K are often found to be mutated in both solid and non-solid 
malignancies132 resulting in increased metabolism and proliferation together with reduced 
apoptosis in the cancer cells.
PI3K-AKT signaling in B cells
In lymphocytes, the most abundant isoform of PI3K is the so-called PI3Kδ, consisting 
of the p110δ catalytic subunit, dimerized with the p85α regulatory subunit. Expression of 
this isoform seems to be restricted to leukocytes.133 It has been shown that signaling via 
PI3Kδ is critical for development, survival and activation of B cells. Most of this knowledge 
is derived from mouse knock-out experiments, and so far one case of p85α deficiency has 
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1been described in humans,
134 but the conservation of these proteins and their function 
between man and mice suggest a similar role in development. In B cells, the pathway can 
be activated in many ways: via the tyrosine residues on CD19, via BR-mediated signaling, 
via TLR signaling, via CD40-CD40L interaction and via BAFF-R engagement (Figure 7). In 
mice, it was shown that PI3K suppresses expression of Rag via Foxo, which binds to the 
promotors of Rag1 and Rag2.130, 135 Hereby, PI3K signaling enables “tonic” signaling and 
proliferation of preB cells in the bone marrow. In both p110δ and p85α deficient mice, 
nearly normal BCP development was seen, although at a later stage B cells developed 
abnormally.136, 137 Experiments with single and double knock-out mice showed that, at least 
in mice, p110α can compensate for the lack of p110δ in BCP in bone marrow. However, 
mice deficient for both p110α and p110δ had a complete block at the pre-B cell stage with 
an elevated fraction of cells that contain two rearranged heavy chain alleles, due to a failure 
to inhibit Rag expression.138 Furthermore, upon pre-BR signaling PI3K is activated to induce 
proliferation, and deficient mice showed reduced numbers of immature B cells.139 In the 
naive mature B cells in peripheral blood, PI3K signaling was shown to integrate BR signaling 
and BAFF-R signals, in such a way that mature B cells that lost their BR were fully rescued by 
activation of PI3K signaling.123 PI3K promotes Ca2+ mobilization and nuclear translocation of 
NFκB, thereby enabling survival of mature B cells in the absence of antigenic stimulation.140 
Upon antigen encounter, PI3K is activated via BR signaling and CD19 signaling. Studies 
in CD19 and PI3Kδ double deficient mice have shown that combined action of the two 
protein is required for survival and differentiation of B cells.141 Besides its role in survival 
and proliferation, PI3K has also been shown to suppress AID, which is required for SHM and 
CSR, indicating a role in affinity maturation in the lymph node.142, 143 A recent report by Chen 
et al. showed that it is the signaling balance between PTEN and PI3K that regulates CSR.144 
However, whether this is regulated via PI3K-AKT signaling directly or via FOXO, remains to 
be investigated. In addition, Sander et al. showed that PI3K-signaling and the transcription 
factor FOXO1 are essential antagonistic regulators within the germinal center, controlling 
polarization and cellular selection.84 In summary, PI3K signaling is required throughout the 
total B cell development from bone marrow until final CSR and memory formation in the 
lymph node.
PI3K-AKT signaling in T cells
In T cells PI3K signaling can be induced via T cell receptor mediated signaling, 
co-stimulatory signals via CD28, the IL2 receptor and diverse chemokine receptors.145 
Via AKT-mTOR signaling this cascade is important for the regulation of T cell activation 
and differentiation. Additionally, Foxo regulates expression offor example CD62L and 
CCR7, which are important secondary lymphoid tissue homing factors for T cells. Studies 
in diverse knock-out mice136, 137, 146 have indicated that besides mTOR signaling, PI3K also 
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feeds into Tec mediated activation of NF-AT, NFκB and MAPK signaling in T cells, also 
affecting activation in an mTOR independent fashion.147 Using PTEN knock-out mice, it was 
shown that balance in PI3K signaling is important to maintain homeostasis and lineage 
stability in Treg cells.148 Furthermore, PTEN loss in CD4+ T cells, enhanced their helper 
function, without inducing auto-immunity or lymphoma.149 Opposed to this, mice without 
p110δ, showed reduced T dependent antibody responses150 indicating loss of T cell help 
to B cells. Regarding the CD8+ T cells, it was shown that p110δ is required for primary and 
memory antiviral responses and responses against intracellular bacteria in mice.151 These 
studies suggest that dysregulation of PI3K signaling can lead to disturbed activation, 
differentiation and function in all major T cell subsets.
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Figure 7. 
BR-signaling induces activation of the PI3K-AKT signaling cascade. There are multiple receptors on the B cell 
plasma membrane that can activate this cascade.
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1PRIMARY ANTIBODY DEFICIENCIES
When an inborn defect occurs at any stage of B cell development, differentiation, 
activation, maturation or signaling, this can lead to reduced numbers (or absence) of B 
cells or to reduced or incorrect function of the B cells, which in turn results in reduced 
or absent production of antibodies.10-13 This heterogeneous group of diseases is called 
Primary antibody deficiencies (PAD). Common variable immunodeficiency (CVID) is the 
most diagnosed PAD.152 Unfortunately, in the majority of CVID cases (90-95%) no genetic 
defect can be found.9, 11, 153  In other groups of patients, genetic defects that can explain 
the occurrence of the disease have been found.8 Examples of those will be discussed here, 
grouped by the stage of B-cell development that is affected by the defect.
Defects that affect precursor B-cell development
Over the years, multiple genetic defects have been identified that cause a (partial) stop 
in B cell precursor differentiation in the bone marrow, often resulting in reduced numbers 
or even lack of B cells in the peripheral blood. Depending on the mechanism that is affected 
by the mutation patients can have different clinical phenotypes. 
Defects in B cell commitment
Already at the stage of B-cell commitment, mutations in key-transcription factors have 
been found. Recently, patients with heterozygous mutations in IKAROS, causing loss of B 
cells in the peripheral blood and decreased early B-cell precursors in bone marrow, have 
been described.154, 155 Furthermore, 4 patients with E2A mutations have been described.156 
The mutations found in these patients affected only one of the two transcription factors 
(namely E47) the gene encodes for, leaving the other (E12) unharmed. And thus, the 
phenotype in patients was less severe than in E2A KO mice, which have a complete block 
in B cell development. The patients did have CD19+ B cells in the peripheral blood, but 
these were all BR-.157 In line with this, one patients was described carrying a homozygous 
premature stop codon in exon 6 of PIK3R1,134 which results in the absence of p85α but 
normal expression of the p50α and p55α regulatory subunits of PI3K. In bone marrow 
aspirates <0,1% CD19+ B cells could be detected, suggesting a B lineage commitment 
problem. 
V(D)J-recombination defects
In a group of patients with defects in both T- and B cells, mutations are found in genes 
that are involved in V(D)J recombination, like RAG1 and RAG2,158, 159 Artemis,45, 160, 161 and 
DNA-PKcs.162, 163 Since V(D)J-recombination cannot be performed in absence of any of these 
proteins, cells cannot form a functional heavy chain, and B cell precursor differentiation is 
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stopped at the first checkpoint in the pre-B-I stage. This classically leads to absence of B 
cells and T cells in the peripheral blood and the clinical phenotype of Severe Combined 
Immunodeficiency (SCID). Only homozygous or compound heterozygous loss-of-function 
mutations lead to disease. However, it was shown that some patients with RAG mutations 
can present with less severe phenotypes of combined immunodeficiency.164 In addition, 
mutations in Ligase4 (LIG4) have been described to cause SCID,165 whereas other patients 
with LIG4 mutations have a broader clinical phenotype with primordial dwarfism.166 
Defects in (pre-)BR expression and signaling
There are cases of patients that lack one of the BR-components due to a mutation, like 
a mutated Igu-heavy chain (IGHM gene),167, 168 or a mutated surrogate light chain protein 
lambda5/14.1 (IGLL1 gene).169 They cannot express a BR, which leads to a stop at the pre-B-I 
stage and absence of B cells in the peripheral blood. Other patients cannot express their 
BR because of a lack of CD79a,170, 171 leading to a comparable immunological and clinical 
phenotype: agammaglobulinemia. These causes are all autosomal recessive and therefore 
very rare. A more frequent cause of agammaglobulinemia is X-linked agammaglobulinemia 
(XLA), caused by mutations in Bruton`s tyrosine Kinase (BTK).172-174 About 85% of cases of 
agammaglobulinemia can be explained by a defect of this protein,175 which results in 
defective pre-BR signaling and pre-B cells die from neglect. In some cases, the defect has 
a leaky phenotype and a few mature B cells can be found in the peripheral blood. A similar 
disease causing mechanism was found in a patient without peripheral B cells and with a 
stop at the pre-B-I stage, that was found to have a mutation in SLP-65, which is also critical 
for (pre-) BR-signal transduction.176 
Patients without defined genetic defect in precursor B-cell differentiation
One last group of patients that have been described to have abnormal precursor B 
cell differentiation are a subgroup patients hypogammaglobulinemia, especially patients 
with common variable immunodeficiency (CVID). Some of these patients have low B cell 
numbers in the peripheral blood, suggesting a defect arising in bone marrow. Indeed 
people have described aberrancies in the B cell precursor subsets of CVID patients.177-180 
Their findings suggest problems with autonomous proliferation in the pre-B-II stage in a 
group of CVID patients, but also a role for B-cell extrinsic factors, like the niche provided by 
the bone marrow stroma, that could have reduced function in CVID. Additionally, it has been 
suggested that a group of CVID patients might have problems in V(D)J-recombination,181 
since in these patients, also the T cell compartment is affected and in their bone marrow, 
pro-B and pre-B-I cells form the majority of B cell precursors. 
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1Disturbed peripheral B cell maturation
Over the past decades, different genetic defects in factors that control peripheral B cell 
development have been discovered. By affecting different processes, all of these defects 
lead to antibody deficiencies.10, 13, 78 To indicate how different genetic mutations can affect 
B cell development, some defects are described here.
Survival defects
In order to survive in the periphery, naive B cells are dependent on signaling via B-cell 
activating factor receptor (BAFF-R), a member of the TNF alpha family receptors, upon 
binding of BAFF, a soluble factor in the serum. Human patients with BAFF-R deficiency182 
display a strong B cell lymphopenia with relatively increased numbers of transitional B cells 
are reductions in more mature B cell compartments. This results in reduced serum IgM and 
IgG levels, but normal IgA levels. IgA+ plasma cells were found in the gut of these patients. 
Transmembrane activator and CAML interactor (TACI) is a related receptor from the same 
family and mutations impair the development of IgA- and IgG-secreting plasma cells 
and promote lymphoproliferation.183 However, TACI mutations are not always penetrant 
and mutations can be found in healthy relatives of patients PAD-patients with the same 
mutation. 
Defects in activation, migration and BR-signaling
Upon antigenic stimulation, the signal from the BR is processed intracellularly. In the case 
of NFKB and NEMO deficiencies, signaling though the BR via NEMO and NFKB is defective, 
resulting in reduced activation of the B cells. However, dependent on the nature of the 
mutation, the disease phenotype can be very broad and include other cells and tissues in 
which this signaling cascade is required.184 Augmentation of BR signaling is done by the B 
cell receptor co-complex, also called CD19 complex. Several patients with deficiencies in 
proteins in this complex like CD19,104, 105, 185-187 CD81,188 and CD21189-191 have been described, 
all mutations lead to hypogammaglobulinemia and reduced formation of memory B 
cells, although the phenotype is less severe in the CD21 deficient cases. When factors 
that are required for correct homing to the lymph node are deficient, B cell maturation is 
hampered. This has been described for patients with leucocyte adhesion defects type III 
(LAD-III)192 that developed hypogammaglobulinemia, due to defect homing to the lymph 
nodes. After arrival in the lymph node, B cells require T cell help via inducible co-stimulator 
(ICOS), which is expressed on follicular T-helper cells. Homozygous deletion of this protein 
results in impaired T cell help to follicular B cells resulting in late onset CVID.193
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CSR and SHM deficiencies
B cells require co-stimulation to perform CSR. One essential signal comes from the 
cytokine IL21. Homozygous loss-of-function mutations in IL21R have been recently 
described to cause reduced serum IgG and poor vaccination responses.194 Another 
essential signal is T-cell help in the form of CD40-CD40L interaction. Defects in CD40L result 
in X-linked hyper IgM syndrome (HIGM).195 Autosomal recessive forms of HIGM can be 
caused by mutations in AID196 UNG and MSH6, the latter two are both vital proteins for DNA 
repair. In all these defects, B cells cannot switch to IgA of IgG. In the case of AID deficiency, 
not only CSR in defective, but also targeting of SHM is reduced, thus this defect results 
in reduced SHM as well. A recent field of interest are mutations in PI3K-AKT signaling,197 
which will be discussed separately. 
PI3K-PTEN disbalance due to mutations
Although PI3K-AKT signaling has been studied in the context of lymphocyte 
development for decades, only recently germline mutations were found to cause an 
antibody deficiency due to deregulation of this pathway. In 2006, one case was reported 
of a boy who suffered from low B cell numbers and agammaglobulinemia.198 He was 
one patient of a cohort in which by sequencing of PIK3CD mutations were sought that 
could explain the clinical phenotype. Later in 2012 a case of agammaglobulinemia was 
described as to be caused by deficiency of p85α.134 But only by the end of 2013, mutations 
in PI3K were found to cause a disease entity that is commonly referred to as Activated 
PI3Kδ syndrome (APDS).199 This disease is sometimes also referred to as p110δ activating 
mutation causing senescent T cells, lymphadenopathy, and immunodeficiency (PASLI).200 
Patients have mutations in PIK3CD199, 200 (referred to as APDS1) or PIK3R1201, 202 (referred to as 
APDS2), resulting in hyper activation of PI3Kδ. This leads to disturbed T cell differentiation, 
increases in short lived effector T cells, but reduced memory T cell formation. Additionally 
both via reduced T cell help and B cell intrinsic defects, B cells fail to mature into class 
switched plasma cells that secrete high affinity antibodies and B cell memory is reduced. 
Although the clinical phenotype of the disease is highly variable, cohort studies203, 204 have 
indicated that patients suffer from recurrent respiratory tract infections, failure to control 
EBV and CMV infections, progressive airway damage, lymphadenopathy and have an 
increased risk of lymphoma`s.197 A group of patients that share the mechanism of disease 
are patients with loss of function mutations in PTEN. A subgroup of those patients also 
suffers from infections and was found to have hypogammaglobulinemia.205, 206 Both groups 
of patients indicate the need of tight regulation of the PI3K-AKT pathway in human B and 
T cell immunology.
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1OVERVIEW OF THIS THESIS
In this thesis we aimed to study how specific defects lead to disturbances in B cell 
development and repertoire formation and thereby cause antibody deficiencies. In order 
to study antibody deficiencies, good insight in B cell development is crucial, but at the same 
time, patients with specific defects can give new insights in which factors are important for 
B-cell developmental processes. This work contributes to our understanding of genotype-
phenotype correlations and with that can help individualize diagnostic work-up, and give 
better prognostic predictions. Furthermore, this leads the way into the field of personalized 
medicine also in the context of rare diseases, the importance of which is underlined in 
the “Nationale wetenschaps agenda, Q081”. Studying these two fields at the same time is 
therefore highly valuable, and not only for patients with antibody deficiencies, but also 
for our general understanding of B cell biology and therefore for other immunological 
diseases and processes such as malignancies, auto-immunity, immune dysregulation and 
regeneration after stem cell transplantation. 
Part two of this thesis focusses on normal BCP development in bone marrow and how 
this results in a broad repertoire of naive B cells. Using a newly established flow cytometry 
panel combined with novel analysis methods, we studied B cell development in healthy 
bone marrow and used bone marrow from patients with known genetic defects as controls. 
The output of naive B cells with a broad repertoire is the final goal of BCP development in 
bone marrow. Therefore, we used next generation sequencing to study the repertoire in 
naive B cells of healthy controls and patients, since we hypothesized that in some CVID 
patients this repertoire would be reduced. Part three of this thesis focusses on deficiencies 
in the BR-co-complex. We have described the second patient with CD21 deficiency. We 
compared the immunobiology of CD21 deficiency to CD19 deficiency, because the clinical 
phenotype of the two deficiencies is different, we wanted to understand more about the 
effect on B cell development in both deficiencies. In part four, we shift to dysregulations 
in PI3K-AKT signaling, studying the effect of PTEN on humoral immunity and the effect of 
PI3Kdelta mutations on B cell development and CD8+ T cell exhaustion. Since some patients 
with PHTS have an antibody deficiency, we hypothesized that their B and T cell phenotype 
and repertoire could be affected by the mutation. Furthermore, we hypothesized that the 
antibody deficiency seen in APDS patients is not only due to reduced T-cell help, but also 
an intrinsic defect in B cells adds to the phenotype. Additionally, we asked ourselves: could 
the increased expression of PD-1 and the increased apoptosis rate om lymphocytes in 
patients with APDS be explained by exhaustion of the T cell compartment? In part 5, the 
general discussion, the importance of our findings is reviewed and future perspectives are 
discussed.
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The studies described in this thesis help understand why disturbances in specific 
genes and processes lead to antibody deficiencies. They showed that B cell precursor 
development in bone marrow is not a simple linear process, but rather a complex 
interplay of processes that make every individual cell follow its own route of maturation 
into a naive B cell. Furthermore, these studies showed that subtle differences in protein 
function can explain phenotypical differences between different disease entities in CD19-
complex deficiencies. Showing how genotype-phenotype correlations can be a tool in 
patient-prognostics. These studies also showed that the balance in the PI3K/PTEN-AKT 
signaling cascade is critically important for both humoral and anti-viral immunity, since 
disturbances lead to antibody deficiencies and reduced viral immunity due to exhaustion. 
This is especially important in the context of new, personalized, specific treatments for 
these patients.
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ABSTRACT
B cells arise from hematopoietic stem cells in bone marrow. Identification 
and characterization of the different precursor B-cell subsets contributes to 
understanding normal B-cell development. During differentiation, B cells 
form a functional B-cell receptor via the process of V(D)J-recombination. 
Changes in rearrangement status guide the differentiation of B cell 
precursors (BCP). In addition to changes in rearrangement status and 
expression of BR molecules, BCP undergo other immunophenotypic 
changes in their consecutive stages. We studied BCP differentiation in 
human bone marrow using samples from healthy controls together with 
patients with known genetic defects in V(D)J recombination or pre-B cell 
receptor (preBR) signalling to further unravel immunophenotypic changes 
and to determine the effect of specific differentiation blocks caused by the 
specific genetic defects. 
We designed a 10-color flow cytometry panel, to study human BCP 
development in bone marrow, that enables reliable gating of previously 
described populations, based on B-cell receptor-related markers. 
However, when we included information from other markers, we found 
heterogeneity within the preB-I and preB-II populations, during which V(D)
J recombination takes place with expression of surface markers that seems 
asynchronous to the expression of cyIgμ. Next Generation Sequencing of 
complete IGH rearrangements in sorted cell populations was performed to 
determine the rearrangement status at DNA level.
Our data indicate that BCP differentiation is not a single linear route 
of differentiation, but rather a complex process of V(D)J)recombination-
driven checkpoints, divergence, parallel pathways and convergence to 
form a unique and functional B cell receptor. Understanding this process 
requires an integrated approach of hallmark protein expression analysis 
with DNA rearrangement status on a single-cell or on a small homogeneous 
cell population level.
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INTRODUCTION
B cells arise from hematopoietic stem cells in bone marrow and develop in a stepwise 
manner.1, 2 Identification and characterization of the different precursor B-cell subsets 
contributes to understanding normal B-cell development.3, 4 Expression of transcription 
factor PAX5 marks commitment to the B cell lineage, which promotes expression of 
B-cell specific genes such as CD79a (also called Igα) and CD19 while supressing B-lineage 
inappropriate genes. Since CD79a (cyCD79a) expression is one of the first signs of B cell 
lineage commitment, cyCD79a+ CD19- cells are in the human nomenclature defined as pro-B 
cells followed by expression of CD19 in pre-B-I cells. During this stage, V(D)J recombination 
of the immunoglobulin (Ig) heavy chain locus is initiated by recombination activating 
genes (RAG1 and RAG2).5-11 If this rearrangement process results in a functional protein, 
Igµ is expressed in the cytoplasm (cyIgµ), which marks the pre-BII-stage. If rearrangement 
of the first allele does not result in a productive Igµ molecule, the second allele will be 
rearranged. Igµ is expressed together with the surrogate light chains λ14.1 and VpreB on 
the plasma membrane as pre-B-cell receptor (preBR).12, 13 Upon preBR signalling, a cascade 
of events is induced: downregulation of the recombination machinery to ensure allelic 
exclusion, proliferation followed by opening of the Ig light chain (IGL) locus, which is being 
rearranged under the influence of a second expression wave of RAG1 and RAG2.10, 14 After 
successful IGL rearrangement, a functional B cell receptor (BR) in the form of IgM is 
expressed, marking progression to the immature B-cell stage. Once, next to IgM, IgD is 
expressed on the plasma membrane, the immature B-cell becomes a naive mature B-cell 
and moves to the peripheral blood.
In addition to changes in rearrangement status and expression of Ig molecules, B-cell 
precursors (BCP) undergo also other immunophenotypic changes in their consecutive 
stages. Pro-B cells express stem cell markers such as CD34 and CD10, whereas later stages 
start to express specific B-cell markers such as CD19 and CD20. Additionally, cells that are 
in their rearrangement process express TdT in two waves, one during the heavy chain 
rearrangement and one during the light chain rearrangement which ensures junctional 
diversity by random addition of non-templated nucleotides. Expression of these markers 
and immunoglobulin or BR-molecules can be studied using flow cytometry.15
Most knowledge about B cell development in bone marrow came from mouse studies, 
however detailed insight into normal human precursor B-cell development is important 
to identify and unravel pathophysiological processes in hematological malignancies and 
Primary Immune Deficiencies (PID), which are caused by genetic defects.16 Furthermore, 
precursor B-cell analysis in genetically identified PID can help elucidating the role of 
specific genes in precursor B-cell development,13, 17 because absence or dysfunction of 
essential proteins cause a full or incomplete block at specific developmental stages.18-20 
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Here, we studied BCP differentiation in human bone marrow, using samples from healthy 
controls together with patients with genetic defects in V(D)J recombination or preBR 
signalling, to further unravel immunophenotypic changes and to determine the effect 
on differentiation blockades caused by specific genetic defects. We developed a 10-color 
panel together with a new analysis strategy using principle component analysis and viSNE 
analysis21 that allowed more detailed analysis of previously described cell populations. This 
10-color panel was first validated against our previously used 4-color panel.7, 18, 22 Secondly, 
we analysed DNA rearrangement status and the gating strategy based on BR-related 
markers (cyCD79a, cyIgμ, IgM, IgD, CD19) was compared with gating based on membrane 
markers such as CD10 and CD20 as is also done in literature.23-25 Gating based on BR-related 
markers allowed us to define the crucial steps of B cell development better than gating 
based on surface markers alone and we argue that intracellular markers are required 
to delineate BCP development. We detected considerable heterogeneity in marker 
expression, especially in in the pre-BI and pre-BII stages, suggesting that B cell development 
in bone marrow is not a linear process, but rather a complex asynchronous network with 
points at which maturation diverges or converges and parallel pathways, that is dictated 
by V(D)J-recombination-driven checkpoints. We propose that our immunophenotyping 
panel can be used in multi-center studies with the standardization stringency developed 
by the EuroFlow consortium,26 thus allowing to mutually compare the data-files generated 
on patients with primary immunodeficiency with those of individuals with undisturbed B 
cell development.
MATERIALS AND METHODS
Bone marrow and peripheral blood samples
Bone marrow samples from healthy controls were left over from healthy children 
who donated bone marrow for transplantation into a diseased sibling or were collected 
from patients that had a bone marrow biopsy to rule out other diseases then lymphoid 
PID. In general, bone marrow samples were considered normal when no malignant cells 
were detected in combination with normal BCP differentiation upon standard diagnostic 
testing. Patient bone marrow samples were collected for PID-diagnostics and analyzed 
in this study with informed consent and according to the guidelines of the local medical 
ethics committee.
Flow cytometric immunophenotyping of bone marrow
10-color flow cytometric immunophenotyping of bone marrow samples was performed 
on a LSR Fortessa (BD BioSciences, San Jose, CA, USA) with instrument setting according 
49
Flowcytometric B cell precursor analysis in human bone marrow
2.1
to EuroFlow SOP [26] extended to 10-colors in two EuroFlow laboratories. After bulk lysis 
according to EuroFlow SOP26, 27 cells were stained for surface markers and intracellular 
markers in two consecutive steps. The next antibodies were used for extracellular staining: 
IgM-BV510 (MHM-88) CD38-BV605 (HIT2), CD20-PB (2H7, all Biolegend, San Diego, CA, USA), 
CD34-APC (8G12), IgD-PeCF594 (IA6, both BD Biosciences), CD19-PC7 (J3-119, Beckman 
Coulter, Fullerton, CA, USA) and CD10-APC-C750 (Cytognos, Salamanca, Spain). Cells were 
fixed and permeabilized using the Fix&Perm reagent kit (An der Grub, Vienna, Austria) 
according to manufacturer’s instructions. The next antibodies were used for intracellular 
staining: IgM-PerCPcy5.5 (MHM-88, Biolegend), TdT-FITC (HT6, Supertechs, Rockville, MD, 
USA) and CD79a-PE (HM47 Beckman Coulter) (See Table 1 for complete panel).
Patient bone marrow samples were analyzed in parallel with a diagnostic 4-color panel 
as described before,7, 18 for comparison of the new 10-color panel to the 4-color diagnostic 
panel (gold standard). An overview of the antibodies used in all panels can be found in 
Supplemental Table 1.
The data was analyzed with Infinicyt software Version 1.8 (Cytognos, Salamanca, Spain). 
Principle component analysis was performed with the Infinicyt software. This method 
calculates the most discriminating projections based on selected parameters, into a single 
Automated Population Separator (APS) bi-dimensional graph. Multiple APS graphs (APS1, 
APS2 etc) can be generated, depending on which parameters contribute more or less to 
the principle components on the X-axis and Y-axis. ViSNE projection21 was calculated using 
Cytobank (Cytobank, Inc, Santa Clara, CA, USA).28 This method generates a 2D dotplot in 
which the X- and Y-axis are defined by virtual parameters called tSNE1 and tSNE2, in which 
all events are projected integrating information on all selected parameters. In a viSNE plot 
the distance of one event to other events represents how similar events are, with the most 
similar events plotting closest to each other.21
For repertoire analysis, two bone marrow samples without malignant cells and with 
normal BCP differentiation (determined with standard diagnostic testing) were enriched 
for B cells using a RosetteSepp human B-cell enrichment cocktail (Stem cell Technologies, 
Vancouver, Canada) according to manufacturer’s instructions and as described before.29 
Subsequently, the B-cell enriched samples were frozen in liquid nitrogen and thawed prior 
to sorting. The sorting was done with the same antibodies that were used in the 10-color 
flow-cytometry tube and performed on an Aria-III FACS-sorter (BD Biosciences). After 
sorting the cells were washed and DNA was isolated using a direct lysis method as described 
before.30 The IGH rearrangements were amplified in a 2-step PCR reaction and sequenced 
by NGS. IGH rearrangements were amplified (35 cycles) using the forward VH1-6 FR2 and 
reverse JH consensus BIOMED-2 primers which were extended with Illumina P5 and P7 
adapter sequence.31 Subsequently, PCR products were purified by gel extraction (Qiagen, 
Valencia, CA), followed by a nested PCR reaction (12 cycles) to include the sample-specific 
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indices and Illumina sequencing adapters using primers from the Illumina TruSeq Custom 
Amplicon Index Kit (Illumina, San Diego, CA, USA). The PCR concentration was measured 
using the Quant-it Picogreen dsDNA assay (Invitrogen, Carlsbad, CA). The libraries were 
analyzed by NGS (221 base pair paired-end) on the MiSeq platform (Illumina, San Diego, 
CA, USA) with use of an Illumina MiSeq Reagent Kit V3, according to the manufacturer’s 
protocol (Illumina, San Diego, CA, USA). Paired sequences were aligned using paired-end 
read merger (PEAR),32 and the fastq files were converted to fasta files.33 Subsequently, the 
sequences were trimmed to remove the primer sequenced and were uploaded in IMGT/
High-V-Quest,34 and subsequently the IMGT output files were analysed in the ARGalaxy 
tool (https://bioinf-galaxian.erasmusmc.nl/argalaxy).35 For the analysis only a single 
sequence per clone (defined as same V gene, same J gene and the nucleotide sequence of 
the CDR3 region) were included. In-frame rearrangements are defined to have an in-frame 
rearrangement without a stop codon. Unproductive rearrangements are either out-of-
frame rearrangements or in-frame rearrangements with a stop codon.
RESULTS
Subset definition based on B cell receptor related markers is consistent between different 
panels
To study human bone marrow we designed a 10-color flow cytometry panel in a 
single tube (Table 1), to make optimal use of available material and integrate information 
about both intracellular and extracellular markers on each individual cell. We tested this 
10-color panel against our validated 4-color diagnostic panel.7, 18 Bone marrow samples 
from healthy controls and PID patients were analysed using both flowcytometry panels. B 
cells and BCP were defined as cytoplasmicCD79a+ (cyCD79a+). The five major populations 
(pro-B, pre-BI, preB-II, immature and mature B cells (Figure 1A)) were gated based on CD19, 
nTdT, cyIgμ, IgM and IgD expression (B-cell receptor (BR)-related markers) (Figure 1B and 
supplementary methods). This was related to the subset distribution of the 4-color panel, 
that we used as a gold standard. Since IgMD+ cells (mature B cells) can also be detected in 
peripheral blood, we do not consider them a precursor stage. In ten independent samples 
Fluoro- 
chrome
PB BV510 BV605 FITC PE PE-
CF594
PerCP-
Cy5,5
PE-
Cy7
APC Alexa 
750
Target CD20 IgM CD38 TdT CD79a IgD cyIgM CD19 CD34 CD10
clone 2H7 MHM-88 HIT2 HT6 HM47 IA6 MHM-88 J3-119 8G12 HI10a
volume
(undiluted)
1 μl 1.3 μl 1 μl 10 μl 5 μl 3 μl 2.5 μl 5 μl 2.5 μl 5 μl
Table 1. Set-up of fluorochromes and epitopes of the 10-color EuroFlow BCP tube
Shaded fields indicate intracellular markers
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Figure 1. Major BCP subsets in human bone marrow. 
A. Schematic representation of the BCP subsets in human bone marrow, the green bars indicate when 
recombination processes take place. B. Population definition based on BR-related markers. All cyCD79a expressing 
cells are considered BCP or B cells. Pro-B cells are defined as CD19- TdT+, pre-BI cells are defined as CD19+ cyIgμ- 
IgM-, pre-BII cells are defined as CD19+ cyIgμ+ IgM-, immature B cells are defined as CD19+ IgM+ IgD- and mature B 
cells are defined as CD19+ IgM+ IgD+. C. BCP subset distribution in the same sample that was acquired in parallel 
with two different panels. Population definition was in both cases done as indicated above. 
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(n= 4 controls and 6 patient samples) both panels revealed the same precursor B-cell subset 
distribution. Three representative cases are shown: one of normal BCP development, a RAG 
deficient patient and a BTK deficient patient (Figure 1C). This indicates that gating based 
on BR-related markers is consistent between both panels and gives comparable results 
in both healthy controls and PID patients with BCR signaling and a V(D)J recombination 
defect. 
Population definition based on only BR-related markers, shows heterogeneity within the 
population
When using only the BR-related markers (cyCD79a, CD19, cyIgµ, IgM and IgD) we 
defined 4 subsets of BCP. However, when we took the other markers into account (TdT, 
CD34, CD10, CD20 and CD38) we found that these populations are not homogeneous. 
Especially pre-BI and pre-BII cells showed heterogeneity in the non-BR related markers 
(Figure 2A). In the pre-BI population, cells were mainly TdT+ and CD34+, but some cells have 
lost one or both markers, while at the same time being positive for CD10 and negative for 
CD20, indicating they are not switched memory B cells from peripheral blood. This was 
also observed for the loss of CD10 and CD38 and the gain of CD20, indicating that there 
could be more different subsets within this population (Figure 2A). Pre-BII cells, on the 
other hand, were cyIgµ+ and mainly CD34- and TdT-, but some pre-B-II cells still express 
CD34 and TdT. The expression of CD20 was highly heterogeneous in this population and, 
the expression was gradual (Figure 2A). To study this heterogeneity in more detail, we 
performed a viSNE analysis on each separate population (Figure 2B). After performing 
the viSNE analysis, we indicated the intensity of the individual non-BR-related markers for 
each cell. Within the pre-BI population, a clearly separate group of cells is found that is 
TdT- CD34-. Vice versa, in the pre-BII population a small population of CD34+ TdT+ cells was 
found. In both populations a gradual expression pattern of CD20 was detected, which was 
also present in the immature B cells. 
Asynchronous marker expression in pre-B stages is found in PID patients
The heterogeneity within populations that we observed seemed to be the highest 
in the pre-BI and pre-BII stages. To further examine the relation between expression of 
non-BR-related markers and cyIgμ, we compared pre-BI and pre-BII cells from controls to 
patients with a RAG deficiency and a BTK deficiency. We found that a fraction of the pre-BI 
cells in controls, loses CD34 and/or TdT expression and some upregulate CD20 (Figure 3A). 
In the RAG deficient patient, TdT expression remains intact, but again we see loss of CD34 
and gain of CD20. Apparently, cells can upregulate CD20 in the absence of a functionally 
rearranged heavy chain. The same upregulation occurs in case of a BTK-deficiency. 
In addition, in the pre-BII cells of controls and BTK deficient patients, some of the cells, 
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although expressing cyIgμ, still have CD34 and/or TdT expression. Those cells seem to 
have prolonged TdT expression. Since RAG deficient patients do not have pre-BII cells, we 
could not compare this subset for these patients. Thus, we observed that surface marker 
expression can behave asynchronously with the progress in BR formation. Additionally, 
RAG or BTK deficient cells can lose CD34 expression, without downregulating TdT. 
Integration of all markers into one analysis strategy.
After we observed that marker expression can be asynchronous, we integrated all 
markers into one analysis strategy that was based on population gating using 2D dotplots 
(Supplemental Figure 1). However since the process of BCP differentiation seems gradual 
at some stages and some markers have gradual expression instead of clear positive 
and negative populations, not all populations can be clearly defined. To integrate data 
from multiple markers on each individual cell a principle component analysis based 
multidimensional view (APS graph) was generated based on a reference data set of 5 
samples of healthy control bone marrow samples in Infinicyt software.36 In the APS1 view 
(Figure 4A) the cells are separated in a fashion that seems to follow their maturation from 
less mature pro-B cells in the lower right to mature B cells at the left of the diagram. In 
RAG deficiency BTK deficiencyHealthy control
A
RAG deficiency BTK deficiencyHealthy control
BPre-B-I Pre-B-II
 cyIgu
 Ig
M
 CD34
 T
dT
CD10
 C
D
20
 cyIgu
 Ig
M
 CD34
 T
dT
CD10
 C
D
20
no pre-BII cells
present in sample
no pre-BII cells
present in sample
no pre-BII cells
present in sample
Figure 3. Pre-BI and pre-BII marker expression in control and patient samples. 
A. Dotplots representing pre-BI cells from a control sample, and two patient samples, indicating the uncoupling 
of expression of cyIgμ and surface markers like CD34, CD20 and CD10. In both the control and the patients, cells 
without cyIgμ can lose CD34 expression and gain CD20 expression. B. Dotplots representing pre-BII cells from a 
control sample, and two patient samples. In both the control and the patients, cells with cyIgμ expression can still 
express CD34 and TdT, and CD20 expression is heterogeneous.
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the APS2 diagram, again the order of maturation is visible, but now the populations with 
heterogeneous CD20 expression are more stretched out, indicating the gradual expression 
of this marker. In both diagrams, the populations as we identified them previously seem 
to overlap, indicating a gradual differentiation. To indicate the position of each population 
in these diagrams, we plotted the 2SD line of each population as a reference. Using the 5 
healthy donor samples as a reference, we plotted in the BCP cells from a sixth, independent, 
0 20 40 60 80 100
Normal <5
RAG
deficiency
Pro-B
Pre-B-I
Pre-B-II
Immature
Mature 
A
APS1 5 pooled controls APS2 5 pooled controls
APS1 5 pooled controls,
2 SD lines
APS2 5 pooled controls,
2 SD lines
APS1 independent control APS2 independent control
APS1 RAG deficiency APS2 RAG deficiency
Normal <5
0 20 40 60 80 100
BTK
deficiency
0 20 40 60 80 100
Normal <5
Healthy
control
APS1 BTK deficiency APS2 BTK deficiency
B
Figure 4. Supervised APS view of BCP populations in healthy bone marrow (n=5) indicated by lines at 2SD 
intervals.  
A. BCP populations in a pool of 5 healthy bone marrow samples that were used to create the APS view. Lines 
indicate the 2 SD range of each population, dot indicate individual cells. The different populations are indicated 
by the different colors. B. 2 SD lines of BCP populations derived from a pool of 5 healthy donors, dots indicate total 
BCP from a sixth healthy donor, a RAG deficient patient and a BTK deficient patient, plotted against the reference 
pool. Bars indicate the BCP subset distribution of each sample, compared to age matched controls.
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healthy donor (Figure 4B) into the same principal components (fixed, supervised APS plot). 
The events fall within the ranges of the other 5 healthy controls. However, if we plot the 
BCP events from a patient with a RAG deficiency or a BTK deficiency, we can see where a 
blockade arises. Using a reference of 5 healthy samples, showed at which points blockades 
are located in patients with genetic defects. However, in this representation, some cells fall 
outside the 2SD lines of both pre-BI and pre-BII. This is the case in both the control and the 
patient samples. A combination of the APS plot and the bar graph gives the best impression 
about the position of the differentiation block, the relative subset distribution and whether 
the combination of expression of all markers in patients deviates from controls.
Downregulation of CD34 and TdT between pre-BI and pre-BII stage.
When we focused on the cells that were neither within the 2SD interval of the pre-BI 
cells nor in the pre-BII 2SD interval in healthy controls (in controls between 1 and 3% of all 
BCP cells), we found that they are also present in normal BCP differentiation, although not 
as many as in the patient samples (Figure 5A). These cells are defined as pre-BI or pre-BII 
based on the absence or presence of cyIgμ but the expression of TdT, CD34, CD10 and 
CD20 is asynchronous with their cyIgμ status (Figure 5B). We can divide the pre-BI cells 
in true pre-BI cells that are CD19+ cyIgμ- CD34+ TdT+ (pre-BI +/+) and another, more het-
erogeneous group that is CD19+ cyIgμ- but where CD34 and or TdT expression is negative 
(pre-BI -/-). These cells are not switched memory B cells coming from peripheral blood, 
because they all express both CD10 and CD38. The same split can be made within the pre-
BII cells, dividing them in pre-BII cells that are CD19+ cyIgμ+ CD34- TdT- (pre-BII -/-) and a het-
erogeneous group that is CD19+, cyIgμ+ but that still have CD34, TdT or both these markers 
(pre-BII +/+). In the APS views that are based on all BCPs, these cells end up between pre-BI 
and pre-BII. If we create an APS view of only the pre-BI and pre-BII stages, we can examine 
how heterogeneous these populations are (Figure 5C,D).
Rearrangement status classifies the intermediate stages
To further dissect this, we sorted the pre-B populations into four populations: pre-BI 
+/+ (CD19+ cyIgμ- CD34+ TdT+), pre-BI -/- (CD19+ cyIgμ- CD34- TdT-), pre-BII -/- (CD19+ cyIgμ+ 
CD34- TdT-) and pre-BII +/+ (CD19+ cyIgμ+ CD34+ TdT+). We isolated DNA from these sub-
sets and sequenced complete IGH rearrangements using next-generation sequencing. We 
found that in the pre-BI +/+ cells, the majority of complete rearrangements is unproduc-
tive with an in-frame: unproductive ratio of 1:9, which is in line with the observation that 
these cells do not express cyIgu, yet. In the pre-BII -/- cells, the in-frame: unproductive 
ratio is 4:1, with approximately 80% of rearrangements in frame, which is in line with the 
observation that these cells all express cyIgu. In the pre-BI -/- population, the in-frame: 
unproductive ratio is 3:1, and in the pre-BII +/+ population, this ratio is also 3:1. In these 
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populations, the relative amount of in-frame complete rearrangements is approximately 
the same, however, in one population the cells do not express cyIgu, whereas they do in 
the other populations. This indicates that in the pre-BI -/- cells in-frame rearrangements 
are present, but they are either not productive (i.e. not leading to a functional protein) or 
they are not (yet) expressed. The pre-BII +/+ already express cyIgu, but did not yet down-
regulate CD34 and TdT.  
DISCUSSION
In this study, we validated a 10-color flow cytometry panel, to study human BCP 
development in bone marrow of immune deficient patients in more detail on crucial 
developmental thresholds than what was previously done. We could reliably gate 
populations as they were gated and described before, based on BR-related markers. In 
our standardized measurements we could superimpose PID samples over healthy controls 
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and describe abnormalities form normal development found in patients. Unexpectedly, 
when we included information from additional markers, we found heterogeneity within 
especially the preB-I and preB-II populations, during which V(D)J recombination takes 
place with expression of surface markers that seems asynchronous to the expression of 
cyIgμ. NGS analysis of complete IGH rearrangements in sorted populations was used to 
determine the rearrangement status at the DNA level. 
We studied BCP differentiation in the human bone marrow, using healthy control 
samples and PID patients with proven genetic defects in either V(D)J-recombination or 
pre-BR-signalling as a control. We showed that BR-related marker based population 
definition is consistent over samples and different panels, but this results in heterogeneous 
populations when other markers, like CD34, TdT and CD20 are considered. Upon more 
in-depth study of expression patterns of these markers, we found that in some specific 
populations, expression of these markers is asynchronous to the process of BR-formation. 
This effect is more visible in patients with defects in V(D)J-recombination. Specifically, we 
found that CD20 can be upregulated in the absence of cyIgμ expression and that cells 
can lose TdT expression and CD34 expression without having expression of heavy chain 
protein in the cytoplasm.
We combined the population-gating based strategy that is often used in flow cytometry 
with principle component analysis. We showed that the populations of precursor B-cells 
seem to overlap, indicating a continuous process rather that a step-wise differentiation. 
This is in line with asynchronous marker expression that we see between surface markers 
e.g. each cell seems to up-and –down regulate its phenotype markers at its own pace. Even 
more, some phenotype markers that were previously thought to be V(D)J-recombination 
dependent, seem to progress even in the absence of cyIgμ expression, as indicated by loss 
of CD34 and gain of CD20 in patients with genetic defects in V(D)J-recombination. Some of 
the cellular phenotypes that we found in controls are more common in genetically defined 
patient samples. This indicates that, even though cells cannot successfully rearrange their 
IgH-locus (RAG deficiency10, 37), they will still lose CD34 expression as if they are progressing 
to the next stage. In addition to that, we found that CD20 expression is gradually increasing 
over the course of several stages. However, CD20 expression is heterogeneous in many 
populations. Especially in patient samples, we often detected high CD20 expression in 
populations that were assumed to be early in B-cell differentiation. Even though the exact 
role of CD20 on B cells is not found yet, it is still a useful marker indicating B-cell development 
and if highly expressed in combination with loss of CD10 and CD38, indicating maturity of 
the B cells. CD20 expression does not seem to be related with BR-rearrangement.
Both in PID patients and in control samples we identified cells outside the reference 
borders of the defined populations (e.g. pre-BI and pre-BII) in the APS plots, although the 
numbers were much lower in control samples Especially in the RAG deficient patient this 
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is striking, because it seems as if some cells can progress in surface marker expression by 
expressing CD20 and loosing CD34, without having a functionally rearranged heavy chain. 
This further supports the idea that expression of CD20 and CD34 is not in all cells strictly 
linked to heavy chain rearrangement status.
To further dissect this, we sorted preB-I and preB-II cells and further divided these 
populations based on their CD34 and TdT expression. DNA extracted from these cell 
populations was used to study complete IGH-rearrangements using NGS. In preB-I +/+ 
cells we showed that almost around 90% of detectable rearrangements are unproductive. 
Since these cells do not express cyIgu yet, we hypothesize that these cells have not yet 
rearranged an in-frame IGH, and thus they still express CD34 and TdT. In preB-II cells that 
are CD34- TdT- , around 75% of detectable rearrangements were in-frame. These cells all 
express cyIgu, and some have an unproductive rearrangement on one allele combined with 
an in-frame rearrangement on their second allele, which explains the 25% of unproductive 
rearrangements in this population. The preB-II +/+ cells also contain approximately 75% 
of in-frame rearrangements. Possibly, these cells have only just completed their in-frame 
rearrangement, started expressing cyIgμ and still need to downregulate CD34 and TdT. 
However, our data is not sufficient to conclude this. Also, we detected around 75% in-frame 
rearrangements in pre-Bi -/- cells. These cells have an in-frame heavy chain rearrangement 
on the DNA level, however, they do not express cyIgu protein. To further investigate this, 
single-cell analysis on DNA, RNA and protein level might give further insight in how and 
why V(D)J-recombination status and phenotypic marker expression are linked.
In conclusion, we have introduced a new 10-color reference approach consisting of 
standardized cytometry staining and analytical tools for the analysis of BCP in human 
bone marrow. Furthermore, our data indicate that BCP differentiation is not a single 
linear route of differentiation, but rather a complex process of V(D)J)recombination-
driven checkpoints, divergence, parallel pathways and convergence to form a unique 
and functional B cell receptor. Understanding the process of BCP differentiation requires 
an integrated approach of single-cell DNA, RNA and protein analysis applied to a model 
systems with genetically defined differentiation steps and blocks. 
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SUPPLEMENTAL TABLES AND FIGURES
Supplemental Table 1. Markers of the different panels
4 color panel (10 tubes) 10 color tube
CD10 CD36 cyIgμ cyCD79a
CD34 CD3 TdT TdT
IgD CD16/CD56 cyCD79a cyIgμ
CD19 CD13/CD33 VpreB CD19
CD20 CD71 CD34
IgM CD20
CD138 CD10
CD45 IgM
CD22 IgD
CD38
 
Supplemental Table 2. Expression of markers and population definition 
cyCD79a CD34 TdT CD19 CD10 CD38 cyIgM IgM IgD CD20
All BCP +
pro-B + + + - + + - - -
pre-BI + + + + + + - - -
pre-BII + - - + + + + - -
immature + - - + + + + + -
mature + - - + + + +
peripheral blood + - - + - - ++
plasma blasts + - - dim/- - ++ double – or single + -
 
Empty field indicates that this marker is not used for gating this population
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ABSTRACT
The antigen receptor repertoires of B and T cells form the basis of 
the adaptive immune response. The repertoires should be sufficiently 
diverse to recognize all possible pathogens. However, careful selection 
is needed to prevent responses to self or harmless antigens. Limited 
antigen receptor repertoire diversity leads to immunodeficiency, whereas 
unselected or misdirected repertoires can result in autoimmunity. The 
antigen receptor repertoire harbors information about abnormalities in 
many immunological disorders. Recent developments in next generation 
sequencing allow the analysis of the antigen receptor repertoire in much 
greater detail than ever before. Analyzing the antigen receptor repertoire 
in patients with mutations in genes responsible for the generation of the 
antigen receptor repertoire will give new insights into repertoire formation 
and selection. In this perspective we describe strategies and considerations 
for analysis of the naive and antigen selected B-cell repertoires in primary 
immunodeficiency (PID) patients with a focus on severe combined 
immunodeficiency (SCID) and common variable immunodeficiency (CVID).
Key words: V(D)J recombination, next generation sequencing, CVID, 
immunodeficiency, repertoire
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GENERATION OF THE T-AND B-CELL REPERTOIRE 
V(D)J recombination of immunoglobulin and T-cell receptor loci
The antigen receptor repertoire is defined as the total set of different B-cell (BR) or T-cell 
receptors (TRs). The loci encoding these receptors consist of multiple variable (V), diversity 
(D) and joining (J) genes, which can be recombined via V(D)J recombination to ensure the 
enormous diversity of the antigen receptors. V(D)J recombination starts with induction of 
DNA double strand breaks (DSBs) by the recombination activating gene products RAG1 
and RAG2 between the coding element and the recombination signal sequence (Figure 
1A).1 The DNA ends that contain the recombination signal sequence, the so-called signal 
ends, are blunt DNA ends, which can be ligated directly to form the signal joint. The other 
ends (called the coding ends because they contain the coding sequence of the Ig or TR 
gene) are blocked by a covalent phosphodiester bond between the top and the bottom 
strand of the DNA. These DNA hairpins are recognized, processed and repaired by the non-
homologous end joining pathway (NHEJ) (Figure 1A). First, the Ku70/80 heterodimer forms 
a ring around the DNA end that can migrate into the DNA after initial binding. Ku70/80 
bound to a DNA end can then attract the DNA dependent protein kinase catalytic subunit 
(DNA-PKCS), which acquires protein kinase activity upon DNA end binding. DNA-PKCS 
autophosphorylation induces a conformational change in the DNA-bound complex of 
Ku70/80 and DNA-PKCS, collectively called the DNA-PK complex.
2, 3 After this conformational 
change, Artemis opens the DNA hairpins.4, 5 If the ends are compatible, they can be ligated 
by ligase IV, which forms a stable complex with XRCC4. XLF (XRCC4 like factor), which 
has also been called ‘Cernunnos’.6 Before ligation, non-templated (N) nucleotides can be 
inserted by TdT or deleted via exonuclease activity (Figure 1B).7, 8 In addition to the NHEJ 
components, several other factors are required to ensure efficient ligation of so-called 
‘difficult breaks’ or ‘complex DNA damage’. Extensive analysis of DSB repair kinetics revealed 
that these DSBs are mainly localized to heterochromatin and require opening of the closed 
chromatin structure in order to be repaired by NHEJ during the G1 phase of the cell cycle 
or HR in the G2 phase. Chromatin opening probably requires the initial phosphorylation 
of histone H2AX,  the ATM kinase, the MRE11/RAD50/NBS1 complex and several enzymes 
necessary for ubiquitin addition near the DSB, including RNF8 and RNF168.9-11
Antigen receptor repertoire diversity
The total diversity of the unique TRs and BRs is the sum of combinational diversity based 
on the usage of different combinations of V, (D) and J genes and junctional diversity due 
to nucleotide deletions by exonuclease activity, non-templated (N) nucleotide insertions 
that are introduced by the enzyme terminal deoxynucleotidyl transferase (TdT) and the 
presence of palindromic (P) nucleotides that arise due to asymmetric hairpin opening by 
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Artemis (Figure 1B). In addition, combination of the different chains (TRα and TRβ, TRγ and 
TRδ, or heavy and light chains) also contributes to the overall diversity. The immunoglobulin 
heavy chain (IGH) locus consist of 38-46 functional VH, 25 DH and 6 JH genes resulting in a 
combinational diversity of >5.7x103. In combination with the 200 possible Igκ and 124 Igλ 
rearrangements, this results in a combinational diversity of >1.8 x106. The total diversity of 
the BR is estimated to result in a total BR repertoire of >1012. 
STRATEGIES FOR B-CELL RECEPTOR REPERTOIRE ANALYSIS
Naive versus antigen-selected B-cell receptor repertoire
The B-cell repertoire in peripheral blood can be divided into the naive and antigen-
selected repertoire (Figure 1C). The naive repertoire, present in the transitional and naive 
mature B cells, has not encountered antigen and most closely resembles the initial repertoire 
formed by V(D)J recombination during precursor B-cell differentiation. The naive repertoire 
can be regarded as the end-stage product of V(D)J recombination. However, it should be 
Figure 1. V(D)J recombination and B cell development 
A. Schematic overview of V(D)J recombination. DNA double strand breaks are introduced by the RAG proteins, 
subsequently the DNA is processed and ligated by DNA repair proteins from the NHEJ pathway. B. Examples 
of VDJ junctions showing junctional diversity by nucleotides that are removed, non-templated (N) nucleotides 
(blue) that are added, or presence of palindromic (P) nucleotides (red). C. The B-cell repertoire in peripheral blood 
can be divided into the naive repertoire and the antigen-selected repertoire.
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noted that by analyzing the naive repertoire only those B cells can be studied that reach 
the naive mature B-cell stage. For studying disturbances in the V(D)J recombination itself, it 
can be better to analyze complete V(D)J or incomplete DJ rearrangements in bone marrow 
(see below). Analysis of the naive repertoire is preferably performed on DNA or RNA 
obtained from sorted naive B-cells. Alternatively, IGM transcripts can be analyzed in total 
RNA from peripheral blood mononuclear cells, of which only the unmutated sequences 
are taken into account. Usually, sequences with 98% V region identity are considered to be 
unmutated, since PCR and sequence errors might occur.12 
The antigen-selected repertoire is the repertoire of cells that encountered antigen, 
i.e. of memory B-cells. This repertoire is different from the naive repertoire, because it has 
undergone SHM with subsequent selection in the germinal center. The antigen selected 
repertoire can be analyzed in sorted memory B-cells or by sequencing of IGG and IGA 
transcripts from RNA isolated from peripheral blood mononuclear cells. 
In summary, for BR analysis it is important to select and sort the correct B-cell population 
depending on the research question. 
Qualitative characteristics of the repertoire
BR repertoire encloses a lot of information about different processes of B-cell 
development. The V, D and J usage and junction composition, defined as the number of 
N- and P- nucleotides, deletions and the length of the CDR3 region, provide information 
about the V(D)J recombination process. 
Increased numbers of P-nucleotides13 or deletions,14 and decreased numbers of 
N-nucleotides are indications for a NHEJ defect.15 In addition, skewing in the usage of V and 
J genes can be observed, as is the case in the TR alpha repertoire in both Xlf knockout mice 
and an XLF-deficient patient.16 Vera et al. hypothesized that the reduced thymocyte lifespan 
does not allow the T cells to undergo multiple waves of VαJα rearrangements that can be 
needed for positive selection of the T cells. Finally, several characteristics like increased 
usage of certain auto-reactive VH genes, the charge of the CDR3 and increased length of 
the CDR3 have been associated with autoimmunity or impaired selection in patients with 
primary immunodeficiencies.17-20 Patients with CD19 and CD40L deficiency lack selection 
against long CDR3 and VH4-34, which is known to encode intrinsically self-reactive cold 
agglutinin antibodies that recognize carbohydrate antigens on erythrocytes.20 Similarly, a 
patient with RAG deficiency and autoimmunity has been described who lacked selection 
against these inherited autoreactive features and in addition had skewing of the CDR3 
repertoire for rearrangements with a certain CDR3 length.21
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Productive and unproductive IGH repertoire
The BR rearrangements can be amplified from DNA or from RNA. Rearrangements 
amplified from RNA are mostly functional (also called productive), which means that they 
code for a functional Ig protein. Amplification of rearrangements from DNA allows analysis 
of both productive and unproductive rearrangements, which have not been selected. The 
latter is interesting because analysis of productive and unproductive IGH rearrangements 
in naive B cells in controls shows that the productive rearrangements in naive B cells have 
a lower number of total N-nucleotides (13.8 vs 20.2nt) consequently leading to a shorter 
complementarity determining region (CDR) 3 length (Figure 2A). This might be explained 
by the fact that in bone marrow only B-cells are selected with a shorter CDR3 region. This 
indicates that analysis of unproductive rearrangements could give additional information 
about the V(D)J recombination process and selection. 
The antigen-selected repertoire is mostly studied at RNA level, by amplifying IGG, IGA 
or IGE transcripts with primers located in or upstream of the V gene and in the constant 
gene. In addition to studying above mentioned characteristics of rearrangements, somatic 
hypermutations (SHM) can be studied.20
Diversity of the repertoire
For several years, conventional cloning and sequencing were the golden standard to 
study BR rearrangements. However, only small numbers (20-100) of rearrangements could 
be studied, which give a limited overview on the diversity of the total repertoire. Therefore, 
the current next generation sequencing (NGS) approaches, which enables to study 
thousands of rearrangements, give new opportunities for studying the diversity of the 
repertoire. Although the potential BR repertoire is estimated to be over 1012, this number 
exceeds the total number of different B cells present in an individual. When analyzing the 
diversity of the repertoire by NGS, only a small fraction of the total B-cell population is 
analyzed. When studying the antigen receptor repertoire diversity, it is of great importance 
to take into account the number of B cells that was used to generate the repertoire data. 
If you start with 100,000 B cells, one cannot expect to find more than 100,000 different 
productive rearrangements. Since every B cell contains only one DNA copy of a productive 
rearrangement, the total number of productive rearrangement can be estimated when 
using a fixed DNA input of sorted B-cells. Every cell contains around 6pg of DNA, so 100ng 
DNA represent approximately 16,667 cells, which also equals the number of productive 
rearrangements that can be expected. In general every B cell contains only one productive 
rearrangement, however multiple B cells with the same rearrangements can be present in 
the B cell pool being studied. 
When using RNA for the repertoire analysis it is difficult to estimate the number of cells, 
because every B cell contains multiple RNA copies of the same rearrangement, and plasma 
71
Repertoire analysis in PID 
2.2
cells contain more RNA copies of the rearrangement compared to other B-cell subsets. So, 
when multiple copies of the same rearrangement are found, these can be derived from the 
same B cell, two independent B cells, or they can be a technical duplication. One should 
therefore be careful interpreting the data, and for repertoire calculations it is best to only 
take the unique productive rearrangements in to account, unless randomly barcoded 
primers to identify individual B cells are used.22
In literature different methods for diversity calculations are used. Species Richness, and 
Shannon entropy are frequently used methods.23, 24 The Species Richness takes into account 
the number of different rearrangements in a sample, whereas the Shannon entropy also 
takes the frequency of the rearrangement into account.23 The latter methods are usually 
performed on rearrangements derived from an individual PCR amplification. Boyd et al. 
used a slightly different method in which occurrences of rearrangements between six 
individual PCR within the same individual was measured.25 These occurrences, also called 
coincidences, could only be derived from clonally related B cells. Immunocompetent 
individuals should have little coincidences since they have a diverse repertoire, while 
immunocompromised individuals are likely to have more coincidences since they have a 
more restricted repertoire.
B-CELL RECEPTOR REPERTOIRE ANALYSIS IN SCID
In patients with primary immunodeficiencies antigen receptor repertoire formation 
or selection can be disturbed, resulting in restricted antigen receptor repertoire diversity. 
Depending on the genetic defect this can result in severe immunodeficiency as is the case 
in SCID patients with defects in RAG1/RAG2 or in components of the NHEJ pathway with 
severely impaired V(D)J recombination.6, 14, 26-29 These genetic defects not only result in a 
quantitative V(D)J recombination defect, but also in a qualitative defect. Because of the 
qualitative V(D)J recombination defects, there are no peripheral B-cells or the number of 
B-cells is too low for reliable analysis. In this case the repertoire can be studied by analyzing 
incomplete or complete BR rearrangements in bone marrow derived precursor B cells. 
NHEJ defects leads to aberrant formation of V(D)J junctions and greatly impact junctional 
diversity, which implies that NHEJ defects cause a quantitative and qualitative antigen 
receptor repertoire defect. For example, mutations in Artemis and DNA-PKcs,13, 29 which affect 
hairpin opening, result in a significant increase in the number of P-nucleotides, whereas 
defects in XRCC4 result in significantly reduced numbers of N-nucleotide insertions.15 
Also other genetic defects, like ATM and NBS deficiency, result in reduced diversity of the 
naive B cell repertoire. These proteins are not directly involved in the V(D)J recombination 
process itself, but are important for sensing of the DNA double strand breaks and for keeping 
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the two DNA ends together during V(D)J recombination. As the result of less efficient V(D)J 
recombination, patients have reduced numbers of naive B cells in the periphery, which can 
in  addition show an increased proliferation history which results in even more restriction 
of the repertoire. This is what we have shown in patients with mutations in ATM causing 
Ataxia Telangiectasia (AT), which is involved in DSB sensing and juxtaposition of DNA ends, 
impair antigen receptor repertoire diversity.30 Similar observations have been done in 
patients with the Nijmegen Breakage Syndrome (NBS).31 
B-CELL RECEPTOR REPERTOIRE ANALYSIS IN CVID
No qualitative defect in the naive IGH repertoire of CVID patients
CVID is the most common primary antibody deficiency characterized by 
hypogammaglobulinemia and poor response to vaccination resulting in infections 
and in some patients to non-infectious complications including autoimmunity, 
lymphoproliferative disease, malignancies and granulomas. In the majority of patients 
(95%), the genetic defect is unknown, but several studies have demonstrated defects 
in B-cell differentiation. Therefore, CVID patients could have a restricted BR repertoire 
underlying the disease. 
Driessen et al. showed that a subgroup of CVID patients also have a reduced number 
of naive B cells, with an increased proliferation history, like the AT and NBS patients.32 
Therefore, we hypothesized that a subgroup of patients with CVID might have a reduction 
in the diversity of the naive IGH repertoire, possibly caused by less efficient V(D)J 
recombination. We studied the naive IGH repertoire in 18 patients described by Driessen 
et al.32 and 10 healthy controls. We sorted naive B cells and amplified the VH-JH junctions 
in six independent PCRs using 100ng DNA per PCR. For the analysis of the qualitative 
parameters we combined the rearrangements of all six individual PCRs and selected the 
productive or unproductive unique rearrangements based on the V and J gene and the 
amino acid sequence of the CDR3.
All of the qualitative parameters we studied were similar to healthy controls in 
this group of CVID patients. The composition of the junctions in both productive and 
unproductive rearrangements was normal (Figure 2A). The only differences were a slightly 
higher number of N-nucleotides (average difference of 0.7 nucleotides) in productive 
rearrangements, and a very small decrease (on average 0.04 nucleotides) in the number 
of P-nucleotides in unproductive rearrangements. However, this did not result in a 
shorter CDR3 length (Figure 2B). Similar to controls, the productive rearrangements had 
significantly less deletions and N-nucleotide insertions, indicating selection for shorter 
CDR3 length. Furthermore, the CDR3 length distribution and composition of hydrophilic 
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and hydrophobic amino acids was also similar to controls (Figure 2B and 2C). These data 
suggests that these CVID patients do not have a qualitative defect in the naive repertoire. 
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Figure 2. Naive B-cell repertoire in control and CVID patients
The naive B-cell repertoire was measured in 10 controls (C) and 18 CVID patients, resulting in total 293,216 unique 
productive rearrangements for control and 539,220 for CVID, and 127,261 unique unproductive rearrangements 
for control and 305,402 for CVID. A. Junction characteristics of CVID patients are similar to controls. Average 
number of total number of deletions, N-nucleotides and P-nucleotides are indicted per patient. B. Similarly, the 
CDR3 length distribution (mean with SEM) of IGH rearrangements is comparable to controls. In addition, the 
frequency of amino acids in the CDR3 (median with range) is also comparable. The positively charged amino 
acids are indicated in red and the negatively charged in blue. D. The diversity of the naive B-cell repertoire in CVID 
patients is comparable to controls, however one patient has a very restricted repertoire similar to patients with 
Nijmegen breakage syndrome (NBS) and Ataxia Telangiectasia (AT). Data is shown in box and whiskers (10-90 
percentile). E. The repertoire of this patient remains very restricted over time. * p<0.05, ** p<0.01, *** p<0.001,**** 
p<0.0001. 
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Diversity of the naive IGH repertoire is normal in most CVID patients
To measure the diversity of the naive IGH repertoire we used the method proposed 
by Boyd et al.25 Based on the occurrence of rearrangements between six independent 
PCRs the diversity of the repertoire can be calculated. We expressed the diversity of the 
repertoire in a diversity score, in which a low value indicate a restricted repertoire and a 
high value represents a more diverse repertoire. Both in the control as in the CVID patients 
there is some spread in the diversity of the repertoire (Figure 2D). However, one CVID 
patient clearly had a more restricted repertoire that the controls. This repertoire was as 
restricted as patients with NBS and AT deficiency (Figure 2D). To assess if this reduction 
in the repertoire is stable over time, the repertoire was analyzed at a second time point 
seven years later (Figure 2E). At both 46 and 53yr of age this patient had a very restricted 
repertoire. At the second time point there were even 10 rearrangements present in all 
individual PCRs, indicating that in the small sample of blood that we took at least six B cells 
had the same IGH rearrangement. Interestingly, this patient has a family history of breast 
cancer indicative for a possible DNA repair defect. These data show that patients with a 
restricted repertoire can be identified using this method, however, most CVID patients 
have a very diverse naive repertoire. Based on the B-cell patterns identified by Driessen et 
al, it is expected that most of the CVID patients will have problems after the naive B-cell 
stage. It will therefore we very interesting to also study the antigen-selected repertoire in 
patients with CVID. 
FUTURE PERSPECTIVES
Developments in NGS give possibilities to study the antigen receptor repertoire of 
patients at a very detailed level than ever before. Different strategies can be followed to 
address many research questions related to the pathophysiology of PID. In this perspective, 
we focused on SCID and CVID, but it has already been proven valuable for many other 
PIDs.33 The next challenge will be linking antigen receptor repertoire data to antigen 
reactivity and specificity, which might in future be linked to specific clinical features.
METHODS
Repertoire analysis using next generation sequencing 
Naive B cells were sorted from peripheral blood from 18 CVID patients and 10 healthy 
controls. DNA was isolated using direct lysis and IGH rearrangements were amplified 
and sequenced using Roche 454 sequencing as previously described.30 In short IGH 
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rearrangements were amplified from in a multiplex PCR using the forward VH1-6 FR1 and 
reverse JH consensus BIOMED-2 primers.34 PCR products were purified by gel extraction 
(Qiagen, Valencia, CA) and Agencourt AMPure XP beads (Beckman Coulter). Subsequently, 
the PCR concentration was measured using the Quant-it Picogreen dsDNA assay (Invitrogen, 
Carlsbad, CA). The purified PCR products were sequenced on the 454 GS junior instrument 
according the manufacturer’s recommendations. Sequences were demultiplexed based 
on their multiplex identifier sequence and trimmed using the IGGalaxy tool.35 Fasta files 
were uploaded in IMGT/High-V-Quest,36 and subsequently the IMGT output files were 
analyzed in the IGGalaxy tool.35 Information on junction characteristics, CDR3 length and 
composition were extracted from the data provided by IMGT. The repertoire diversity score 
was calculated by dividing 1 to the clonality score, which is given by the IGGalaxy tool and 
is based on the calculation of Boyd et al.25 
Statistics
Significance differences were calculated using the two-tailed Mann-Whitney test in the 
GraphPad Prism program (GraphPad Software, Inc.). 
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ABSTRACT 
Background and aims: Good syndrome (GS) is a rare immunodeficiency 
presenting with thymoma and antibody deficiency. Severe recurrent 
infections and autoimmune manifestations are common in GS patients. 
Although GS pathogenesis is largely unclear, the severe reduction of 
peripheral B cells suggests impaired differentiation of B cell precursors 
(BCP) in bone marrow (BM). 
Methods: We analyzed BM samples from 6 GS patients, 15 healthy 
donors (HD) and 19 genetically confirmed agammaglobulinemia patients. 
BCP differentiation in different stages (ProB, PreB-I, PreB-II, Immature) was 
studied using flow cytometry.
Results: GS patients showed a severe reduction of BCP (CD22+) but 
highly increased T cells numbers (CD3+). GS patients had a significantly 
higher frequency of ProB cells and PreB-I cells compared to HD. PreB-II 
cells and Immature cells were significantly decreased in GS patients. 
Agammaglobulimia patients showed a relative expansion of ProB and PreB-I 
cells compared to HD, with a significant reduction later in differentiation at 
the pre-BII and immature stages. GS and agammaglobulinemia patients 
showed a different type of arrest in BCP development. GS patients generally 
showed a relative increase in ProB cells, together with a decrease in PreB-I 
cells compared to agammaglobulinemia patients. 
Conclusions: The absence of peripheral blood B cells in GS patients is 
accompanied by very low numbers of BCP in the BM of these patients. The 
BCP that are present show an arrest in differentiation mainly after ProB stage, 
which is different from patients with monogenic agammaglobulinemia, in 
whom a block is found after PreB-I stage, which is linked to the absence of 
pre-B cell receptor signaling.
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CAPSULE SUMMARY 
Good syndrome is a rare immunodeficiency presenting with thymoma, 
hypogammaglobulinemia and almost absent B cells. To investigate the origin of the B-cell 
lymphopenia in these patients, we studied B cell differentiation in the bone marrow of 
Good syndrome patients. We found very low numbers of (prescursor)B cells in bone marow 
of Good syndrome patients which showed a differentiation arrest after the pro-B-cell stage, 
which is different from other patients with agammaglobulinemia with a defect in preB-cell 
receptor signaling. 
TO THE EDITOR
Good syndrome (GS)1 is a rare immunodeficiency presenting with thymoma, 
consisting of neoplastic thymic epithelial cells and non-neoplastic maturing thymocytes, 
hypogammaglobulinemia and almost absent B cells.2-3 Both sexes are equally affected and 
age of onset is between 40 and 70 years. Patients suffer from severe recurrent infections 
with mainly encapsulated bacteria and opportunistic pathogens.1, 3 Several reports 
indicate a poor prognosis and survival in GS patients due to the high susceptibility for 
severe bacterial infections and because of autoimmunity.3
Although GS pathogenesis is largely unclear, the severe reduction of peripheral B 
cells suggests impaired differentiation of B cell precursors (BCP) in bone marrow (BM). In 
this study we analyzed the clinical and immunological phenotype of 9 GS patients . We 
included BM samples from 6 GS patients and clinical data for 3 additional GS patients. 
Additionally, BM samples from 15 healthy donors (HD) (age >10 years) and 19 patients 
with agammaglobulinemia (X-linked agammaglobulinemia, μ-chain-, CD79- or BLNK 
deficiency) were included. These agammaglobulinemia patients all have a defect before 
the pre-BII cell stage because of defects pre- B-cell receptor signalling. This study was 
performed according to the guidelines of the Medical Ethics Committee of the Erasmus 
MC and was approved by the regional ethical committee in Stockholm. 
Clinical and immunological characteristics of the GS patients are shown in Table 1. All 
9 GS patients (4 females, 5 males) had undergone thymectomy and 8 had histologically 
confirmed thymoma. The predominant infections were similar to what was previously 
described in GS patients.2-4 Those comprise mainly respiratory tract infections and 
in some cases opportunistic infections were recorded. All patients were treated with 
immunoglobulin substitution therapy. One patient suffered from autoimmune pure red 
cell aplasia two years after thymectomy. 
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Figure 1.
Immunophenotyping of BCP in BM of Healthy donors (HD) (n=15), Good syndrome (GS) (n=6) and 
agammaglobulinemia (n=19; for subtypes see D panel) patients. A. Relative frequencies of CD3+ T cells and 
CD22+ B cells in BM samples. CD22+ B cells were CD3/D13/CD33/CD36/CD16/CD56-). B. Relative frequencies 
of BCP populations: proB (CD19-cyIgμ-), PreB-I (CD19+ cyIgμ-), PreB-II (CD19+ cyIgμ+IgM-) and Immature B cells 
(CD19+ vyIgμ+ IgM+ IgD- CD10+ CD38+). C. Subset distribution of BCP subsets in BM for all individual GS patients. D. 
Subset distribution of BCP subsets in BM for HD (pooled) and agammaglobulinemia patients divided on genetic 
diagnosis.
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Concurrent peripheral blood analysis (Supplementary Table 1) in GS patients revealed 
a severe reduction of peripheral blood B cells, 5 patients had a mild reduction in T cells 
counts, 4 patients had reduced levels of CD4+ T cells and 3 patients had lower CD8+ counts 
(Supplementary Table 1).
BCP maturation stages in BM samples were studied using flow cytometry, as previously 
described.5 Only in 6 out of 9 patients precursor B-cells were present. The relative sizes 
of 4 different populations (ProB, PreB-I, PreB-II, Immature) were expressed as percentages 
of total BCP. Mature B cells were excluded from the calculations. Statistical analysis was 
performed with GraphPad Prism software (GraphPad Software, La Jolla, Ca); Mann-Whitney 
test was used.
GS patients showed a severe reduction of BCP (CD22+) but highly increased frequency of 
T cells (CD3+) compared to HD (P=0.0015; P=0.0057 respectively) and agammaglobulinemia 
patients (P=0.0006; P=0.0492 respectively) (Figure 1 A).
GS patient had a significantly higher frequency of ProB cells (CD19- CD34+ TdT+ cyIgμ-) 
and PreB-I cells (CD19+ TdT+ CD34+ cyIgμ-) compared to HD (P=0.0005 and P=0.0005 
respectively) (Figure 1B). However, relative frequencies of PreB-II cells (CD19+ CD34- TdT- 
cyIgμ+) and Immature cells (CD19+ cyIgμ+ IgM+ IgD-) were significantly decreased in GS 
patients compared to HD (P=0.0005 and P=0.0005 respectively). Thus, there is a significantly 
reduced number of BCP in the BM of GS patients and the BCP that are present are mainly 
ProB cells and PreB-I cells.
The composition of the BCP compartment in GS patients differs from the 
agammaglobulinemia patients (Figure 1B). Agammaglobulimia patients showed a relative 
expansion of ProB and PreB-I cells compared to HD (P<0.0001 and P <0.0001 respectively), 
combined with a significant reduction later in differentiation (Pre B-II and Immature cells 
P=0.0016 and P <0.0001 respectively) due to a defect in preB-cell receptor signaling, which 
precludes further differentiation.
GS and agammaglobulinemia patients showed a different type of arrest in BCP 
differentiation (Figure 1 C, D). In GS patients there was a trend towards a relative increase 
in mainly the ProB cells (P=0.0013), together with a decrease in PreB-I cells compared 
to agammaglobulinemia patients (P=0.0170). Also the immature B cell subsets are 
significantly reduced in BM from GS patients (P=0.0111). The arrest in GS patients seems 
to occur after the ProB stage, whereas in agammaglobulinemia patients a differentiation 
arrest occurs after the Pre B-I stage.
GS has been compared to common variable immunodeficiency (CVID) previously. In 
both diseases BAFF-R and TACI mutations have been identified.6 To our knowledge, this is 
the first comparison to patients with monogenic causes of agammaglobulinemia who also 
have a block in BCP development in bone marrow.
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Previous studies on the T cell compartment of GS patients revealed frequent CD4+ 
lymphopenia,4 a case with increasing γδ T cells7 and a case presenting CD8+ T cell large 
granular lymphocyte leukemia with an exhausted phenotype.8 The clonal expansion of CD8+ 
T lymphocytes in bone marrow had been described and associated with B-lymphopoiesis 
deficiency. The authors hypothesized this was due to a CD8+ T cell-driven immune response 
against BCP.9 Other hypotheses have been proposed to explain GS pathogenicity, such 
autoimmune destruction of B cells mediated by autoantibodies.4 Pathogenic antibodies 
are commonly present in GS patients, for example anti-acetyl choline receptor antibodies 
causing myasthenia gravis.2 The aberrant thymic microenvironment may predispose for 
self-activation of thymocytes against autoantigens, and thus evoke a T-cell response against 
B cells. Additionally, murine models have shown a role for interferon-like cytokines such 
as Limitin, which is produced by bone marrow stromal cells. This was hypothesized to be 
involved in BCP differentiation, promoting cell cycle arrest upon impaired differentiation.4 
Aberrancies in BM stromal environment could cause a maturation arrest of the BCP.
In conclusion, this study demonstrates that the absence of peripheral blood B cells in 
GS patients is reflected in very low numbers of BCP in the bone marrow of these patients. 
The BCP that are present show an arrest in differentiation mainly after ProB stage, which is 
different from a selected series of patients with defined monogenic agammaglobulinemia, 
in whom a block is found after PreB-I stage, which is linked to the absence of pre-B cell 
receptor signaling.
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ABSTRACT
Signaling via the CD19-complex, consisting of CD19, CD81, CD21 and 
CD225, is critically important for B-cell development, differentiation and 
maturation. In this complex, each protein has its own distinct function. 
Over the past decade, 15 patients with antibody deficiency due to 
deficiencies in the CD19 complex have been described. These patients have 
deficiencies in different complex-members. All deficiencies were caused 
by either homozygous or compound heterozygous mutations. Although 
all patients had antibody deficiencies, the clinical phenotype was different 
per deficient protein. We aimed to provide an overview of what is known 
about the function of the different complex-members, knowledge from 
mouse-studies and to summarize the clinical phenotypes of the patients. 
Combining this knowledge together can explain why deficiencies in 
different members of the same complex, result in disease phenotypes that 
are alike, but not the same.
Keywords: Primary antibody deficiencies, CD19, CD21, CD81, B-cell 
receptor co-complex
Highlights: Thus far 15 patients with deficiencies in the CD19-complex 
have been described
CD19/CD81 deficiency seems to cause a more severe phenotype in 
humans
Mouse models indicate that CD21 is more redundant for protective 
antibody responses than CD19 or CD81.
These patients can shed light on the function of the different complex-
members in humans
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INTRODUCTION
Human B cells are commonly identified by the expression of CD19 on their surface. 
This protein is part of the CD19 complex, also referred to as B cell receptor co-complex, 
consisting of CD19, CD81, CD21 and CD225. Being first described in 19911 this complex 
functions as a co-stimulatory element to amplify antigenic signaling via the B-cell receptor 
(BR). Furthermore, it bridges innate and adaptive immunity by signaling complement.2 The 
complex was shown not only to amplify BR-mediated signaling, but also to prolong the 
signal, by stabilizing the BR in plasma membrane lipid rafts and blocking internalization 
of the BR.3 The different proteins all have their own unique function within the complex, 
which is illustrated by mouse experiments in which single elements are knocked-out or 
inhibited.4-6 These experiments have shown that especially correct balance between 
the different elements of the complex is vital for optimal function of the complex. Over 
the past decade, multiple patients with mutations in elements of the CD19 complex 
have been described.7-13 All of these patients suffer from hypogammaglobulinemia and 
most of them have recurrent infections. However, different deficiencies lead to different 
disease phenotypes and specifically to different levels of disease severity. Studying the 
immunobiology of the B cells in these patients has increased our knowledge on the function 
of the individual proteins and the complex as a whole in human B cell immunology. Here, 
we summarize phenotypic and immunobiological characteristics of patients with CD19 
complex deficiencies and link the phenotype that was described to the function of the 
different proteins in the complex.
FUNCTIONAL CHARACTERISTICS
CD19, is exclusively expressed on B cells.14 Already in bone marrow, early B cell precursors 
start expressing CD19 under the influence of the B cell-fate promoting transcription factor 
PAX5.15, 16 From the cytoplasmic Igµ-negative preB-I stage onwards, CD19 expression can 
be detected during B cell precursor development in bone marrow.17 After this stage CD19 
expression is one of the hallmarks of B cells. In the peripheral blood, it remains on the cell 
surface until differentiation into plasma cells. This member of the Ig-superfamily is a 556 
amino acid, 61 kD protein encoded on chromosome 16. Its cytoplasmic tail serves as a 
specialized adaptor protein to recruit multiple kinases including Lyn, ERK, Vav and PI3K 
upon BR-mediated signaling.3 Especially PI3K signaling was shown to be important for 
CD19-signal transduction.18 
The tetraspanin CD81 is crucial for the expression of CD19 on the plasma membrane 
in human B cells. Similar to other tetraspanins it has four hydrophobic transmembrane 
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domains with which it can cross the plasma-membrane four times, these domains flank 
short amino and carboxyl cytoplasmic termini and a small and a large extracellular loop. 
It is encoded on chromosome 11, and widely expressed on the surface of many cells, 
including lymphocytes, brain and liver cells.19, 20 CD81 associates with cell-specific partners 
such as CD19 (and indirectly CD21) on B cells, whereas in T cells it associates with CD4 and 
CD8.21 In addition it can associate with other, ubiquitously expressed molecules in a range 
of cell types. As for the B cells, the 25 kD protein serves as the anchor of the CD19 complex. 
The third member of the CD19 complex is CD21, or complement receptor 2 (CR2), also 
known as EBV receptor.22, 23 Being a complement receptor it facilitates the capture, binding, 
uptake, presentation and clearance of C3d-opsonized immune complexes.24 Additionally it 
lowers the threshold to signal low-dose antigens and it helps in the induction of tolerance 
and generation of immunological memory and differentiation of B cells. Functioning as 
a complement receptor and engaging in CD19-complex mediated antigenic signaling, 
CD21 forms a bridge between the complement system and the adaptive immune system. 
The 145 kDa protein consists of 15 short consensus repeats, a transmembrane domain and 
a short cytoplasmic tail.22, 25 The 19 exons of the CD21 gene are encoded on chromosome 
1. It is expressed on follicular dendritic cells and B cells,2 where it is first detected on naive 
B cells in the peripheral blood. In healthy individuals, the majority of B cells express CD21,26 
but in several diseases including HIV infection, CVID, systemic lupus erythematosus and 
Down syndrome, increased frequencies of CD19+ CD21- cells can be detected.27-30The last 
member of the CD19 complex is CD225 or Interferon-induced transmembrane protein 1 
(IFITM1), previously also known as Leu-13. The IFITM1 gene is located on chromosome 
11 and encodes a 125 amino acid, 14kD protein. It is predicted to cross the membrane 
several times with its two transmembrane domains.31 It additionally has a short N-terminal 
and C-terminal domain and a short cytoplasmic tail. It has a broad expression and is 
largely known to function in cellular adhesion and migration, and in many species is 
has a function in anti-viral immune response signaling.32 Within the CD19 complex, it is 
associating directly to CD81, and via CD81 it is associating with CD21 and CD19. However, 
so far, the significance of these interaction is not clear.33 No deficiencies of this protein 
in humans have been reported so far, neither are mouse models. However, based on the 
broad expression of the protein and its family members, and its as yet unknown function 
on B cells suggest that it is unlikely that a deficiency would lead to a phenotype with an 
isolated immune deficiency. Therefore, we will not further discuss this protein.
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MOUSE KNOCK-OUT MODELS
After identification of the different components of the CD19 complex, mouse 
models were generated to study the functions of the different proteins in B cell biology. 
Independent studies in CD19-/- mice showed the importance of CD19 mediated signaling 
for differentiation in response to antigens.5, 34 Additional studies in CD19 and PI3Kδ 
double deficient mice have shown that combined action of the two proteins is required 
for survival and differentiation of B cells.35 CD19 KO mice had seemingly normal B cell 
development in bone marrow, and normal numbers of B220+ B cells in peripheral blood, 
however these were mainly of a naive phenotype. Serum Ig-levels of CD19 KO mice were 
markedly decreased, indicating a defect in B cell differentiation after antigenic stimulation. 
Especially the response to T-cell dependent antigens was defective in those mice. The 
cytoplasmic domains of mouse and human CD19 are highly homologous and human 
CD19 could replace mouse CD19 function in CD19-/- mice.36
CD81 was studied in three independently generated CD81 KO mouse-models, all of 
which showed reduced CD19 expression and impaired activation of B cells.37-39 Next to that, 
reduced serum immunoglobulin in response to T-cell dependent antigens was observed, 
very similar to CD19 KO mice. CD81 KO mice expressed strongly reduced levels of CD19 on 
the B cell membrane, which is in line with the observation that CD19 is dependent on CD81 
for expression on the plasma membrane. Because of the expression of CD81 in tissues 
other than lymphocytes, these mice additionally showed defects in brain and germ-cells.
Since in mice CD21 (CR2) and CD35 (CR1) are encoded by the same gene through 
alternative splicing, the first studies were done in CD21/CD35-/- mice.40 These mice 
have normal levels of serum IgM and IgG and normal B- and T cell subset distributions. 
However, upon challenge with a T-cell dependent antigen, decreased titers of antigen 
specific immunoglobulins were found.4 This is consistent with studies that used anti-
mouse-CD21/CD35 antibodies to block function of the complement receptors.6 Additionally, 
the CD21/CD35 KO mice had an increased susceptibility for autoimmune diseases.41 These 
results led to the conclusion that CD21 lowers the threshold for signaling by binding to 
complement. Later studies with expression of human CD21 on CD21/CD35-/- mouse cells, 
showed that human CD21 can take over mouse CD21 function, indicating a high level of 
homology between mouse and human CD21-mediated signaling.42 
To study the interaction between CD19 and CD21 within the CD19 complex, 
CD21/35-/- mice were generated that either lack or overexpress CD19.43 It was shown that 
expression levels of both proteins regulate one another, but that CD19 expression regulates 
IgM and IgD expression independent of CD21. Overall, CD19 function was dominant over 
CD21 function and that CD19 regulates B cell signal transduction independent of CD21 
activation.
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Overall, mouse models showed that all members of the CD19 complex are important 
to transduce antigenic signaling in B cells, especially for T-cell dependent antigens. 
Although the signaling is optimal when all proteins are expressed in the correct balance 
and functioning together as one complex, CD19 signaling seems more critical than CD21 
signaling.
ANTIBODY DEFICIENCIES IN PATIENTS
In 2006, we described the first group of patients with mutations in the CD19 complex.7 
Over the past decade, additional patients have been described and so far, 10 patients with 
CD19 deficiency have been reported (Table 1).7, 8, 10, 44, 45 All these patients have homozygous 
or compound heterozygous mutations in CD19, leading to absence of the protein on the 
plasma membrane of B cells. The phenotype of these patients is quite homogeneous, 
all suffered from moderate to severe recurrent respiratory tract infections, starting in 
childhood. Some had additional bacterial infections including diarrhea, skin infections, 
meningitis and conjunctivitis. All patients were reported to have hypogammaglobulinemia 
in the form of low IgG serum titers, and in many of them additional low levels of serum IgA 
and/or IgM were found. In the majority of patients, vaccination responses are reduced and 
some develop IgA-related nephropathy.46 
Additionally, we reported one CD81 deficient patient, who is the only patient with 
CD81 deficiency described so far.9 Her clinical phenotype is much alike the CD19 deficient 
patients, with quite severe recurrent infections and IgA-related nephropathy and 
vasculitis; she was diagnosed with Henoch-Schönlein purpura before the diagnosis of 
CD19 deficiency was made. In this girl, the disease was caused by a homozygous splice 
site mutation that lead to complete absence of CD81 expression. In addition, no CD19 
expression was found on her B cells due to the disruption of the complex by loss of CD81. 
Whereas in CD81 KO models, some residual expression of CD19 was detected on B cells,37-39 
human CD81 deficiency resulted in complete absence of CD19 on the B cell surface.
In all CD19 deficient patients and the CD81 deficient patient, CD20+ B cell counts were 
normal, but expression of CD19 was undetectable or barely detectable. Furthermore, CD21 
expression was reduced on the B cells of these patients, indicating that without CD19, 
the whole complex is disrupted and less CD21 is available on the cells surface. In family 
members who were heterozygous for the mutations, there was reduced CD19 expression 
on the surface of the B cells, however, these individuals had no clinical signs or symptoms 
of immune deficiency, indicating that reduced levels of CD19 do not cause disease. Upon 
antigenic stimulation, calcium influx was reduced or even absent in CD19 and CD81 
deficient patients. This indicates that there is an early defect in activation. Additionally, 
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they all had very few class switched memory B cells, and experiments showed that the 
number of somatic hypermutations in the few memory B cells that were formed in these 
patients, is reduced.47 This indicates a defect in the early phase of memory formation. This 
is further supported by the observation that the memory B cells compartment of CD19 
deficient patients is more affected than the plasma cell compartment.47 Overall, the clinical 
phenotype that was found in human patients with a CD19 or CD81 defect resembled the 
phenotype of the CD19 KO mice, which clearly indicated the necessity of CD19 for a good 
humoral immune response.
In addition to the CD19 deficient patients, over the past six years, four patients with CD21 
deficiency have been reported.11-13 All of them had low IgG serum levels, but interestingly, 
one of them did not suffer from infections, and one patients has been asymptomatic for 
20 years. The phenotype overall seems milder than the phenotype of the CD19 deficient 
patients, with the infections being less severe and more restricted to the respiratory 
tract. However, the first patient that was described by Thiel et al, developed more serious 
infections in his twenties, so it could very well be possible that the other patients will 
develop more serious infections when they reach adulthood. Experimental data suggest 
that reduced memory formation and reduced IgG levels in CD21 deficiency result from a 
suboptimal threshold for activation rather than an incapability to be activated, as seems 
the case for the CD19 deficiency. The data gathered from these patients is in line with the 
function of CD21 as a linker between BR and CD19 by signaling the complement that is 
bound to opsonized antigen, while the BR is activated by the same antigenic-complex. 
Also, mouse data previously suggested that CD21 is more redundant than CD19 in the 
complex function, which was shown by comparison of Ca-influx assays of CD19-deficient 
and CD21-deficient patients.13 These data indicate that a lack of CD21 can be overcome if 
CD19 is still present, but the other way around, CD21 cannot make up for a lack of CD19.
Overall, 10 patients with CD19 deficiency, one with CD81 deficiency and four with 
CD21 deficiency have been described. All of these patients have hypogammaglobulinemia 
and all but one suffer from recurrent infections. However, CD19/CD81 deficiency seems to 
cause a more severe phenotype with overall earlier onset and higher morbidity, which is 
in line with the data from mouse studies, which showed that CD21 is more redundant for 
protective antibody responses than CD19 or CD81. Calcium influx following BCR stimulation 
is absent or strongly reduced in CD19/CD81 deficient patients, but was shown reduced 
only in a complement dependent way in CD21 deficiency. This difference in response 
indicates that CD19 deficiency results in an activation problem, whereas CD21 deficient 
cells can still response, given that the stimulus is strong enough. Therefore, the different 
function of the components of the CD19 complex and their interlinked expression pattern 
in which CD19 is more dominant can explain the heterogeneous phenotypes of patients 
with different genetic deficiencies. Prolonged follow-up of these patients can improve 
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our understanding of the natural course of these deficiencies and provide more detailed 
information on the redundancy of the various elements in specific infections. 
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The CD19 complex and mutations that cause antibody deficiencies. A. The CD19 complex consists of CD19, 
CD81, CD21 and CD225 and signals in conjunction with the B cell receptor, to reduce the threshold for antigenic 
stimulation. B. Positioning of mutations identified in patients that lead to absent or dysfunctional protein when 
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ABSTRACT
Purpose: Deficiencies in CD19 and CD81 (forming the CD19-complex 
with CD21 and CD225) cause a severe clinical phenotype. One CD21 
deficient patient has been described. We present a second CD21 
deficient patient, with a mild clinical phenotype and compared the 
immunobiological characteristics of CD21 and CD19 deficiency.
Methods: CD21 deficiency was characterized by flowcytometric 
immunophenotyping and sequencing. Real-time PCR, in vitro stimulation 
and next generation sequencing were used to characterize B-cell responses 
and affinity maturation in CD21-/- and CD19-/- B cells.
Results: A compound heterozygous mutation in CD21 caused CD21 
deficiency. CD21-/- B cells responded normally to in vitro stimulation and 
AID was transcribed. Affinity maturation was less affected by CD21 than by 
CD19 deficiency. 
Conclusions: Both CD21 and CD19 deficiency cause hypogammaglob-
ulinemia and reduced memory B cells. CD19 deficiency causes a more 
severe clinical phenotype. B-cell characteristics reflect this, both after in 
vitro stimulation as in affinity maturation.
Keywords: CD21, CD19, CD81, hypogammaglobulinemia, primary 
antibody deficiency
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INTRODUCTION 
Genetic defects leading to primary antibody deficiencies (PAD) have been described 
in both the B cell co-receptor complex and the complement cascade.1, 2 Previously 12 
patients have been described with deficiencies in CD19 and CD81, both part of the B cell 
co-receptor complex.3-9 Thus far, only a single patient with a deficiency in CD21, also part of 
this complex, has been described.10 All of these patients exhibit hypogammaglobulinemia 
and impaired vaccination responses and suffer from recurrent infections. However, age of 
disease onset and severity of infections are variable. 
CD19, CD81 and CD21 form, together with CD225, the B cell co-receptor complex 
(Figure 1) that enhances B-cell receptor (BR) mediated signaling.11-14 In this complex, 
CD81 (a tetraspanin) is essential for CD19 expression on the B-cell membrane.4, 15 CD19 
has a cytoplasmic tail with multiple tyrosine-kinase residues, needed for intracellular 
signaling.11, 13, 16, 17 CD21 is also known as complement receptor 2 (CR2) or EBV receptor.18-20 
It is expressed on both B cells and follicular dendritic cells.21 The 145 kDa protein consists 
of 15 short consensus repeats, a transmembrane domain and a short cytoplasmic 
tail. 20, 22 The 19 exons of the CD21 gene are encoded on chromosome 1q32.20 CD21 
facilitates complement binding via C3d-opsonized immune complexes and responses 
to low dose antigens.18, 20. Functioning as a complement receptor, CD21 is involved in 
antigen uptake and presentation, clearance of immune complexes and apoptotic cells, 
induction of tolerance, generation of immunological memory, and survival, activation, 
and differentiation of B cells.21, 23, 24 Studies in mice have been done with CD21/CD35 
knock-out models, since these proteins are encoded by the same Cr2 locus.25 Results from 
these studies indicate that CD21/CD35 deficiency leads to decreased specific antigenic 
antibody responses26-29 and increased susceptibility to autoimmune diseases.30 In several 
immunological diseases such as HIV and autoimmune disorders increased CD21low/- B-cell 
populations can be found.31-34
Since CD81 is required for expression of CD19 on the plasma membrane, patients 
with CD19 and CD81 deficiencies show a highly similar phenotype with recurrent ear-
nose-throat and respiratory infection starting early in childhood.3-9 Most patients develop 
accompanying skin and gastro-intestinal infections. Upon flowcytometric analysis, all 
patients have normal B-, T- and NK-cell numbers, but reduced transitional and memory 
B-cell numbers. Both CD81 deficiency and CD19 deficiency result in reduced frequencies 
of somatic hypermutations (SHM).7 BR activation upon antigenic in vitro stimulation is 
impaired in CD19 and CD81 deficient cells. This emphasizes the necessity of CD19 and 
CD81 in the co-receptor complex to enable BR signaling. 
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The first patient described with a CD21 deficiency10 suffered from recurrent upper 
respiratory tract infections in early childhood. In his early twenties, this patient developed 
recurrent infections, including respiratory tract and gastrointestinal infections. He had 
hypogammaglobulinemia mainly affecting immunoglobulin (Ig)G; IgA levels were slightly 
reduced and IgM levels were normal. Vaccination responses to protein antigens were 
normal, but the response to pneumococcal polysaccharide vaccination was moderately 
impaired. Flowcytometric analysis revealed normal B- T and NK-cell numbers, but reduced 
memory B cells. BR mediated signaling was affected in a complement-dependent manner 
in case of sub-optimal stimulation but unaffected upon strong stimulation. This underlines 
the complement receptor function of CD21 as an enhancer of B cell co-receptor signaling.
Here we describe a second patient (13-year old, male) with a compound heterozygous 
CD21 deficiency resulting in hypogammaglobulinemia. We compared the clinical and 
immunobiological characteristics of CD21 deficiency with CD19 deficiency. We show that 
CD21 deficient B cells have a normal BR mediated signaling upon maximal stimulation in 
vitro, but slightly reduced SHM frequency and class switch recombination (CSR). 
\
\
\
\\\
\\
\
Dual receptor signaling
BcR
Antigen C3d
CD21
CD19
CD81
CD225
Figure 1.
Schematic representation of the B cell co-receptor complex, in which CD81 is vital for CD19 expression on the cell 
membrane,15 CD19 has an intracellular tail with multiple tyrosine-kinase residues11, 16 and CD21 is able to connect 
to the BR via antigen bound complement.18-21 Co-activation of the BR and B cell co-receptor complex, leads to 
dual receptor signaling.45.
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METHODS
Cell samples and ethical approval
Peripheral blood was obtained from the CD21 deficient patient, age-matched healthy 
controls and both parents of the patient with informed consent and according to the 
guidelines of the local Medical Ethics Committees.
Flowcytometric immunophenotyping
Eight-color flowcytometric immunophenotyping of peripheral blood was performed 
on a Canto II (BD BioSciences, San Jose, CA, USA). Data were analyzed using FACS Diva (BD 
Biosciences) and Infinicyt software (Cytognos, Salamanca, Spain). The following antibodies 
were used: CD19-PerCP-Cy5.5 (SJ25C1), CD21-PECy7 (B-ly4), IgD-biotin (IA6-2), CD27-APC 
(L128), CD38-APC-H7 (HB7; all from BD Biosciences), CD24-PB (SN3; Exbio, Prague, Czech 
Republic), CD45-PO (HI30; Invitrogen, Life Technologies, Carlsbad, CA, USA), IgG-PE (K0103-
41437) and IgA-FITC (IS11-8E10; both Miltenyi, Bergisch Gladbach, Germany), polyclonal 
IgD-FITC and IgM-PE (Southern Biotechnologies, Birmingham, AL, USA). CD21 absence was 
determined using the following four CD21 antibodies: CD21-APC (CR2; BD Biosciences), 
CD21-PB (LT21; Exbio), CD21-PE (LB21; Serotech, Hercules, CA, USA), and CD21-PerCP 
(Bu32; BioLegend, San Diego, CA, USA).
Molecular analysis
DNA was isolated from blood granulocytes after separation using Ficoll Hypaque (GE 
Healthcare, Little Chalfont, UK) according to the manufacturer’s instructions. Sequence 
analysis of CD21 was performed following PCR-amplification of the coding regions with 
TaqGoldTM (Life Technologies), followed by direct sequencing on an ABI Prism 3130 XL 
fluorescent sequencer (Applied Biosystems, Bleiswijk, The Netherlands). Primer sequences 
are available upon request. Sequences were analyzed with CLC DNA-workbench software 
(CLCBio, Aarhus, Denmark) and compared to the NCBI reference sequence (NG_013006).
Sorting of B-cell subsets and Ig transcript analysis
Naive, natural effector and memory B cells from 4 healthy controls and the patient 
were sorted from post-Ficoll mononuclear cells on a FACS Aria I (BD Biosciences) using 
the following antibodies: CD19-PerCP-Cy5.5 (SJ25C1), CD27-APC (L128), CD3-FITC (SK7; 
all from BD Biosciences) and polyclonal IgD-PE (Southern Biotechnologies). mRNA was 
extracted using Genelute mammalian total RNA Kit (Sigma-Aldrich, Saint Louis, MO, USA) 
and converted into cDNA. Taqman based RQ-PCR with gene specific primers and probes 
(sequences available upon request) was used to measure CD19, CD21, CD81, CD79A and 
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PAX5 transcript levels as described before.3, 4 Expression levels were normalized to ABL and 
PAX5.
Ca2+ flux analysis
Post-Ficoll PBMCs from the CD21-deficient patient and a healthy control were used 
to determine free intracellular Ca2+ levels before and after stimulation with anti-IgM 
as described previously.35 Ca2+ influxes for the CD19 deficient cells were determined 
previously (Patient CD19-1.1).3, 4
In vitro stimulation
PBMCs were cultured in 24-well plates (2x106 PBMCs per well) in 1 ml of IMDM culture 
medium, supplemented with 10% FCS, penicillin (100U/ml) and streptomycin (100µg/
ml), at 37˚C and stimulated with anti-IgM (10µg/ml) and anti-CD40 (10µg/ml) and either 
hIL-4 (10ng/ml) or hIL-10 (10ng/ml) as described previously.7 After 3 and after 6 days of 
culture cells were harvested and RNA was isolated. This RNA was used to synthesize cDNA. 
Taqman based RQ-PCR with gene specific primers and probes (sequences available upon 
request) was used to measure CD19, AID and ABL transcription levels as described before.7 
AID levels were normalized to ABL and CD19 levels and compared to expression levels in 
unstimulated cells to calculate the fold increase in transcript levels.
Analysis of SHM and CSR
cDNA was prepared following RNA isolation of post-Ficoll PBMCs of patients and age-
matched healthy controls. This cDNA was used to amplify IGA and IGG transcripts using 
VH1-6 consensus BIOMED-2 primers36 and Cγ (3’Cγ-CH1,37) and Cα (IGHA-R,38) primers. 
The primers were adapted for 454 sequencing by adding the forward A, or the reverse 
B adaptor, the ‘TCAG’ key and multiplex identifier (MID) adaptor. PCR products were 
purified by gel extraction with the QIAQuick gel extraction kit (Qiagen, Valencia, CA, USA) 
and Agencourt AMPure XP beads (Beckman Coulter, Fullerton CA, USA). Subsequently, 
the PCR concentration was measured using the Quant-iTTM PicoGreen® dsDNA Assay Kit 
(Invitrogen). The purified PCR products were sequenced on the 454 GS Junior instrument 
using the GS Junior sequencing kit XL+, sequencing kit and PicoTiterPlate kit (454 Life 
Sciences, Roche, Brandford CT, USA) according to the manufacturers recommendations. 
Using the Antigen Receptor Galaxy Tool39 sequences were demultiplexed based on their 
MID sequence and quality checked. FASTA files were uploaded in IMGT HighV-Quest.40 For 
all sequences the subclass of constant region was determined. Uniqueness of sequences 
was determined by V gene usage, amino acid sequence of the CDR3 and C gene usage. 
Only unique, productive sequences were used to calculate the frequency of mutated 
nucleotides in the VH gene (from CDR1 until FR3). 
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In addition, IGG and IGA transcripts were amplified and analyzed as described 
previously.41, 42 The mutation frequency was determined for the VH segment, with exclusion 
of FR1, of each unique transcript.
Statistical analysis
Differences in mutation frequencies in SHM were analyzed using the nonparametric 
Mann-Whitney U-test (1 tailed) and transcript expression differences were analyzed by 
the two-tailed T test for independent samples (P<0.05 was considered significant) in the 
GraphPad Prism program (GraphPad Software, San Diego, CA, USA).
RESULTS
Clinical and immunological presentation/ case report
Our patient was a 13-year old boy, the second child of non-consanguineous Dutch 
parents without family history of recurrent infections or autoimmune diseases. He was 
referred to the department of Pediatrics of the University Medical Centre Groningen for 
evaluation hypogammaglobulinemia, which was discovered in the work-up for a possible 
auto-immune origin of myalgia and rigidity. He did not have a history of recurrent infections. 
No abnormalities were found upon physical examination. Total serum IgG was 4.4 g/l (ref. 
7-16 g/l for age).IgG subclass analysis showed reduced IgG1 (2.5 g/l), reduced IgG2 (0.5 
g/l) and absent IgG4 (<0.1 g/l), whereas IgG3 was normal (0.2 g/l). IgA levels were reduced 
(0.3 g/l (ref. 0.7-4g/l)), as were IgM levels (0.3 g/l, (ref. 0.4-2.3g/l)). Serum IgE levels were in 
the high normal range (109 g/l). He had been vaccinated according to the Dutch National 
Vaccination Program and his antibody titers were within the normal range, however 
additional booster vaccinations with subsequent determination of antibody levels has not 
been done. Autoimmune antibodies were negative. A C1q binding test was performed to 
analyze presence of immune complexes; no abnormalities were found. Analysis of B- and 
T- cell subsets revealed normal B- T- and NK-cell numbers with slightly increased naive B 
cells and reduced memory B cells (Table 1). However, none of the B cells expressed CD21 
(Figure 2A). 
After three years of follow-up, now 16 years old, the patient is in good health and has 
not experienced any (serious) infection. There has been no further reduction in his Ig levels. 
Flowcytometric immunophenotyping
The absence of CD21 expression on B cells was confirmed using different antibody-
fluorochrome combinations with multiple CD21 clones. Furthermore, following fixation 
and permeabilization, CD21 could not be detected intracellularly either (data not shown). 
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Analysis of parental peripheral blood showed a decreased expression of CD21 on the 
surface of B cells in both parents, as compared to healthy controls (Figure 2A). Expression 
of CD19 on the cell membrane was increased in the CD21-deficient patient and to a lesser 
extent in his parents (Figure 2B). CD81 expression was normal in both the patient and his 
parents, as was CD35 (complement receptor 1) expression (data not shown).
Molecular analysis
Sequence analysis of all 19 exons and splice sites of the CD21 gene revealed the 
presence of two heterozygous mutations (Figure 2C, D): a nonsense mutation in exon 2 
(c.424C>T; p. Arg142Stop), and a two-nucleotide deletion in exon 15 leading to a frame 
shift and a premature stop codon (c.2777_2778delTA; p.Ile926SerfsX14). Both mutations 
lead to premature truncations of the protein in such way that the protein lacks its 
transmembrane and cytoplasmic domain. Analysis of the parents revealed that the mother 
was heterozygous for the mutation in exon 2 and the father was heterozygous for the 
exon 15 mutation (Figure 2C). We concluded that these two truncating mutations lead to 
absence of CD21 expression on the cell membrane and in the cytosol of B cells.
Transcript levels of CD19, CD81 and CD21
To study the nature of the increased membrane expression of CD19 on CD21-deficient 
cells, we determined the transcript levels of CD19, CD21 and CD81 in CD27-IgD+ naive, 
CD27+IgD+ natural effector and CD27+IgD- memory B cells of 4 healthy controls and the 
patient (Figure 3A). In all subsets from the patient, CD21 transcripts were severely reduced. 
CD19 transcript levels in all the patient’s subsets were comparable to normal. CD81 and 
CD79A (anchor protein for the BR) transcript levels in the patient, were in normal ranges 
in all subsets. The increased expression of CD19 did not seem to result from altered 
transcriptional regulation.
Table 1. Distribution of B-cell subsets in our CD21 deficient patient at 13 years of age
 B cell subsets % Absolute 
count
(cells/µl)
Normal 
values
(10-16 jr)
 
Transitional B (CD38high/CD24high) 9,5 52 4-108 Within CD19+ gate
Naive Mature (CD38dim/CD24dim/IgD+/CD27-) 81,0 446 87-390 ..
MZ/Natural effector (CD38dim/CD24dim/IgD+/CD27+) 5,3 29 7-90 ..
Memory (CD38dim/CD24dim/IgD-/CD27+) 1,6 9 10-76 ..
Within memory 
B-lymphocytes
....
          IgM 23,0 5-32%
          IgG 39,5 25-74%
          IgA 37,5 14-47%
Plasmablasts 0,3 Within CD19+ gate
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BR signaling
To study the effects of CD21 absence on BR signaling, we analyzed Ca2+ influx following 
stimulation of the patient’s B cells with anti-IgM. CD21-deficient B cells showed a normal 
initial Ca2+ flux from the rough endoplasmatic reticulum into the cytoplasm, which is 
indicative for a normal response upon stimulation with high amounts of anti-IgM (Figure 
3B). In contrast, cells from CD19-deficient patients showed a defective Ca2+ flux after 
maximal stimulation (Figure 3B).3, 4 Thus, signaling via BR upon stimulation is normal in 
CD21 deficiency, but impaired in CD19 deficiency.
In vitro stimulation
We studied whether the absence of CD21 affected the induction of AID transcription, 
since AID is a major regulator in affinity maturation after antigenic stimulation.43 We 
stimulated total PBMCs from the CD21-deficient patient in vitro for 3 or 6 days with 
anti-CD40, anti-IgM and either hIL-4 or hIL-10 to induce transcription of AID. Using 
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c.2777_2888delTA, p.I926SfsX14
A C
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Figure 2.
CD21 deficiency due to a compound heterozygous mutation. A. CD21 membrane expression on B cells of the 
patient (in red), his parents (in purple), a healthy control (in blue) and CD19 negative lymphocytes from the 
healthy control (in grey). B. CD19 membrane expression on B cells of the patient (in red), his parents (in purple),a 
healthy control (in blue) and CD19 negative lymphocytes from the healthy control (in grey). C. Compound 
heterozygous mutations in the CD21 gene of the patient. Both parents carry one of both mutations. D. Schematic 
representation of CD21 with 15 short consensus repeats (SCR). Position of the mutations found here (R142X and 
I926SfsX14) and the mutations found previously (c.1225+1 G>C and W766X, in Italics)10 are depicted.
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real-time quantitative PCR the levels of AID transcripts were determined after stimulation 
and compared to unstimulated cells. To correct for the amount of B cells present in each 
sample, we normalized for CD19 transcripts. AID transcription was upregulated in B-cells 
of healthy controls after 3 days of stimulation and was further enhanced after 6 days of 
stimulation. Induction of AID transcription in B cells from the CD21-deficient patient was 
less than the normal control after 3 days of stimulation. After 6 days of stimulation, the 
patient cells reached the same levels in AID transcripts as the healthy control cells after 
3 days (Figure 3C). These results show that AID transcription can be induced in CD21-
deficient B cells, but at slower pace.
SHM analysis 
To study the effect of CD21-deficiency on the frequency of SHM, we prepared PBMC 
derived cDNA from the CD21-deficient patient, age-matched CD19-deficient patients 
(6-12 years) and aged-matched healthy controls (6-14 years). IGG and IGA transcripts were 
amplified in a PCR reaction with specific primers and PCR products were sequenced using 
next-generation sequencing. The proportion of unique productive sequences in the CD21 
deficiency is comparable to the healthy controls but lowered in the CD19 deficiency (data 
not shown). SHM frequencies in transcripts of the CD21-deficient patient were slightly 
lower than those of age-matched controls (Figure 4A), but significantly higher than in 
CD19-deficient patients. 
These findings are in line with previous analysis of these transcripts in CD19 deficiency.3, 4
Analysis of CSR
To study Ig CSR, we determined the IGG and IGA constant region subclass usage in 
amplified IGG and IGA transcripts prepared from PBMC derived cDNA. Compared to the 
healthy control, usage of downstream IGG regions (IGG2 and IGG4) was reduced in CD21 
deficiency, resulting in increased IGG1 usage. In CD19 deficiency this increased IGG1 usage 
is even more pronounced (Figure 4B). IGA usage in CD21 deficiency was comparable to 
normal, while in CD19 deficiency both IGA1 and IGA2 transcripts were overall strongly 
reduced and could only be amplified by conventional cloning and sequencing (Figure 4B). 
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Figure 3.
Transcription of CD19-complex members and response to in vitro stimulation. A. Expression levels of CD19, CD21, 
CD81 and CD79A in naive, natural effector and memory B cells of controls (n=4) and the CD21-deficient patient, 
normalized to ABL. B. Ca2+ influx in CD21 deficient B cells resembles influx in healthy control cells upon maximal 
stimulation with anti-IgM. Ca2+ influx in CD19-deficient cells is severely reduced upon maximal stimulation with 
anti-IgM. Response to ionomycin is the same in all samples. Ca2+ influx for the CD19 deficiency was performed by 
Van Zelm et al, previously.3 B. AID transcription in CD21-deficient B cells and healthy control B cells after in vitro 
stimulation with anti-IgM, anti-CD40 and either hIL-4 or hIL-10. Expression after 3 and 6 days was normalized to 
ABL and compared to unstimulated cells from the same samples. CD19 expression levels were used to correct for 
the amount of B cells, present in the sample. In CD21-deficient B cells, AID transcription can be induced.
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Figure 4.
SHM and CSR in CD21 and CD19 deficiency compared to in aged matched donors (all samples between 6 years 
and 14 years of age), data from multiple donors was combined for controls (n=4) and CD19 deficiency (n= 4). 
A. SHM frequency determined in unique productive sequences N represents the number of unique productive 
sequences that were analyzed. B. Usage of IG constant gene segments determined for unique productive 
sequences. In CD19 deficiency no NGS data for IgA was available, sequences were all derived from cloning and 
sanger sequencing. The number in the center of the plots represents the number sequences that were analyzed.
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DISCUSSION
We describe the second patient with a CD21 deficiency caused by two compound 
heterozygous mutations in the CD21 gene. Both mutations cause a premature stop-
codon resulting in truncated proteins both lacking their transmembrane and cytoplasmic 
domains. 
In contrast to the first described CD21-deficient patient, this patient has no remarkable 
infections so far, despite his hypogammaglobulinemia. However, at the age of 13, the 
previously described patient was asymptomatic as well, developing recurrent infections 
only during early adulthood.10 Both patients exhibit hypogammaglobulinemia, with 
normal vaccination responses. This indicates that their immune system is capable of 
mounting a seemingly normal immune response. With time, however, infections have 
occurred in the first patient, resulting in the need for intravenous immunoglobulin (IVIG) 
substitution. This in contrast with CD19 and CD81 deficiencies leading to (severe) recurrent 
infections already in childhood, requiring frequent hospital admission, surgery for chronic 
sinusitis and IVIG at early age.3-9 The CD19-deficient patients often have splenomegaly and 
impaired vaccination responses, indicating that defects in CD19-complex can seriously 
impair B-cell function.
CD21 deficiency, like CD19 deficiency, does not lead to a decrease in absolute B-, T- 
and NK- cell numbers. CD21 deficiency leads to increased naive mature B cells and slightly 
decreased memory B cells, whereas CD19 deficiency and CD81 deficiency result in a more 
prominent decrease in transitional (CD81) and memory B cells (both CD19 and CD81). It 
seems that in CD21 deficiency an immune response is mounted upon encounter of an 
antigenic stimulus, but with reduced memory formation, whereas in CD19 and CD81 
deficiency the immune response is severely hampered. This is in line with the observation 
that in CD19 and CD81 deficiency, signaling upon BR stimulation is impaired, while 
calcium influx upon maximal stimulation is unaffected in CD21 deficiency. Previously, 
Thiel et al showed that calcium influx in CD21 deficiency is impaired only in a complement 
dependent manner.10 Thus, hypogammaglobulinemia in CD19 and CD81 deficiency can, 
at least partially, be explained by defective BR signaling, whereas this is intact in CD21 
deficiency.
Interestingly, the CD21-deficient B cells show an increase in CD19 expression on 
the plasma membrane which was not reflected on transcript level. This increased CD19 
expression on the membrane is also seen in CD21- cells found in auto-immune diseases32-34 
and on CD21low/- cells in healthy individuals, although in health very few of those cells can 
be detected. Increased CD19 expression was also found in CD21/CD35 deficient mice.44-46 
In contrast, in CD19 deficiency, CD21 expression is decreased on the plasma membrane. 
This suggests that CD19 and CD21 expression levels are inter-connected. The formation 
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of a regulatory loop between CD19, CD21 and C3 has previously been postulated in 
mouse studies, which also showed that CD19 can function independent of complement 
activation.44, 45 Our results indicate that this is not due to deregulated transcription. Possibly, 
the increased CD19 expression is compensating for the loss of CD21 whereas in case of loss 
of CD19, CD21 cannot compensate and might even be down regulated.
CD21 deficient B cells respond normal to maximal stimulation, but in the patient we see 
a profound hypogammaglobulinemia and a reduction in class switched memory B cells. 
After in vitro stimulation, AID transcription could be induced in patients B cells (largely 
naive B cells). The delay that we see in the patient sample could be caused by the reduced 
number of memory B cells in the patient sample compared to the healthy control, which 
show fast induction of AID after stimulation. It seems that overstimulation or prolonged 
exposure to antigenic stimuli can induce a proper response, but short or weak stimulation 
does not evoke a response. This would be consistent with CD21 acting as a receptor for 
complement: lowering the threshold for a response to stimulation.18-21, 47
Although the number of memory B cells is reduced in CD21 deficiency, they have a 
close to normal frequency of SHM and show a normal ability for CSR, although they seem 
to switch preferentially to the more upstream constant genes. This contrasts with the CD19 
deficiency where SHM frequency is substantially lower and where the skewing towards 
IGG1 is more pronounced. We hypothesize that CD21 negative B cells need strong or 
prolonged stimulation to evoke an antigenic response. However, when this stimulation is 
strong enough, the cells will respond with almost appropriate affinity maturation. CD19-
deficient B cells cannot respond to even these strong stimuli, resulting in disturbed affinity 
maturation. 
In our patient IgE levels are, opposed to IgA and IgG levels in a high-normal range. It 
seems that class-switching to IgE is not hampered, showing that class-switch machinery 
functions correctly and the reduced usage of downstream genes is rather a reflection of 
an impaired secondary germinal center response than inability of CD21 deficient cells to 
switch to distantly located constant regions.
Thus, in CD21 deficiency the hypogammaglobulinemia and impaired memory 
formation seem to result from a defect in signaling threshold rather than from an intrinsic 
inability to form memory cells whereas in CD19 and CD81 deficiency the clinical syndrome 
can be attributed to a defect in B-cell memory formation already during an early phase of 
memory formation.
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CONCLUSIONS 
In conclusion, CD21 deficiency results in reduced numbers of memory B cells. However, 
the fraction of productive unique sequences is normal and SHM frequency is only slightly 
reduced. CSR is intact but shows a slight preference for switching to upstream genes. An 
increased signaling threshold seems to cause of an impaired immune response, resulting in 
hypogammaglobulinemia and reduced memory B cells. This might partially be restored by 
increased CD19 expression. Prolonged or repeated antigen exposure can probably result 
in normal antigen specific memory formation. In contrast, in CD19 deficiency impaired 
BR signaling is seen and therefore a defect in the early phase of memory formation with 
a more sever clinical phenotype. Whereas CD21 and CD19 belong to the same protein 
complex, absence of CD21 gives a milder immunological and clinical phenotype than 
CD19 deficiency.
ACKNOWLEDGEMENTS
The authors would like to thank A. Muggen for technical support with the Ca2+ flux 
assays. And S. Posthumus-van Sluijs for technical assistance.
This work was supported by ZonMW (Vidi grant 91712323 to M.v.d.B.).
The research for this manuscript was (in part) performed within the framework of the 
Erasmus Postgraduate School Molecular Medicine.
REFERENCES
1. Geha, R.S., et al., Primary immunodeficiency diseases: an update from the International Union of 
Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin 
Immunol, 2007. 120(4): p. 776-94.
2. Gathmann, B., et al., The European internet-based patient and research database for primary 
immunodeficiencies: results 2006-2008. Clin Exp Immunol, 2009. 157 Suppl 1: p. 3-11.
3. van Zelm, M.C., et al., An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med, 
2006. 354(18): p. 1901-12.
4. van Zelm, M.C., et al., CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody 
deficiency. J Clin Invest, 2010. 120(4): p. 1265-74.
5. Kanegane, H., et al., Novel mutations in a Japanese patient with CD19 deficiency. Genes Immun, 2007. 8(8): 
p. 663-70.
Chapter 3.2
122
6. Artac, H., et al., B-cell maturation and antibody responses in individuals carrying a mutated CD19 allele. 
Genes Immun, 2010. 11(7): p. 523-30.
7. van Zelm, M.C., et al., Human CD19 and CD40L deficiencies impair antibody selection and differentially 
affect somatic hypermutation. J Allergy Clin Immunol, 2014. 134(1): p. 135-44.
8. van Zelm, M.C., et al., Antibody deficiency due to a missense mutation in CD19 demonstrates the importance 
of the conserved tryptophan 41 in immunoglobulin superfamily domain formation. Hum Mol Genet, 2011. 
20(9): p. 1854-63.
9. Vince, N., et al., Defects in the CD19 complex predispose to glomerulonephritis, as well as IgG1 subclass 
deficiency. J Allergy Clin Immunol, 2011. 127(2): p. 538-541 e1-5.
10. Thiel, J., et al., Genetic CD21 deficiency is associated with hypogammaglobulinemia. J Allergy Clin Immunol, 
2012. 129(3): p. 801-810 e6.
11. Carter, R.H. and D.T. Fearon, CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. 
Science, 1992. 256(5053): p. 105-7.
12. van Noesel, C.J., A.C. Lankester, and R.A. van Lier, Dual antigen recognition by B cells. Immunol Today, 
1993. 14(1): p. 8-11.
13. Sato, S., et al., Regulation of B lymphocyte development and activation by the CD19/CD21/CD81/Leu 13 
complex requires the cytoplasmic domain of CD19. J Immunol, 1997. 159(7): p. 3278-87.
14. Tedder, T.F., M. Inaoki, and S. Sato, The CD19-CD21 complex regulates signal transduction thresholds 
governing humoral immunity and autoimmunity. Immunity, 1997. 6(2): p. 107-18.
15. Shoham, T., et al., Building of the tetraspanin web: distinct structural domains of CD81 function in different 
cellular compartments. Mol Cell Biol, 2006. 26(4): p. 1373-85.
16. Bradbury, L.E., V.S. Goldmacher, and T.F. Tedder, The CD19 signal transduction complex of B lymphocytes. 
Deletion of the CD19 cytoplasmic domain alters signal transduction but not complex formation with TAPA-1 
and Leu 13. J Immunol, 1993. 151(6): p. 2915-27.
17. Tuveson, D.A., et al., CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. 
Science, 1993. 260(5110): p. 986-9.
18. Aegerter-Shaw, M., et al., Expansion of the complement receptor gene family. Identification in the mouse of 
two new genes related to the CR1 and CR2 gene family. J Immunol, 1987. 138(10): p. 3488-94.
19. Iida, K., L. Nadler, and V. Nussenzweig, Identification of the membrane receptor for the complement 
fragment C3d by means of a monoclonal antibody. J Exp Med, 1983. 158(4): p. 1021-33.
20. Weis, J.H., et al., A complement receptor locus: genes encoding C3b/C4b receptor and C3d/Epstein-Barr virus 
receptor map to 1q32. J Immunol, 1987. 138(1): p. 312-5.
21. Carroll, M.C. and D.E. Isenman, Regulation of humoral immunity by complement. Immunity, 2012. 37(2): p. 
199-207.
22. Moore, M.D., et al., Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (complement 
receptor type 2) of human B lymphocytes. Proc Natl Acad Sci U S A, 1987. 84(24): p. 9194-8.
23. Erdei, A., et al., Expression and role of CR1 and CR2 on B and T lymphocytes under physiological and 
autoimmune conditions. Mol Immunol, 2009. 46(14): p. 2767-73.
123
CD21 deficiency
3.2
24. Twohig, J., et al., Defective B cell ontogeny and immune response in human complement receptor 2 (CR2, 
CD21) transgenic mice is partially recovered in the absence of C3. Mol Immunol, 2007. 44(13): p. 3434-44.
25. Molina, H., et al., A molecular and immunochemical characterization of mouse CR2. Evidence for a single 
gene model of mouse complement receptors 1 and 2. J Immunol, 1990. 145(9): p. 2974-83.
26. Ahearn, J.M., et al., Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell 
response to T-dependent antigen. Immunity, 1996. 4(3): p. 251-62.
27. Molina, H., et al., Markedly impaired humoral immune response in mice deficient in complement receptors 1 
and 2. Proc Natl Acad Sci U S A, 1996. 93(8): p. 3357-61.
28. Pozdnyakova, O., et al., Impaired antibody response to group B streptococcal type III capsular polysaccharide 
in C3- and complement receptor 2-deficient mice. J Immunol, 2003. 170(1): p. 84-90.
29. Marchbank, K.J., et al., Expression of human complement receptor 2 (CR2, CD21) in Cr2-/- mice restores 
humoral immune function. J Immunol, 2000. 165(5): p. 2354-61.
30. Rettig, T.A., et al., Evasion and interactions of the humoral innate immune response in pathogen invasion, 
autoimmune disease, and cancer. Clin Immunol, 2015. 160(2): p. 244-254.
31. Doi, H., S. Tanoue, and D.E. Kaplan, Peripheral CD27-CD21- B-cells represent an exhausted lymphocyte 
population in hepatitis C cirrhosis. Clin Immunol, 2014. 150(2): p. 184-91.
32. Moir, S., et al., Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment 
in HIV-infected viremic individuals. J Exp Med, 2008. 205(8): p. 1797-805.
33. Suryani, S., et al., Differential expression of CD21 identifies developmentally and functionally distinct subsets 
of human transitional B cells. Blood, 2010. 115(3): p. 519-29.
34. Wehr, C., et al., A new CD21low B cell population in the peripheral blood of patients with SLE. Clin Immunol, 
2004. 113(2): p. 161-71.
35. Muggen, A.F., et al., Basal Ca(2+) signaling is particularly increased in mutated chronic lymphocytic 
leukemia. Leukemia, 2015. 29(2): p. 321-8.
36. van Dongen, J.J., et al., Design and standardization of PCR primers and protocols for detection of clonal 
immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the 
BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia, 2003. 17(12): p. 2257-317.
37. Tiller, T., et al., Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR 
and expression vector cloning. J Immunol Methods, 2008. 329(1-2): p. 112-24.
38. Berkowska, M., Generation of an Immunocompetent B-cell repertoire, in Immunology. 2012, Erasmus 
University: Rotterdam. p. 175.
39. Moorhouse, M.J., et al., ImmunoGlobulin galaxy (IGGalaxy) for simple determination and quantitation of 
immunoglobulin heavy chain rearrangements from NGS. BMC Immunol, 2014. 15(1): p. 59.
40. Alamyar, E., et al., IMGT((R)) tools for the nucleotide analysis of immunoglobulin (IG) and T cell receptor 
(TR) V-(D)-J repertoires, polymorphisms, and IG mutations: IMGT/V-QUEST and IMGT/HighV-QUEST for NGS. 
Methods Mol Biol, 2012. 882: p. 569-604.
41. Driessen, G.J., et al., B-cell replication history and somatic hypermutation status identify distinct 
pathophysiologic backgrounds in common variable immunodeficiency. Blood, 2011. 118(26): p. 6814-23.
Chapter 3.2
124
42. van Zelm, M.C., et al., Human CD19 and CD40L deficiencies impair antibody selection and differentially 
affect somatic hypermutation. J Allergy Clin Immunol, 2014.
43. Revy, P., et al., Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form 
of the Hyper-IgM syndrome (HIGM2). Cell, 2000. 102(5): p. 565-75.
44. Hasegawa, M., et al., CD19 can regulate B lymphocyte signal transduction independent of complement 
activation. J Immunol, 2001. 167(6): p. 3190-200.
45. Barrington, R.A., et al., Uncoupling CD21 and CD19 of the B-cell coreceptor. Proc Natl Acad Sci U S A, 2009. 
106(34): p. 14490-5.
46. Haas, K.M., et al., Complement receptors CD21/35 link innate and protective immunity during Streptococcus 
pneumoniae infection by regulating IgG3 antibody responses. Immunity, 2002. 17(6): p. 713-23.
47. Shishido, S.N., et al., Humoral innate immune response and disease. Clin Immunol, 2012. 144(2): p. 142-58.
125
CD21 deficiency
3.2

PART 4
Dysregulation of the
PI3K-PTEN balance

4.1Chapter
A mediastinal mass in a young child
Marjolein Wentink1, Daphne Peeters2, Mirjam van der Burg1, 
Clementien Vermont3, Liesbeth Duijts4¥, Gertjan J. Driessen2,3¥* 
1Dept. of Immunology, Erasmus MC, University Medical Center Rotterdam, 
Rotterdam, The Netherlands 
2 Dept. of Pediatrics, Juliana Children`s Hospital, Haga Teaching Hospital, 
The Hague, The Netherlands 
3 Dept. of Pediatrics, division of Immunology and Infectious diseases, 
Sophia Children`s Hospital, Erasmus MC, Rotterdam, The Netherlands
4 Dept. of Pediatrics, divisions of Respiratory Medicine and Allergology, and 
Neonatology, Sophia Children`s hospital, Erasmus MC, Rotterdam, The 
Netherlands 
 
¥ These authors contributed equally 
Submitted manuscript

131
Case report APDS
4.1
CASE PRESENTATION
A three-year-old girl was referred to a pediatric pulmonologist for dyspnea and recurrent 
upper respiratory tract infections (RTIs). The patient was born full term to unrelated Dutch 
parents after an uneventful pregnancy and birth. The year before presentation she had 
suffered from a pneumonia and over 10 upper RTIs. Apart from the recurrent RTIs, which 
started in infancy, her medical history was not significant and did not include allergies 
or eczema. An adenotonsillectomy was performed at the age of two years, and she was 
treated with multiple antibiotic regimens and inhalation therapy with salbutamol and 
corticosteroids, with no relieve of symptoms. 
PHYSICAL EXAMINATION FINDINGS
A dyspneic girl was seen. She had a small stature (-1,7 SD for age), but her weight 
was appropriate for her age and height. Chest examination revealed mild intercostal 
retractions and bilateral rhonchi, crackles and wheezing. Examination of the heart and 
abdomen showed a regular cardiac rate without murmurs and a non-tender abdomen 
with enlargement of spleen and liver. The patient did not have palpable lymph nodes. 
DIAGNOSTIC STUDIES
A chest X-ray showed bilateral pulmonary infiltrations. A spirometry controlled in- and 
expiratory high resolution chest CT-scan showed compression of the left main bronchus by 
an undefined subcarinal mediastinal mass as well as diffuse bronchiectasis with atelectasis 
(Figure 1A). A chest MRI confirmed the mediastinal mass and indicated it was not a cyst. 
It also showed bilateral hilar lymphadenopathy. Ultra-sound of the abdomen showed 
hepatosplenomegaly without lymphadenopathy or other abnormalities. Examination of 
the trachea by bronchoscopy revealed tracheal deviation to the right, due to compression, 
nodular hyperplasia of the bronchial mucosal surface and purulent secretion. Pathological 
evaluation of the broncho-alveolar lavage fluid showed no signs for malignancy, however, 
it was highly cellular, with 44% T cells (ref. 5.9%±7.7) and only 8% B cells (ref. <5%). 
Microbiological examination of sputum was positive for Streptococcus pneumoniae. 
Cultures where negative for (atypical) mycobacteria. Serum levels of immunoglobulins 
were normal, but the antibody response to pneumococcal polysaccharide vaccination 
was insufficient. Also, despite previous vaccination, antibodies against poliovirus, 
pneumococcal conjugate vaccination and H. Influenzae were not detected in serum. The 
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patient was further evaluated by a pediatric immunologist. Upon immunological evaluation 
reduced memory B-cell subsets were found in the peripheral blood (Table 1), compatible 
with the possibility of an antibody deficiency. To rule out malignancy and to provide 
decompression of the trachea, the mediastinal mass was removed by uncomplicated 
thoracoscopic surgery, under full anesthesia without any complications. Macroscopically, 
the mass seemed to consist multiple lobular lymph nodes. Pathological review confirmed 
the mass to be lymphatic tissue with dysplastic germinal centers. No malignant cells were 
found.  Other diagnostic tests revealed no signs of viral, bacterial, (atypical) mycobacterial 
or yeast infections or most common immunological diseases.
Question: What is the diagnosis in this young girl?
Genetic evaluation 3 years after presentation revealed a mutation in PIK3CD, exon 13 
(c.1537G>A) resulting in an amino acid substitution p.E525K.
Diagnosis: Activated PI3Kdelta syndrome (APDS)
DISCUSSION
Over the past years, multiple patients with gain-of-function mutations in PI3Kdelta 
have been described. These patients suffer from Activated PI3Kdelta syndrome (APDS) and 
share clinical characteristics such as recurrent RTIs, bronchiectasis, hepatosplenomegaly, 
generalized lymphadenopathy and antibody deficiency. Because 96% of APDS patients 
Figure 1.  
Compression of the left main bronchus by an undefined subcarinal mediastinal mass (indicated with an arrow) 
and diffuse bronchiectasis with atelectasis on the chest CT-scan of a 3-year-old with recurrent RTIs. 
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suffer from recurrent RTIs, many patients will be examined by the pulmonologist first. 
Infections are not the only thoracic problem in APDS patients. Most patients have 
pulmonary damage including bronchial wall thickening, tree-in-bud opacities and/or 
bronchiectasis, which are seen on chest CT-scans from a young age onwards and which 
are not in all cases related to the severity of RTIs. Additionally, lymphadenopathy is a 
common problem in APDS because of the fast proliferation but poor differentiation of B 
and T cells. Lymphadenopathy can present in the form of nodular lymphoid hyperplasia 
in the mediastinum and intestines, and in the mucosal tissue of the bronchus. Mediastinal 
lymphadenopathy may cause severe obstruction of the airways, increasing the risk of RTIs 
Table 1. Immunophenotyping of peripheral blood, at the time of presentation at the immunologist  
Immunophenotyping of 
lymphocyte subsets
% Absolute count 
(x109/L)
Normal values 
(2-5 yr)
White Blood cell count   5,4  
Lymphocytes 19,3 1,0 1.7-6.9
CD3+ T-lymphocytes   0,84 0.9-4.5
CD16.56+CD3- NK-cells   0,27 0.1-1.0
CD19+ B-lymphocytes   0,23 0.2-2.1
B-cell subsets      
   Transitional B (CD38high/CD24high) 60,0 138 24-333
   Naive Mature 
(CD38dim/CD24dim/IgD+/CD27-)
28,6 66 170-1691
   MZ/Natural effector 
(CD38dim/CD24dim/IgD+/CD27+)
5,8 13 16-226
   Memory (CD38dim/CD24dim/IgD-/CD27+) 1,5 3 20-149
          IgM 28%   3-32%
          IgG 36%   13-63%
          IgA 36%   4-42%
   Plasmablast 3,9    
T-cell subsets      
  CD4+ T-lymphocytes 29,9 0,3 0.5-2.4
     - Naive (CD45RO-CCR7+CD27+CD28+) 6,4    
     - Central Memory (CD45RO+CCR7+CD27+CD28+) 5,8    
     - Effector Memory (CCR7-) 87,5    
  CD8+ T-lymphocytes 57,5 0,5 0.3-1.6
     - Naive (CD45RO-CCR7+CD27+CD28+) 2,8    
     - Central Memory (CD45RO+CCR7+CD27+CD28+) 0,5    
     - Effector Memory (CCR7-) 95,0    
CD4/CD8 ratio 0,5    
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and secondary pulmonary damage. Because of the wide spectrum of possible clinical 
manifestations, including bronchiectasis, lymphoproliferation and auto-immune disease, 
APDS patients need a thorough pre-operative screening.
Recent cohort studies show that, besides infections, patients with APDS often have 
auto-immunity (34% of patients) and lymphoid malignancy (13% of patients). Furthermore, 
viral infections can have a more severe course. Especially EBV and CMV infections are 
poorly controlled. This may result in severe illnesses such as encephalitis and disseminated 
infections. Recurrent EBV infections also increase the risk for lymphoma. Therefore, it 
is crucial that these patients are carefully monitored by both the pulmonologist and 
immunologist.
Immune phenotyping revealed an inversed CD4/CD8 ratio and increased transitional 
B-cells. APDS is caused by dysregulation of the PI3K-AKT pathway. Heterozygous gain-
of-function mutations in two genes (PIK3CD and PIK3R1), which together encode the 
heterodimer PI3Kdelta, cause hyperactivation of the PI3K-AKT-pathway in patient’s 
lymphocytes.
Analysis of the phosphorylation status of AKT can show increased activation of the 
PI3K-AKT-pathway. This has been described in APDS patients, and was confirmed in our 
patient by phospho-flow. The hyper-activation causes fast proliferation and differentiation 
of naive T-cells into short-lived effector T-cells, skewing the subset distribution of CD4+ and 
CD8+ T-cells and reducing the memory T-cell subset. Within the B-cell compartment, there 
is increased apoptosis and reduced memory formation, leading to antibody deficiencies.
Patients with antibody deficiencies are treated with immunoglobulin replacement 
therapy and preventive anti-microbial agents. Since APDS not only causes an immune 
deficiency but also dysregulation, some of the symptoms respond well to steroid-
treatment. However, specifically in young children, long-term use of prednisone and 
related drugs can cause serious side effects. Therefore, other treatment options are 
currently being investigated. The mammalian target of rapamycin (mTOR) signaling 
pathway is downstream of PI3K-AKT signaling. In APDS, dysregulated mTOR signaling is 
one of the driving mechanisms of disease, causing fast proliferation and differentiation and 
preventing memory formation in the immune system. Rapamycin inhibits mTOR signaling 
and is therefore considered as a possible treatment to reduce immune dysregulation. 
Rapamycin is currently used by both pediatric and adult immunologists in the treatment of 
APDS. Additionally, specific PI3Kdelta-inhibitors might be of use to inhibit PI3K-AKT hyper 
activation. The first results of trials with these inhibitors as a treatment for APDS in adults 
are promising. Furthermore, inhalation therapy with PI3Kdelta-inhibitors might prevent 
extensive pulmonary damage.
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CLINICAL COURSE
One-and-a-half years after removal, the mediastinal mass was back to its original 
size. Meanwhile, the patient received subcutaneous immunoglobulin substitution and 
maintenance antibiotics, although these did not entirely prevent RTIs. Her symptoms 
responded well to steroid treatment and she became prednisone dependent. After the 
discovery of APDS in 2013, the patient’s DNA was sequenced revealing an APDS-causing 
mutation. Treatment with rapamycin was started and prednisone could be tapered and 
stopped. The frequency of RTIs decreased and she rarely needed antibiotic treatment. 
She and her mother reported she was more energetic and additionally her height growth 
increased. Physical examination revealed no more hepatosplenomegaly. She is carefully 
monitored by the pulmonologist and immunologist, because of her current pulmonary 
damage, future risks of auto-immunity and malignant transformation, and for the effects 
of long-term rapamycin treatment. 
CLINICAL PEARLS
Patients with APDS commonly suffer from recurrent RTIs (96%) and therefore will 
mainly present first at the pulmonologist
A mediastinal mass as part of generalized lymphadenopathy may obstruct the airways 
in APDS, increasing the risk of pulmonary infections and persistent severe damage
Patients who suffer from APDS induced pulmonary problems benefit from dual 
treatment with immunoglobulin and immune suppression
Rapamycin is a treatment option in children with APDS who are steroid dependent. 
Steroid treatment in especially in young children can have severe effects on growth and 
development. In adults, PI3Kdelta inhibitors can be considered.
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ABSTRACT
PTEN deficiency in humans is associated with PTEN Hamartoma Tumor 
Syndromes (PHTS). It causes increased activation of the PI3K/Akt pathway 
and we here show that the humoral immune response is deregulated 
resulting in CSR and SHM deficiency. This is clinically apparent in part of 
the PHTS patients as antibody deficiency. In conclusion, PI3K/Akt signaling 
is important for the human B-cell response to antigens and deregulated 
signaling is implicated in the pathophysiology of antibody deficiency. 
Keywords: PTEN, PI3K, Akt, AID, PHTS, Cowden, macrocephaly, 
immunodeficiency, Common Variable Immunodeficiency Disorders, 
B-cell, Activated PI3K Delta Syndrome, PIK3CD, hypogammaglobulinemia, 
primary antibody deficiency, somatic hypermutation, class switch 
recombination.
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TO THE EDITOR
Autosomal dominant germline mutations in PTEN are associated with PTEN Hamartoma 
Tumor Syndromes (PHTS), including Cowden syndrome, characterized by hamartomas, 
malignant tumors, macrocephaly and neurodevelopmental delay.1 Immunodeficiency 
has recently been reported in PHTS,2 but the mechanism of disease is not clear. Therefore 
we performed a detailed study of the peripheral B-cell development of nine patients with 
PHTS, to explore the role of PI3K/Akt signalling in the humoral immune response in these 
patients (details are described in the supplemental methods). 
We included nine patients bearing heterozygous germline mutations in PTEN (clinical 
and genetic details are given in Table E1, Figure E1 and methods in the Online repository). 
Three patients suffered from hypogammaglobulinemia fulfilling the Common Variable 
Immunodeficiency Disorders (CVID) diagnostic criteria, of whom one has been previously 
reported as a case of hypogammaglobulinemia and macrocephaly.3 Peripheral B-cell subset 
distribution was studied by analysing the relative and absolute B-cell subset size of two 
naive and three memory B-cell subsets (Figure 1). PHTS patients were compared to 45 age 
matched healthy controls. Absolute counts of transitional B-cells were increased (Figure 
1A). Data of three memory B-cells subsets showed that absolute counts of class switched 
CD27+IgG+ memory B-cells, which originate from a T-cell dependent differentiation 
pathway,4 were decreased in PHTS (Figure 1B). We observed a trend towards a more severe 
reduction of switched memory B-cell subsets in patients with hypogammaglobulinemia 
(data not shown). In summary, the T-cell dependent B-cell response is deregulated in PHTS. 
Analysis of peripheral T-cell subsets revealed that the absolute counts of naive, memory 
and effector CD4+ and CD8+ T-cells were comparable to healthy controls (Figure E2 in the 
Online Repository). 
CSR was studied at the molecular level by analysing the IGG and IGA subclass distribution 
of IGH transcripts (Figure 2). We compared the IGG and IGA subclass distribution between 
patients and controls by Chi-square analysis. In PHTS IgG subclass distribution differed 
significantly from controls (P=0.002), which was the result from an increase of CSR to IgG1 
and a decrease to IgG2. CSR distribution seemed more clearly affected in PHTS patients 
with hypogammaglobulinemia compared to PHTS without hypogammaglobulinemia 
(data not shown). Similar results were obtained for CSR to IgA2, which was significantly 
reduced in PHTS (P<0.0001). So, mutations in PTEN cause abnormalities in CSR to distal IgG 
and IgA subclass regions. 
The SHM frequency was determined by mutational analysis of the IGG and IGA 
transcripts (Figure 2C). Mutational analyses showed a significant decreased SHM frequency 
in both IGG and IGA transcripts of PHTS patients, indicating that SHM is affected in PTEN 
deficiency. In mice levels of AID expression are regulated by PI3K/Akt signalling.5-7 We 
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hypothesize that in PHTS patients decreased SHM is caused by a deregulating effect of Akt 
signalling on AID expression and function, which has to be established in future studies. 
PTEN deficiency results in abnormalities in B-cell development indicative of CSR deficiency 
and SHM deficiency, which is clinically apparent as hypogammaglobulinemia in part of the 
PHTS patients. Our data provide evidence that increased PI3K/Akt signaling deregulates 
the human humoral immune response, which is in accordance with recent observations in 
patients with autosomal dominant activating mutations in the PIK3CD gene, coding for the 
P110δ subunit of PI3K.8, 9 These patients suffer from recurrent infections and have a variable 
severe antibody deficiency, similar to PHTS patients. The clinical outcome of an individual 
patient most likely depends on inter-individual differences in any of the multiple factors 
Figure 1. Naive and memory B-cell subsets in PHTS patients.
Absolute counts of transitional and naive mature B cells (A) and of three memory B-cell subsets (B). C. relative 
distribution of six memory B-cell subset. Data are compared to age-matched normal controls using the Mann-
Whitney test. Individual data points are displayed and bars indicate medians. Significant values are indicated: 
P<0.01 after Bonferroni correction for multiple comparison. PHTS; PTEN hamartoma Tumor Syndrome.
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that regulate PI3K/Akt signaling and the complex interplay between immune function, 
(auto)antigen exposure, and the timing and cell types involved in immune activation. 
PHTS patients with hypogammaglobulinemia fulfilled the CVID diagnostic criteria. 
We explored whether mutations in PTEN were present in a cohort of 42 CVID patients, 
but no mutations could be detected. PHTS patients show similarities to patients with 
activation mutations in PIK3CD gene:8, 9 a variable antibody deficiency, a tendency to 
develop malignancies, respiratory infections and as far as immunologically findings are 
concerned, increased Akt activity, an increase of the proportion of transitional B cells 
and a decreased proportion of memory B cells. Differences are also present, such as the 
absence of hamartomas and macrocephaly in patients with activating mutations of the 
PIK3CD gene, which can be explained by the fact that P110δ is lymphoid specific. Despite 
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Figure 2. IgA and IgG class switching and somatic hypermutation in IGH transcripts of PHTS patients.
A. Schematic representation of the constant regions in the IGH locus and frequencies of IGG and IGA transcripts 
in PHTS (n=9) were compared to controls (n=8). In the center of each plot the number of analyzed transcripts is 
depicted. B. Somatic hypermutation analysis of IGG and IGA transcripts; the number of analysed transcripts is 
indicated. Grey bars represents the 9 PHTS patients and black bars controls. 
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these differences, our study and the study of Angulo et al.8 and Lucas et al.9 show that 
PI3K/Akt signaling is important for the human B-cell response to antigens and that 
deregulated signaling is implicated in the pathophysiology of antibody deficiency. We 
propose that deregulated PI3K/Akt signaling is an attractive disease causing mechanism to 
be further explored in CVID patients, because heterozygous germline mutations in PTEN 
mutations have been associated with auto-immunity, lymphoproliferation, an increased 
risk to develop malignancies and intestinal nodular interstitial hyperplasia, which are all 
commonly encountered in CVID.
ACKNOWLEDGEMENTS
The authors thank Benjamin Bartol, Jessica Buijs and Jules Meijerink for technical 
assistance.
REFERENCES
1. Marsh, D.J., et al., Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-
Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet, 1998. 7(3): 
p. 507-15.
2. Browning, M.J., et al., Cowden’s syndrome with immunodeficiency. J Med Genet, 2015. 52(12): p. 856-9.
3. Cogulu, O., et al., Two cases of macrocephaly and immune deficiency. Clin Dysmorphol, 2007. 16(2): p. 81-
4.
4. Berkowska, M.A., et al., Human memory B cells originate from three distinct germinal center-dependent and 
-independent maturation pathways. Blood, 2011. 118(8): p. 2150-8.
5. Omori, S.A. and R.C. Rickert, Phosphatidylinositol 3-kinase (PI3K) signaling and regulation of the antibody 
response. Cell Cycle, 2007. 6(4): p. 397-402.
6. Suzuki, A., et al., Critical roles of Pten in B cell homeostasis and immunoglobulin class switch recombination. 
J Exp Med, 2003. 197(5): p. 657-67.
7. Werner, M., E. Hobeika, and H. Jumaa, Role of PI3K in the generation and survival of B cells. Immunol Rev, 
2010. 237(1): p. 55-71.
8. Angulo, I., et al., Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and 
airway damage. Science, 2013. 342(6160): p. 866-71.
9. Lucas, C.L., et al., Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit 
p110delta result in T cell senescence and human immunodeficiency. Nat Immunol, 2014. 15(1): p. 88-97. 
145
Humoral immune response in PTEN deficiency 
4.2
PTEN SUPPLEMENT, ONLINE REPOSITORY
METHODS
Patients
We included nine patients bearing heterozygous germline mutations in PTEN gene. 
Three patients suffered from hypogammaglobulinemia and six did not have a clinically 
apparent antibody deficiency. Data of these patients were compared to 45 age matched 
normal controls. Furthermore, we screened 42 CVID1 patients for the presence of mutations 
in PTEN. The research was approved by the Medical Ethical Committee of the Erasmus MC. 
Patient histories
Patient 1 is a 43 year old woman who suffered from recurrent upper and lower respiratory 
tract infections from childhood and was diagnosed with hypogammaglobulinemia 
at the age of 12 years. Immunoglobulin replacement was initiated. At the age of 30 a 
hemithyroidectomy was performed because of nodular hyperplasia. At the age of 31 a 
melanoma in situ was removed. Thereafter, she suffered from several episodes of lobar 
pneumonia resulting in bronchiectasis despite immunoglobulin replacement. Switched 
memory B-cells were virtually absent. Furthermore, she was treated for a candida 
esophagitis. Dermatologic evaluation showed keratotic plugs hand palms, lipoma’s and 
café-au-lait maculae. At the age of 40 the diagnosis of Cowden disease was made, based on 
the clinical history, including macrocephaly, and heterozygous mutations in PTEN. Patient 
2 is 12 years old and is a daughter of patient 1. She was known with developmental delay 
and macrocephaly, without specific diagnosis. Cerebral MRI showed cortical dysplasia. She 
appeared to have the same PTEN mutation as her mother and the diagnosis of Cowden 
disease was made at the age of 10 years. She suffered from recurrent ENT infections in 
childhood, which improved after adenotomy. Screening for immunodeficiency revealed 
IgA deficiency, IgG2 deficiency and specific polysaccharide antibody deficiency (decreased 
response to pneumococcal polysaccharide vaccination; response to serotype 1,3,4,5,23 
measured 4 weeks after Pneu23 vaccination <0.1 mg/ml). Within two years of follow 
up, she developed a mild hypogammaglobulinemia at the age of 12 years. She is not 
receiving immunoglobulin replacement therapy, because of a stable clinical condition. 
She is suffering from recurrent upper respiratory tract infections during the winter periods, 
which respond well to antibiotic treatment. 
Patient 3 is a 6 year old boy, who has previously been published as a case of macrocephaly 
and hypogammaglobulinemia (case 2).2 This child of non-consanguineous parents suffered 
from recurrent febrile episodes from the age of three months. Several dysmophic features 
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were observed, including macrocephaly. There was a mild developmental delay and 
brain MRI revealed delay in myelinisation of the periventricular white matter. He suffered 
from frequent upper respiratory tract infections. At the age of 21 month a diagnosis of 
hypogammaglobulinemia was made, in the presence of a decreased response to tetanus 
(<100IU/ml). Immunoglobulin replacement was initiated, after which the frequency 
and severity of infections improved. At the age of 6 years, a de novo heterozygous PTEN 
mutation was detected. 
Patients without antibody deficiency:
Patient 4 Macrocephaly, delayed motor and metal development.
Patient 5 Macrocephaly, delayed motor and metal development.
Patient 6 Macrocephaly, delayed motor and metal development, periventricular white 
matter abnormalities on cerebral MRI.
Patient 7 Macrocephaly, delayed motor and metal development, lipoma’s.
Patient 8 Macrocephaly, resection of sigmoid carcinoma.
Patient 9 Macrocephaly, resection borderline ovarian tumor, fibroadenoma breast. 
Flow cytometry
Six-color flow cytometric immunophenotyping of peripheral blood was performed on 
a CantoII (BD Biosiences) and data were analyzed using FACS Diva software (BD Biosiences). 
The following monoclonal antibodies were used: CD19-PerCP-Cy5.5, CD19-PE-Cy7, CD19-
APC (all SJ25C1), CD5-APC (  L17F12 ), CD45-PerCP (2D1), CD19-APC (SJ25C1), CD38-PE, 
CD38-APC and CD38-PE-Cy7 (  HB7), CD27-APC (L128), CD3-PerCP-Cy5.5 (SK7) and CD8-
APC-Cy7 (SK1) all from BD Biosciences, polyclonal IgD-FITC, IgD-PE and IgM-PE (all from 
Southern Biotechnologies), polyclonal IgG-FITC (Kallestad), IgA-FITC and IgA-PE (IS11-8E10; 
Miltenyl Biotech), CD24-FITC ( gran-B-ly-1; Sanquin), CD21-PE ( LB21; Serotech), CD45RO-
FITC ( UCHL1; DAKO), CD4-PC7 (SFCI12T4D11)  and CD45-RA-RD1 (2H4; all from Beckman 
Coulter). The cell counts of the peripheral B-cell subsets (transitional B-cells, naive mature 
B-cells, and six memory B-cell subsets) and T-cell subsets were compared to age matched 
controls. 
Analysis of SHM and CSR
SHM were analyzed as described previously.3 In short in VH3-Cα, VH4-Cα, VH3-Cγ, and 
VH4-Cγ transcripts were amplified, cloned into pGEM-T easy vector (Promega, Madison, WI) 
and sequenced using Sanger sequencing on the ABI Prism 3130 XL fluorescent sequencer 
(Applied Biosystems). Sequences were analyzed with the International ImMunogGeneTics 
database (IMGT, http://imgt.cines.fr) V-quest analysis tool in order to assign the V, D and J 
segments but also for the identification of SHM’s. The mutation frequency and IGHV isotype 
and subclass distribution was determined for VH gene of each transcript in 7 controls and 9 
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patients. The number of transcripts and mutations frequency per individual can be found 
in Online repository Table E2.
Statistical analysis
Statistical analysis was performed with Graphpad Prism 5.0 software (Graphpad 
Software, San Diego, CA, USA). Whenever two groups with continuous outcomes were 
compared, the Mann-Whitney test was applied. For categorical variables the χ2 or Fisher’s 
exact tests were used. For groups with unequal variances, an unpaired t-test with Welsh 
correction was applied. Statistical significance was set at two sided P<0.05. In case of 
multiple comparisons we performed Bonferroni correction for multiple testing.
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Figure E2. Naive, memory and effector T-cell subsets in PHTS patients.
Absolute numbers of CD4+ (A) and CD8+ (B) T-cell subsets. C. Relative distributions of CD4+ and CD8+ T-cell 
subsets. Naïve T-cells (CD45RA+CD27+); memory T-cells (CD45RA-CD27+) and effector T-cells (CD45RA+/-CD27-).
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ABSTRACT
Background: Mutations in PIK3CD and PIK3R1 cause activated PI3K-δ 
syndrome (APDS), by dysregulation of the PI3K-AKT pathway.
Methods: We studied precursor and peripheral B-cell differentiation 
and apoptosis via flowcytometry. Furthermore, we performed AKT-
phosphorylation assays and somatic hypermutations and class switch 
recombination analysis.
Results: We identified 13 patients of whom 3 had new mutations in 
PIK3CD or PIK3R1. Patients had low total B-cells numbers with increased 
frequencies of transitional B cells and plasmablasts, while the precursor 
B-cell compartment in bone marrow was relatively normal. Basal AKT 
phosphorylation was increased in lymphocytes from APDS patients and 
natural effector B cells where most affected. PI3K mutations resulted in 
altered SHM and CSR and increased apoptosis.
Conclusions: The B-cell compartment in APDS patients is affected by the 
mutations in PI3K. There is reduced differentiation beyond the transitional 
stage, increased AKT phosphorylation and increased apoptosis. This B-cell 
phenotype contributes to the clinical phenotype.
Keywords: B cells, PI3Kδ, APDS, B-cell differentiation, apoptosis
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INTRODUCTION 
Gain of function mutations in PIK3CD and PIK3R1 have been described to cause 
activated PI3K-δ syndrome (APDS),1 which is also referred to as p110 delta activating 
mutation causing senescent T cells, lymphadenopathy, and immunodeficiency (PASLI).2 
The disease is characterized by recurrent respiratory tract infections, progressive airway 
damage, EBV and CMV viremia and lymphopenia due to dysregulation of the PI3K-AKT 
pathway in T cells.1-6 Earlier studies have described hyperactivity in the PI3K-AKT pathway 
in patient T cells, resulting in increased proliferation and fast differentiation into short 
living effector T-cells. This results in reduced memory formation and reduced numbers of 
CD4+ T cells, resulting in ineffective control of infections. Moreover, patients have been 
reported to suffer from B-cell lymphomas,7 primary sclerosing cholangitis8 and hyper IgM 
syndrome.9, 10 These latter reports suggest B cell involvement in APDS. Additionally one 
patient has been described, who lacked the pα-subunit of PI3K, which caused absence of 
B-cell lineages and agammaglobulinemia.11 Moreover, the first APDS patient described, 
was identified in a cohort of children with primary B-cell immunodeficiencies.12 Recent 
studies on patients with loss of function mutations in Phosphatase and tensin homolog 
(PTEN), the oppositional counterpart of PI3K, have indicated that hyperactivation of the 
PI3K-AKT pathway leads to reduced antibody production and T cell lymphopenia.13, 14 This 
indicates that besides T cells, the B cells can be heavily affected in APDS.
PI3K is critically important in B-cell development and function.15-22 It can be activated 
via multiple surface receptors like the B-cell receptor (BCR),21 CD19 and TLRs19, 22 and in 
turn, PI3K can activate AKT via induction of PIP3.16, 17, 23 Phosphorylated AKT regulates 
multiple downstream effectors,24 executing different cellular functions such as regulation 
of metabolism, growth and proliferation (via mTOR),25-27 and transcriptional regulation (via 
FoxO).28, 29 Furthermore, mice lacking PTEN show that the PI3K-AKT signaling cascade is 
needed for proper induction of AID, which is the main regulator of somatic hyper mutation 
and class switch recombination.18, 30, 31 All of these downstream effectors of AKT have specific 
functions in the different developmental stages of B cells, indicating that dysregulation 
of this signaling network has major impact on B-cell development, homeostasis and 
maturation.32
We describe 13 patients with genetically confirmed APDS, suffering from recurrent 
infections. Our aim was to specifically investigate the precursor and peripheral B-cell 
compartment in these patients. We show a skewed distribution of the B-cell subsets in 
peripheral blood, while the composition of the precursor B-cell compartment was relatively 
normal. Additionally, we show that the pAKT/AKT ratio is disturbed in various B-cell subsets 
and that B-cell memory formation is hampered. Furthermore, B cells from APDS patients 
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show an increased rate of apoptosis. All of this contributes to hypogammaglobulinemia 
and recurrent infections.
MATERIALS AND METHODS
Cell samples and ethical approval
From all patients DNA from blood granulocytes, after separation using Ficoll Hypaque, 
was available for Sanger sequencing and mutation confirmation. Frozen bone marrow 
samples were available from three patients, fresh bone marrow was available from one 
patient. Frozen peripheral blood mononuclear cells were available in variable amounts 
from six patients. From some patients, additional material could be collected during 
clinical visits. Peripheral blood was obtained from the patients and (age matched) healthy 
controls, with informed consent and according to the guidelines of the local Medical Ethics 
Committees. Clinical data were provided by treating physicians.
Flowcytometric immunophenotyping of peripheral blood and bone marrow
Eight-color flowcytometric immunophenotyping of peripheral blood was performed 
on a Canto II (BD Biosciences, San Jose, CA, USA). Data were analyzed using FACS Diva (BD 
Biosciences) and Infinicyt software (Cytognos, Salamanca, Spain). Antibodies against the 
following markers were used: CD16-PE (3G8), CD4-PerCP-Cy5,5 (SK3), CD3-APC (SK7), CD38-
FITC (HB7), CD21-APC (B-ly4), TCRgd-PE-Cy7 (11F2), IgG-PE (G18-145) (all BD Biosciences), 
CD27-BV421 (O323) IgD-FITC (IA6-2), IgM-PerCP-Cy5,5 (MHM-88), IgM-BV510 (MHM-88), 
CD5-PE (UCHT-2), IgD-PerCP-Cy5,5 (IA6-2) (all Biolegend, San Diego, CA, USA) CD45-PO 
(HI30), IgE-FITC (H15701) (all Invitrogen, Carlsbad, CA, USA), CD8-FITC (UCH-T4), CD56-PE 
(C5.9) (both Cytognos), CD45RA-APC-Alexa750 (2H4), CD19-Pe-Cy7 (J3-119), CD24-APC-
Alexa750 (ALB9), CD38-APC-Alexa750 (LS198-4-3) (all Beckman Coulter, Fullerton, CA, USA) 
IgA-FITC (IS11-8E10), IgA-PE (IS11-8E10) (both Miltenyi, Bergisch Gladbach, Germany).
Bone marrow mononuclear cells were firstly isolated using Ficoll Hypaque (GE 
Healthcare, Little Chalfont, UK) according to the manufacturer’s instructions, and frozen 
in liquid nitrogen. Prior to staining, cells were thawed and washed. Flowcytometric 
immunophenotyping of bone marrow samples was performed on a LSR Fortessa (BD 
BioSciences). For extracellular staining we used antibodies against the following markers: 
IgM-BV510 (MHM-88), CD38-BV605 (HIT2), CD20-PB (2H7, all Biolegend), CD34-APC (8G12), 
IgD-PeCF594 (IA6, both BD BioSciences), CD19-PC7 (J3-119, Beckman Coulter, Fullerton, 
CA, USA) and CD10-APC-C750 (Cytognos). For intracellular staining we used antibodies 
against IgM-PerCPcy5.5 (MHM-88, Biolegend), TdT-FITC (HT6, Supertechs, Rockville, MD, 
USA) and CD79a-PE (HM47 Beckman Coulter). We analyzed the data in Infinicyt software 
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Version 1.8 (Cytognos). Annexin and 7-AAD staining was performed using the FITC Annexin 
V Apoptosis Detection Kit I (BD Biosciences) together with the antibodies for extracellular 
staining of the bone marrow, according to manufacturer’s instructions.
Molecular analysis
Sequence analysis of PIK3CD and PIK3R1 was performed following PCR-amplification 
of the regions that harboured previously described mutations with TaqGoldTM (Life 
Technologies) or Expand long template PCR system (Roche, Basel, Swiss), followed by 
direct sequencing on an ABI Prism 3130 XL fluorescent sequencer (Applied Biosystems, 
Bleiswijk, The Netherlands). Primer sequences are available upon request. Sequences were 
analyzed with CLC DNA-workbench software (CLCBio, Aarhus, Denmark) and compared to 
the NCBI reference sequences (NM_005026 and NM_181523).
Phospho-flow
For phospho-flow analysis, freshly isolated or previously frozen and thawed PBMC`s 
were rested for 1 hour in medium without FCS and stained with anti-CD20-BV421 (2H7, 
Biolegend) prior to stimulation with anti-IgM (Southern Biotech, Birmingham, AL, USA) and 
anti-CD19 (J3-119, Beckman Coulter). PMA was used as positive control. Cells were fixed 
using Cytofix (BD Biosciences) buffer according to manufacturer’s protocol. After fixation, 
cells were washed and incubated with anti-CD19-PC7 (HIB19, Biolegend) for 15 minutes 
at room temperature prior to permeabilization with Perm Buffer III (BD-Biosciences) 
according to manufacturer’s protocol. Cells were then stained with antibodies against 
pAKT-Alexa488 (55/PKBa/Akt) or AKT-alexa488 (M89-61) (both BD Biosciences),CD3-BV711 
(UCHT-1, BD Biosciences), CD27-APC (L128, BD Biosciences), CD56-BV510 (HCD56, 
Biolegend), and IgD-PE (SBA) for 30 minutes at room temperature and analysed on an LSRII 
flow cytometer (BD Biosciences). Different T cell and B-cell subsets were analysed for AKT 
and pAKT expression using Infinicyt software. pAKT/AKT ratio`s where calculated using 
mean fluorescent intensities.
SHM and CSR analysis
SHM and CSR were analyzed as described previously.33, 34 In short, IGA and IGG 
transcripts were amplified from PBMC-derived cDNA of patients, data for healthy controls 
were collected previously.34 These transcripts were purified and sequenced using 454 
sequencing. Using IMGT HighV-Quest35 and an extended version the Antigen Receptor 
Galaxy Tool.36, 37 Sequences were analyzed for AID targeting, SHM and CSR. 
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Analysis of apoptosis after in vitro stimulation
Frozen PBMCs from patients (n=3) and healthy controls (n=5) where thawed and 
cultured 24-well plates (1x106 PBMCs per well) in 1 ml of RPMI + HEPES culture medium, 
supplemented with 10% FCS, penicillin (100U/ml) and streptomycin (100µg/ml) at 37˚C 
and stimulated with either anti-Ig antibodies (mix of anti-IgM, anti-IgA and anti-IgG, 10ug/
ml) and anti-CD19 antibody (2ug/ml) or with PMA (20nM). Unstimulated cells where used 
as a negative control. Cells where harvested after 3, 6 and 24 hours. For the last time-point 
2 patient samples and 4 healthy control samples could be included. The cells where stained 
with tryphane blue and counted in a Countess II FL (Life-technologies), to determine the 
number of living cells per well. Before culturing and at each time-point and stimulation 
condition flow cytometric analysis of the cells was performed using antibodies against 
the following targets: CD27-BV421 (O323), IgM-BV510 (MHM-88), CD38-BV605 (HIT2), 
Annexin-V-APC (all Biolegend), Fixable Viability Dye eFluor® 520 (eBioscience), CD20-PE 
(L27), IgD-PeCF594 (IA6, both BD BioSciences), CD24-APC-Alexa750 (ALB9), CD19-PC7 (J3-
119, both Beckman Coulter). After staining, cells were fixed in 1% paraformaldehyde prior 
to flow cytometric analysis on a LSR Fortessa (BD BioSciences). Analysis was performed 
using Infinicyt software Version 1.8 (Cytognos).
Statistical analysis
Relative distributions of B-cell subsets were analyzed using a two-tailed T-test, (p<0.05 
was considered statistically significant) and pAKT/AKT ratio`s, AID targeting frequencies, 
and apoptosis rates were compared using the non-parametric Mann-Whitney U test 
(p<0.05 was considered statistically significant) in the GraphPad Prism program (GraphPad 
Software, San Diego, CA, USA).
RESULTS
Mutation analysis and patient identification
We identified 13 patients from nine different families (Table 1). Nine patients were 
heterozygous for the previously described E1021K (c.3061G>A) mutation,1, 2 one carried 
the previously described E525K (c.1537G>A) mutation,2 and one patient a novel R929C 
(c.27845C>T) mutation (Figure 1). This variant is mapped to the catalytic domain of p110δ, 
like the E1021K mutation. This patients has a comparable clinical phenotype as patients 
with proven pathogenic mutations and pAKT was increased in all lymphocyte subsets (as 
discussed below), thus we concluded that this mutation is disease causing. We identified 
one patient with a new heterozygous N564K (c. 1692C>G) mutation in PIK3R1 ( 1), which is 
located in the SH2 domain of PIK3R1 coding for the p85α regulatory subunit. This mutation 
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is predicted to influence binding to p110δ. Again, clinical phenotype and pAKT status 
matched APDS patients. Additionally, we identified one patient with a mutation in a splice-
site of PIK3R1: (c.1425+2A>T), which is the same site that harbors a previously described 
mutation.4
Clinical phenotype
All patients were diagnosed with an immune deficiency prior to mutational analysis. 
Our cohort consists of both children and adults (age range: 3y- 43y) (Table 1). Five patients 
are female and eight are male. All patients suffered from both upper and lower respiratory 
tract infections. Most infections were found to be caused by S. pneumonia and H. influenza. 
For 11 patients Ig-levels were determined. IgG was either normal (n=6/11) or decreased 
(n=5/11). IgA levels were reduced in four out of 11 patients and IgM levels were either 
normal (n= 6/11) or increased (n= 5/11). In seven patients vaccination responses against 
S. pneumoniae (polysaccharide vaccine) were tested; none of them responded to this 
vaccination. Where other vaccination responses were determined, these were normal. 
In 11 patients CT-chest results were available, showing bronchiectasis in two out of 11 
patients, atelectasis in three out of 11 patients and thickening of the bronchial wall in 
five out of 11. Evident splenomegaly (confirmed by either ultrasound or CT-scan) was 
reported in three patients, and another patient has had episodes with splenomegaly. Most 
patients were treated with Ig-substitution (either subcutaneously or intravenously) (n=8) 
and/or prophylactic antibiotics (n=7). Two patients receive immunosuppressive drugs 
to treat their immune dysregulation and one patient is treated with tacrolimus because 
of a renal transplant. Patient PI3K-1 was treated successfully with a hematopoietic stem 
cell transplantation. Since then, his hepatosplenomegaly resolved. Patient PI3KR1-1 
who harbors a heterozygous mutation in the SH2 domain of PIK3R1, coding for the p85α 
regulatory subunit, additionally suffers from macrophephaly, tracheomalacy and a double 
aortic arch in the context of megalencephaly-capillary malformation syndrome (MCAP). 
Figure 1.
Schematic representation of the PIK3CD and PIK3R1 proteins and their major domains. Indicated in red are the 
mutations found in this study.
C-lobeN-lobeHelicalC2RBDABD
iSH2 SH2SH2SH3 PP BH
c.1425+1 G>A
splice site mutation
N334K C416R
E525K E1021K
PIK3CD: p110δ catalytic subunit
PIK3R1: p85α regulatory subunit
N564K
R929C
c. 1425+2 A>T
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B-cell differentiation in peripheral blood and bone marrow
For all patients, data on total lymphocyte counts was available. In 9 out of 13 patients 
fresh PBMC were available for phenotypical analysis. Total B cell numbers were normal 
(n=3/13) or decreased (n= 10/13) and total T cell numbers were normal (n=9/13) or 
decreased (n=4/13) (Table 1). Upon extended B-cell subset analysis we observed a relative 
increase in transitional (IgMD+, CD38+, CD24+, CD27-) B cells (upto 60%) in the majority of 
our patients (Figure 2A). In addition, we found a relative increase in plasma blasts (CD38hi, 
CD27hi) in all patients (Figure 2A), which were almost exclusively IgM positive. The naive 
(IgM/IgD+, CD27-), natural effector (IgD+, CD27+) and memory B-cell subsets (IgD-, CD27+) 
where relatively low in most patients (Figure 2A). Further dissection of the memory B cell 
compartment showed that the distribution of both non-switched memory B cells (IgM+ 
and/or IgD+, CD27+) and switched memory B cells (IgA+ or IgG+ , CD27+ or CD27-) was highly 
variable among patients, with a marked decrease in IgG+ CD27+ memory B cells (Figure 
2B).CD27- switched memory B-cell subsets38 where not different between patients and 
controls. Considering the IgA+ CD27+ memory B-cell subsets, we can distinguish patients 
with either normal or reduced numbers, however, division of the patients in these two 
groups is not associated with the type of mutation, age or another factor.
From 4 patients, bone marrow samples were available (3 frozen previously, 1 fresh 
sample) for flow cytometric immunophenotyping. cyCD79a expression was used as B-cell 
marker. Upon first analysis of proB cells (CD19- cyIgM-, IgMD-), preB-I cells (CD19+ cyIgM-, 
IgMD-), preB-II cells (CD19+, cyIgM+, IgMD-) and immature B cells (CD19+, cyIgM+, IgM+ 
IgDdim/+), relative B-cell precursor subsets distribution was comparable between patients 
and controls (n=3) (Figure 2C). However, upon extended analysis, including CD34, TdT 
and CD20 expression, both the preB-I and the preB-II cells can be dissected in smaller 
populations. Here, differences in population sizes between controls and patients were 
observed (Supplemental Figure 1A, B), especially the CD34- TdT+ subsets with in the preB-I 
subset is increased in 3 out of 4 patients. We also found that the CD20 relative distribution 
of CD20+ and CD20- cells is disturbed in preB-I cells from patients (Supplemental Figure 
1C).Furthermore, we found an increase in CD19- B cells in patients. On average 1,1% (range: 
0,0%- 2,2%) of CD19- cells was found in controls; in patients this ranged from 3,3% up 
to 36.6%. These cells were not pro-B cells and did not express CD38, and thus were not 
plasma cells. Upon staining with Annexin V combined with 7-AAD, cells that were positive 
for both markers showed a dim CD19 expression (Supplemental Figure1D), indicating that 
the CD19- cells might be apoptotic cells.
pAKT in B-cell subsets
To determine the effect of the mutations in PI3K on AKT phosphorylation, we set up 
a phospho-flow assay to determine the ratio of pAKT/AKT in the patients and controls. 
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Figure 2. Immunophenotyping of B cells in peripheral blood (control n=8, APDS n=7) and bone-marrow 
(control n=3, APDS n=4).
A. Transitional, naïve and natural effector B cells from patients are significantly decreased, compared to controls, 
plasmablasts are relatively increased. (medians and interquartile range are indicated) B. Within the memory B cell 
compartment, specifically the IgG+ CD27+ subset is decreased in APDS patients. (medians and interquartile range 
are indicated) C. relative distribution of proB cells (CD19- cyIgM-, IgMD-), preB-I cells (CD19+ cyIgM-, IgMD-), preB-II 
cells (CD19+, cyIgM+, IgMD-) and immature B cells (CD19+, cyIgM+, IgM+ IgDdim/+) is comparable between patients 
and controls. (red lines represent the median).
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We could discriminate B, T and NK cells, and within the B cells, 4 subsets: CD27- IgD+ naive 
B cells, CD27+ IgD+ natural effector B cells, CD27+ IgD- memory B cells and CD27- IgD- B 
cells. We determined levels of pAKT and AKT in all subsets, in order to compare the pAKT 
expression to the total AKT expression. The total AKT expression was lower in the patients 
(Figure 3A). We found an increase in the pAKT/AKT ratio in the unstimulated cells from the 
patients, which was most prominent in the CD27+ IgD+ fraction (Figure 3B). There was no 
difference between patients with mutations that were previously described and patients 
with new mutations. Upon stimulation with B-cell specific stimuli (anti-CD19 with anti-IgM) 
or PMA, control and patient cells showed increased pAKT levels, confirming the specificity 
of our assay (Supplemental Figure 2).
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Figure 3. Phospho-flow analysis of APDS lymphocytes and control lymphocytes. 
A. Normalized histograms pf pAKT expression of unstimulated total B cells, T cells and NK cells from pooled 
healthy controls (dark grey) and APDS patients (red). B. pAKT/AKT ratios of unstimulated samples from healthy 
controls (n= 8) and APDS patients (n=8). B-cell subsets where defined as: naive (IgD+, CD27-), natural effector (IgD+ 
CD27+) and memory B cells (IgD- CD27+) (error bars represent SEM). 
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SHM and CSR analysis
We studied the effect of PI3K mutations on SHM in sequences from IGG and IGA in 7 
patients and compared them to a cohort of healthy controls.34 In one patient (PI3K-4.1), 
we were unable to obtain IGG transcripts; this is consistent with the lack of IgG memory B 
cells in this patient. In another patient (PI3KR-2) we could not amplify any IGA transcripts. 
In one patient (PI3K-3) we could not amplify any IGA or IGG transcripts. There were no 
differences between patients and controls in CDR3-length or VDJ-gene family usage. 
The frequency of SHM is on average lower in patients compared to controls, although 
not significantly. When patients are compared to controls based on age, most patients 
are in the low-normal range. However, between individual patients the results are highly 
variable, with a few patients that have markedly decreased SHM frequencies (Figure 4A). 
There was no difference in the ratios of replacement/silent mutations, neither in the frame 
work regions, nor in the CDR-regions indicating normal antigen selection. We determined 
the constant gene region usage in all sequences and compared each individual patient to 
4 age-matched controls. In class switch recombination within IgA subclasses there seemed 
to be a trend in the patients towards reduced IgA2 usage. Within the IgG subclasses, there 
is a reduction in IgG2 and IgG4, the more distal gene segments, in the patients (Figure 
4B). Although our data on SHM and CSR suggest reduced ability of AID to initiate these 
processes, the targeting of AID is not significantly different between patients and controls 
(Figure 4C).
Apoptosis after in vitro stimulation
Since we observed abnormalities in CSR in some of the APDS patients, we aimed to 
study CSR in vitro in two patient samples and healthy control samples. However, upon 
stimulation of naive B cells in vitro, all of the patients cells where dead after three days in 
culture (data not shown). Therefore, we stimulated total PBMCs from three patients and 
five healthy controls for a short period in vitro with B cell specific stimulation (anti-CD19 
and anti-Ig antibodies) and aspecific stimulation (PMA), to see if stimulation induced 
apoptosis in different B-cell subsets. After three and six hours of culture, we found reduced 
numbers of live cells in the wells containing the patients PBMCs (Figure 5a). After 24 hours, 
cell numbers where reduced in all wells, including the control wells. We stained the cells for 
Annexin V and a fixable viability dye combined with surface markers to enable detection 
of early apoptotic cells (Annexin V+, viability dye-) and late apoptotic cells (Annexin V+, 
viability dye+) within different B cells subsets. At all time-points, the number of both early 
and late apoptotic cells was increased in the patients B cells (Figure 5b and c) and in the 
patients non-B lymphocytes (data not shown). The apoptosis rate was not associated with 
stimulation. Within the B cells, we identified transitional B cells (CD38hi, CD24hi) naïve B cells 
(CD27-, IgM+ and/or IgD+), natural effector B cells (CD27+, IgD+) and memory B cells (CD27+, 
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Figure 4. Analysis of SHM frequency, CSR and AID targeting in patients and healthy controls.
A. Median SHM frequency of controls (black dots) and APDS patients (red squares) B. Schematic overview of IGH 
locus and relative distribution of Ca and Cg subclass usage in patients and age matched healthy controls. Error 
bars in healthy controls represent SEM C. AID targeting represented by the percentage of SHM at AID targeting 
motifs in the patients and age matched healthy controls. (red lines represent the median).
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Figure 5. Analysis of in vitro apoptosis in B cells in patients (n=3 for 3 and 6 hours, n=2 for 24 hours) and 
healthy controls (n=5 for 3 and 6 hours, n=4 for 24 hours).
A. Number of life cells per well in controls (light grey) and patients (dark grey) after 3, 6 and 24 hours. B+C. Mean 
relative amount of early apoptotic cells (Annexin V+, viability dye-) and late apoptotic cells (Annexin V+, viability 
dye+) within the total B cell compartment in controls and patients after 3, 6 and 24 hours. (error bars represent 
the SEM). Patients samples where significantly different from the control samples (P<0.05, determined by Mann 
Whitney) but stimulation did not increase apoptosis rates. D. Distribution of life cells (green) early apoptotic 
cells (yellow) and late apoptotic cells (orange) within different B cell subsets in patients and controls at 3, 6 and 
24 hours without stimulation in vitro. B-cell subsets where defined as: transitional (CD38hi, CD24hi), naive (IgD+, 
CD27-), natural effector (IgD+ CD27+) and memory B cells (IgD- CD27+) (error bars represent SEM).
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IgD-). At all time-points we observed more early and late apoptotic B cells in the patients 
samples (Figure 5d, Figure S3) than in the control samples. This effect was stronger in the 
transitional and naïve B cell subsets than in the natural effector and memory subsets.
DISCUSSION
In our cohort we identified 11 patients with known mutations in PIK3CD and two 
patients with new mutations in PIK3R1. Total peripheral blood B cells were reduced, 
and peripheral blood B-cell subsets showed a skewing towards transitional B cells and 
increased plasma blasts in most patients. In bone marrow, increases in CD19- cells and in 
CD34- TdT+ cyIgµ- cells were detected. Phospho-flow analysis showed increased pAKT/AKT 
ratios in unstimulated patient cells, which was observed in all B-cell subsets. Levels of SHM 
were decreased in some patients, and CSR seemed skewed in the majority of the analyzed 
patients.
Patients have difficulties producing sufficient amounts of functional memory B cells and 
plasma cells. This is reflected in the absent response to vaccination with the polysaccharide 
S. Pneumoniae vaccine, a T-independent response. However, in a few patients in our 
cohort other vaccine responses (all T-dependent) were tested and those were found to be 
normal. This is in line with previous publications, in which the response to Tetanus toxoid 
was found to be normal.1, 5, 32
The phenotype and functional consequences for PI3KCD or PI3KR1 deficiency is 
described as highly variable.5 In line with this, we find a great inter patient variability in 
the B cell compartment of our patients. In combination with the low number of PI3KR1 
patients in our cohort, we cannot draw conclusions on what discriminates these two 
groups of patients. Until now, no major differences have been reported.38 
Mutations in PI3K can affect maturation and differentiation of B cells and in many 
stages of development.39 In the bone marrow, stepwise development is regulated by many 
transcriptional activators that in some instances depend on BR-signaling. PI3Kδ has been 
shown to play an important but non-essential role at the pre-B-cell receptor checkpoint 
in bone marrow.40 P110δ deficient mice show a normal B-cell development41 since p85α 
was shown to be able to take over the role of P110δ role in autonomous pre-BR signaling.42 
However, in these patients over-active signaling because of constitutive activation of 
the PI3K-AKT pathway may cause disturbance at the check-point. This might lead to cells 
routing to alternative maturation pathways because of increased proliferation signals 
and increased tonic signaling at the pre-B I stage might cause increased apoptosis. We 
hypothesize that the increase of CD34- TdT+ cells that we observe in our patients, might be 
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the result of alternative maturation pathways. The loss of CD19 expression could be one of 
the first markers of apoptotic cells.
After differentiation in the bone marrow, transitional B cells move to the peripheral 
blood, where they can encounter antigens. In APDS patients, the number of transitional 
B cells is relatively increased, mainly because the numbers of all of the other subsets 
are decreased. This might indicate that cells do not easily pass the phase of antigenic 
stimulation. This might be due to an already hyperactive metabolic state of cells that not 
have encountered antigen yet, as indicated by our phospho-flow results. This may lead to 
cell death rather than differentiation. 
A relation between PI3K and the induction of AID has been described in mice and in 
patients with PTEN mutations before.14, 18, 29 According to our data, AID targeting seems to 
be intact, however, SHM frequencies are either reduced or in the lower normal range and 
there is reduced usage of the downstream IGG genes (IGG2 and IGG4). Switching to these 
gene segments is seen more often when B cells enter the germinal center for a second 
time, to undergo a second round of affinity maturation. Our data suggest that cells can 
switch to IgA and IgG in a primary response, but only few cells enter the germinal center 
for a second time. This is supported by the finding that the CD27- memory compartment, 
which is formed in the first response to an antigen, of our patients is comparable to normal, 
but the CD27+ IgG+ compartment is significantly reduced. 
Previously, increased spontaneous apoptosis rates were observed in subsets of CVID 
patients.43-45 To test if apoptosis could contribute to the reduced memory B-cell formation 
in APDS, we stimulated cells from APDS patients in vitro and assessed the relative amounts 
of early and late apoptotic cells. Our data indicate increased apoptosis in all B-cell subsets of 
APDS patients, which is not dependent on stimulation. Although memory cells from APDS 
patients also show increased apoptosis, it seems that the naive compartment (transitional 
B-cells and naive B-cells) are more prone to apoptosis than the memory compartment 
(natural effector B-cells and memory B-cells).
CONCLUSIONS
We conclude that the novel mutations in PIK3CD and PIK3R1 we found in our cohort 
lead to APDS with a comparable clinical phenotype as has been described earlier and 
with comparable increased pAKT status in multiple B-cell subsets. Our data show that the 
clinical phenotype is not only due to reduced effector function of CD8+ T cells. There are 
reduced effector and memory B-cell compartments, which have aberrancies in SHM and 
CSR. The reduced memory formation might be caused by increased apoptosis of the B 
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cells. All of this contributes to the hypogammaglobulinemia and subsequent infections 
that are seen in these patients.
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Supplementary figure 1. Abnormal populations in bone marrow.
A+B. Subsetting of preB-I cells (A) and preB-II cells (B) based on CD34 and TdT expression. Patient samples show 
an increase in CD34- TdT+ cells, compared to healthy controls. Healthy control plots consists of pooled data from 
three healthy controls, mean percentage is indicated with the range in brackets. C. CD20 expression in preB-I 
cells. Patient samples have a higher percentage of CD20+ preB-I cells. D. Expression of CD19, Annexin V and 7-AAD 
in live B cells (green), early apoptotic B cells (blue) and late apoptotic B cells (orange), represented as histograms 
that are normalized for population size.
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Supplementary figure 2.
Phospho-flow analysis of pAKT after stimulation. Normalized histograms of pAKT expression of unstimulated 
(grey), CD19/IgM stimulated (red) and PMA stimulated (green) total B cells, T cells and NK cells of pooled healthy 
controls and APDS patients. All subsets respond to aspecific stimulation with PMA, but only the B cells respond 
to anti-CD19/anti-IgM stimulation.
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Supplementary figure 3.
Distribution of life cells (green) early apoptotic cells (yellow) and late apoptotic cells (orange) within different 
B cell subsets in patients and controls at 3, 6 and 24 hours with B cell specific stimulation (anti CD19 + anti-Ig 
antibodies) or aspecific stimulation (PMA) in vitro. B-cell subsets where defined as: transitional (CD38hi, CD24hi), 
naive (IgD+, CD27-), natural effector (IgD+ CD27+) and memory B cells (IgD- CD27+) (error bars represent SEM).
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ABSTRACT 
Pathogenic gain-of-function mutations in the gene encoding phospho-
inositide 3-kinase delta (PI3Kδ) cause Activated PI3Kδ Syndrome (APDS), a 
disease characterized by humoral immunodeficiency, lymphadenopathy 
and an inability to control persistent viral infections including EBV and CMV. 
Understanding the mechanisms leading to impaired immune response is 
important to optimally treat APDS patients. Immunosenescence of CD8+ 
T cells was suggested to contribute to APDS pathogenesis. However, the 
constitutive activation of T cells in APDS may also result in T cell exhaus-
tion. Therefore, we studied exhaustion of the CD8+ T cell compartment in 
APDS patients and compared them to healthy controls and HIV patients, 
as a control for exhaustion. The subset distribution of the T cell compart-
ment of APDS patients was comparable to HIV patients with decreased 
naive CD4+ and CD8+ T cells and increased effector CD8+ T cells. Like in HIV+ 
patients, expression of activation markers and inhibitory receptors CD160, 
CD244 and PD-1 on CD8+ T cells was increased in APDS patients, indicat-
ing exhaustion. EBV-specific CD8+ T cells from APDS patients exhibited an 
exhausted phenotype that resembled HIV-specific CD8+ T cells in terms 
of inhibitory receptor expression. Inhibition of PD-1 on EBV-specific CD8+ 
T cells from APDS patients enhanced in vitro proliferation and effector 
cytokine production. Based on these results, we conclude that total and 
EBV-specific CD8+ T cells from APDS patients are characterized by T cell 
exhaustion. Furthermore, PD-1 checkpoint inhibition may provide a possi-
ble therapeutic approach to support the immune system of APDS patients 
to control EBV and CMV.
Keywords: Activated PI3Kdelta syndrome, APDS, p110δ, PI3K, CD8+ T 
cells, exhaustion, PD-1, CD160, CD244, checkpoint inhibition;
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INTRODUCTION
The phosphoinositide 3-kinase – AKT (PI3K-AKT) signalling pathway is involved in many 
crucial cellular processes including regulation of metabolism, proliferation, apoptosis, cell 
cycle regulation and protein synthesis.1-3 In human lymphocytes, the PI3Kδ isoform, a het-
erodimer consisting of the catalytic subunit p110δ (encoded by PIK3CD) and regulatory 
subunit p85α (encoded by PIK3R1), is essential for both B cell and T cell development and 
maturation.4-7 For CD8+ T cells PI3Kδ has been shown to be essential for optimal immune 
responses to pathogens.8, 9
Over the past years, patients with gain-of-function (GOF) mutations in PI3Kδ have been 
described.10-12 These patients suffer from a specific form of primary immune deficiency 
called Activated PI3Kδ Syndrome (APDS).13, 14 This disease is characterized by disturbed 
humoral immunity resulting in hypogammaglobulinemia, recurrent respiratory tract 
infections an absent response to polysaccharide vaccination, pulmonary damage, lymph-
adenopathy, hepatosplenomegaly, an increased risk for haematological malignancies 
and an inability to control persistent viral infections such as Epstein-Barr virus (EBV) and 
Cytomegalovirus (CMV).13, 14 Immunophenotypically, these patients have decreased num-
bers of total CD4+ and especially naive CD4+ T cells together with increased CD8+ effector 
T cells. Furthermore, they have a relative increase in their transitional B cells accompanied 
by reduced memory B cells.15 Several studies indicated that the effector function of their T 
cells is defective, causing an inability to control chronic viral infections including CMV and 
EBV.13,14
Impaired T cell effector function can be caused by different mechanisms, one of which 
is senescence.16, 17 Hallmarks of senescence are permanent cell cycle arrest18, 19 and resis-
tance to apoptosis.20, 21 Importantly, senescent T cells are metabolically and functionally 
active and retain their cytotoxic functions and ability to produce and secrete cytokines.22,23 
Reduced telomere length and surface-expression of CD57 were used to define senescent 
T cells. However, to reliably distinguish senescence from other causes of T cell impairment 
additional markers like senescence-associated β-galactosidase and cyclin-dependent 
kinase inhibitor 2A (p16Ink4A) can be used.24, 25 Although senescence is age-dependent, 
other factors such as CMV-infection can contribute to senescence.26 
Exhaustion of T cells due to chronic antigenic stimulation is another mechanism lead-
ing to impaired T cell effector functions. T cell exhaustion was first described in chronic 
viral infections such as Lymphocytic Choriomeningitis Virus (LCMV) infection in mice27-29 
but is also recognized as an underlying mechanism in immunological failure in human 
viral infections including HIV infection30-33 and tumors.34-36 Exhaustion is a hierarchical 
process37, 38 by which CD8+ T cells first lose their proliferative capacity and IL-2 secretion, fol-
lowed by diminished secretion of effector cytokines such as tumour necrosis factor (TNF)
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α and interferon (IFN)γ and eventually they become sensitive to apoptosis, which leads 
to the loss of these cells.29, 38, 39 Simultaneously, these cells upregulate several inhibitory 
receptors including programmed death receptor (PD)-1, CD160, and CD244 which, when 
co-expressed, indicate later stages of exhaustion.40-43 These inhibitory receptors are consid-
ered to play a central role in exhaustion. Blocking these inhibitory receptors on exhausted 
CD8+ T cells can restore or improve their function in chronic viral infections as shown in 
vitro41, 42, 44-46 and in vivo.40, 47-51 Additionally, inhibitory receptor blockade was introduced 
into the clinic to re-activate exhausted T cells in cancer.52, 53 
Previously, total and virus-specific CD8+ T cells in APDS patients were shown to have 
upregulated CD57 expression, and reduced proliferative capacity. These findings were 
interpreted as T cell senescence.12, 54-56 However, patients’ lymphocytes also exhibited an 
increased rate of apoptosis compared to healthy controls,11, 15, 54 which is not in line with the 
resistance to apoptosis that has been ascribed to T cell senescence.21 Increased apoptosis 
sensitivity is associated with exhaustion rather than senescence.39, 57 Additionally, APDS 
patient T cells have been reported to express more PD-1, a receptor associated with T cell 
activation and exhaustion.12, 54, 55 The PI3Kδ pathway is critical for TCR signalling in CD8+ 
T cells58 and chronic antigen stimulation alone is sufficient to lead to CD8+ T cell exhaus-
tion.59 This raises the question whether GOF mutations in PI3Kδ lead to changes in the 
activation of T cells which might pre-dispose for T cell exhaustion rather than or in addi-
tion to immune senescence. Understanding the mechanisms leading to impaired immune 
response in APDS patients is a requirement to define the best treatment options for these 
patients that can support the control of viral infections, which could in turn reduce virus-re-
lated morbidities in these patients. 
To elucidate the role of exhaustion in APDS patients, total CD8+ T cells and CD4+ T 
cells from APDS patients were phenotypically characterized and compared to T cells from 
healthy individuals and HIV-infected patients (HIV+ patients). We have included PBMC from 
HIV infected patients since it is well established that HIV infection leads to exhaustion of 
HIV-specific CD8+ T cells but not CMV-specific CD8+ T cells in HIV infected patients39, 41 and 
can therefore serve as a positive control for exhaustion. Furthermore, virus-specific CD8+ T 
cells in all three groups were characterized and the effect of PD-1 blockade on proliferation 
and effector functions was investigated. Our findings indicate that indeed CD8+ T cells from 
APDS patients are more similar to the ones from HIV+ patients and exhibit characteristics of 
exhaustion. Importantly, we show that blocking PD-1 signalling can increase virus-specific 
CD8+ T cell proliferation and cytokine production. Our findings suggest that CD8+ T cells in 
APDS patients undergo exhaustion and that this may contribute to the impaired control 
of persistent viral infections like EBV and CMV. These findings raise the possibility of check-
point inhibition as a treatment strategy to support APDS patients to control recurrent or 
chronic viral infections. 
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MATERIALS AND METHODS
Cell samples and ethical approval
This study was carried out in accordance with the recommendations of Erasmus MC 
Medical Ethics Committee with written informed consent from all subjects. All subjects 
gave written informed consent in accordance with the Declaration of Helsinki. The proto-
col was approved by the Erasmus MC Medical Ethics Committee. 
Ten APDS patients were included with a median age of 27 years (range 6 - 44 years), 
and a gender ratio of six males to four females. Nine of the patients have a mutation in the 
PIK3CD gene (seven patients: E1021K mutation, one patient: S312R mutation, one patient 
R929C mutation)15 and one patient has a mutation in the PIK3R1 gene (N564K). From the 
patients including in this study 9/10 received immunoglobulin substitution therapy and 
4/10 received prophylactic antibiotics. None of the patients received steroids or immune 
modulating drugs at the time of sampling. None of the APDS patients had active EBV 
or CMV infection at the time of sampling. Three of the APDS patients are EBV-antibody 
positive and 2 are EBV-antibody negative, for the other patients the EBV status is not 
known. CMV status is not known from these APDS patients. From the healthy controls 9 are 
EBV positive. The five HIV-infected patients included have a median age of 42 years (range 
35 to 46), gender ratio is 1 female to 4 males, three patients have undetectable viral loads 
(below 20 HIV copies/ml), and two have detectable viral loads (295 and 4900 copies/ml, 
respectively). The median CD4 count is 300 cells/µl (range 50 – 630 cells/µl) and four out of 
the five patients are on antiretroviral therapy. The ten healthy control individuals included 
have a median age of 27 years (range 18 – 51) and a gender ratio of 5 males to 5 females. 
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized venous 
blood by Ficoll-Hypaque (GE Healthcare life sciences) density centrifugation, frozen in 
freezing media (90% FBS/10% DMSO) and stored in liquid nitrogen until used. Clinical data 
were provided by treating physicians. Due to availability of material, not all tests could be 
performed on all samples.
Flow cytometric immunophenotyping
PBMC were thawed, rested for 30-60 min at 37°C and stained with previously deter-
mined optimal amounts of tetramers and antibodies. For phenotyping of surface antigens, 
0.8 - 1x106 cells were washed with Facs wash (FW, Hanks buffered saline solution (HBSS, 
Corning) 3% fetal bovine serum (FBS, Gibco), 0.02% NaN3), stained with tetramer/antibody 
mix for 30 min at 4°C, washed two times with FW and fixed with 1% paraformaldehyde. 
Anti-HLA-A2-PE antibodies (clone BB7.2) were used to identify HLA-A2+ donors. Virus-
specific CD8+ T cells were identified by using APC- or PE-conjugated HLA class I A*0201-
β2-microglobulin tetramers loaded with HIV Gag p17 77-85 (SLYNTVATL) peptide, HIV Pol 
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476-484 (ILKEPVHGV) peptide, EBV peptide (GLCTLVAML), and CMV peptide (NLVPMVATV) 
(all tetramers were prepared in the lab). The following directly conjugated monoclonal 
anti-human antibodies were used: CD3-BV421 (UCHT1), CD4-BV650 (SK3), CD8-BV786 
(RPA-T8), CD45RA-APC-H7 (HI100), CCR7-PE-CF594 and Alexa Fluor 700 (CD197, 150503), 
PD-1-BV711 (CD279, EH12.1), CD160-Alexa Fluor 488 (clone BY55), CD244-PE (eBioC1.7, 
eBioscience), HLA-DR-BV605 (G46-6), CD38-PE-Cy7 (HIT2), CD57-BV605 (NK-1), TNFa-FITC 
(MAb11, eBioscience), and IFNg-PECy7 (4S.B3, eBioscience). All antibodies were purchased 
from BD Biosciences unless otherwise indicated. When AnnexinV-PerCP-Cy5.5 was used to 
exclude dead cells 2.5 mM CaCl2 was added to all solutions.
Between 1-4 x 105 events were collected per sample within 24 hours after staining on a 
LSRFortessa (BD Biosciences, 4 lasers, 18 parameters) and analyzed using FlowJo software 
(version 9.9.4, Tree Star). Data are represented as frequency within a defined population or 
as Median Fluorescence intensity (MFI).
In vitro proliferation
To determine proliferative capacity of proliferation-dye-labeled virus-specific CD8+ 
T cells, thawed PBMC were incubated with 0.1 µM of CellTrace Far Red Cell stain (Invitrogen) 
in PBS for 20 min at 37°C and free dye was removed by adding RPMI-10%FBS and incubating 
for 5 min at 37°C. Cells were spun down and resuspended in RPMI 1640 supplemented 
with 10% heat-inactivated FBS, 2 mM L-glutamine, 100 U/mL penicillin, and 100 µg/mL 
streptomycin sulfate and added to 24-well plates in a concentration of 1x106 PBMC/ml. To 
inhibit PD-1/PDL-1 interaction, 10 µg/ml of anti-PD-L1 antibody (CD274, MIH1, eBioscience) 
or isotype control (Mouse IgG1, eBioscience) was added and cells were incubated for 30 min 
at 37°C. Virus-specific peptide in a concentration of 1µg/ml was added then in appropriate 
wells: Gag peptide (SL9, SLYNTVATL, ANASPEC), Pol peptide (IV9, ILKEPVHGV, ANASPEC), 
CMV peptide (pp65, NLVPMVATV, ANASPEC), EBV peptide (BMLF1, GLCTLVAML, ANASPEC), 
EBV peptide pool (PepMix EBV BMLF1, JPT) or media alone (no peptide stimulation). 
Purified anti-CD28 (1µg/ml, clone CD28.2, BD Biosciences) and anti-CD49d (1µg/ml, clone 
9F10, BD Biosciences) was added to all wells. Cells were incubated for 5 days at 37°C in 
a 5%CO2 incubator. Cells were harvested on day 5, counted and resuspended in RPMI-
10%FBS/1µg/ml Brefeldin A (GolgiPlug, BD Biosciences)/anti-CD28 (1µg/ml)/anti-CD49d 
(1µg/ml) and incubated for 6 hours to determine cytokine production of these cells. For 
intracellular staining for cytokines, PBMC were first stained for surface antigens, fixed and 
permeabilized (Cytofix/Cytoperm, BD Bioscience), incubated with the antibodies (see 
above) for 60 min, washed two times with Perm/Wash Buffer (BD Biosciences) and fixed 
with 1% paraformaldehyde.
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Statistical analysis
All data sets were tested for normal distribution using the D’Agostino-Pearson omnibus 
test. Relative distributions of T cell subsets and comparisons of population frequencies 
data were analyzed using either the non-parametric Mann-Whitney U test or a T-test, 
dependent on whether or not the data were normally distributed (p<0.05 was considered 
statistically significant). When more than two data sets were analyzed in the same test, the 
Kruskall-Wallis test was performed, combined with a Dunn`s multiple comparisons test. 
Correlations were calculated using a Spearman model for correlation, since in the majority 
of groups at least one population was not normally distributed. Statistics were performed 
using the GraphPad Prism program (GraphPad Software, San Diego, CA, USA). Populations 
frequencies per group are represented as mean with standard error of the mean (SEM)
RESULTS
Patient characteristics
We included 10 patients with APDS. From one patient (Pt1) two samples were included, 
one taken at age 7, and one collected at age 25. For analysis of total CD4+ and CD8+ T cells, 
we only included the adult sample. For analysis of virus-specific CD8+ T cells, we included 
samples from both time-points. Most of the patients have been described before.15 The 
majority of patients (n= 7) carried the previously described E1021K mutation in PIK3CD,11, 12 
one carried a R929C mutation in PIK3CD and one carried a N564K15 GOF mutation in PIK3R1. 
One patient carried a missense variant c.935C>G (NM_005026.3) resulting in an amino acid 
change p.S312C (NP_005017.3) in PIK3CD. This latter variant is also found in the general 
population with a minor allele frequency of around 2% (SNP reference: rs61755420)60 and 
can therefore not be classified as disease causing. However, this patient does suffer from 
antibody deficiency and auto-immunity and increased phosphorylation of AKT in lympho-
cyte subsets was found (M.W.J.Wentink, unpublished data). Therefore, we decided to study 
the effect of this variant together with patients with known disease causing mutations. 
Two of the patients were HLA-A2-positive (including the patient with samples available as 
a child and an adult) and EBV-specific CD8+ T cells were analyzed. 
We compared the PBMC from APDS patients to PBMC from 10 healthy controls and 5 
HIV+ patients. 
The phenotype of T cells in APDS patients is distinct from healthy controls and resembles HIV-
infected patients
Previous studies on the T cell compartment of APDS patients showed a reduction of the 
naive CD4+ and CD8+ T cells and an increase in the CD8+ T cell effector memory population.11-13 
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In our patient cohort, we observed a comparable skewing of the T cell populations. The 
frequencies of CD45RA+CCR7+ naive CD4+ T cells were significantly decreased in APDS 
patients compared to healthy controls and comparable with the frequencies in HIV+ patients 
(Figure 1A, B). CD45RA+CCR7+ naive CD8+ T cells were significantly reduced in our APDS 
patient cohort compared to the healthy controls although not as profound as observed in 
HIV+ patients (Figure 1C). Within memory CD4+ T cells, an increase in CD45RA-CCR7+ central 
memory (CM) cells was found for the APDS and the HIV+ patients compared to healthy 
controls (Figure 1D). The CD45RA-CCR7- effector memory (EM) CD4+ T cell frequencies were 
not significantly different when healthy controls, APDS and HIV+ patients were compared 
(Figure 1D). Frequencies of CM CD8+ T cells were comparable between healthy controls and 
APDS patients as were the CD45RA+CCR7- effector memory re-expressing CD45RA (EMRA) 
CD8+ T cell populations (Figure 1E). A significant increase was found for the CD45RA-CCR7- 
effector memory (EM) CD8+ T cell population for APDS patients and HIV+ patients when 
compared to healthy controls. These findings indicate that both patient populations show 
comparable reduction of naive T cells and increased EM CD8+ T cells (Figure 1E). 
To examine the effect of the GOF mutations on chronic activation we determined the 
expression of several chronic activation markers on T cells from healthy controls, APDS 
patients and HIV+ patients. The frequency of CD38brightCD8+ T cells was increased in APDS 
patients compared to healthy controls, however HIV+ patients had an even higher percent-
age of CD38bright CD8+ T cells (Figure 2A). Although the frequency of CD38bright CD4+ T cells 
was also higher in APDS patients compared to healthy controls this was not significant 
(Figure 2D). HLA-DR was examined as a second marker of chronic activation and indeed a 
significant increase was found for HIV+ patients within the CD8+ T cell population. HLA-DR 
expression was significantly increased on CD8+ T cells (Figure 2B) and CD4+ T cells (Figure 
2E) from the APDS patients compared to healthy controls.
We studied the expression of CD57 on CD8+ and CD4+ T cells, since this was reported 
to be increased in a subset of APDS patients. We found that in APDS patients 34.9±5.0% 
(mean ± SEM) of CD8+ T cells express CD57, compared to 25.2%±4.0% in healthy controls 
and 56.4%±5.2% in HIV+ patients (Figure 2C). This indicates that although CD57+ CD8+ T 
cells are increased in APDS patients, this is not significantly different from the frequency in 
healthy controls and lower than the frequency in HIV+ patients. A small but non-significant 
increase of CD57+ cells was also found within the CD4+ T cell population of APDS patients 
compared to healthy controls (Figure 2F). Overall, the expression of activation markers and 
CD57 indicate that T cells from APDS patients tend to be more activated than healthy con-
trols and are therefore more alike T cells from HIV+ patients. 
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Figure 1. 
Immunophenotyping of the T-cell compartment of controls (black dots), APDS patients (black squares) and 
HIV+ patients (black triangles). Red lines and brackets indicate the mean and standard error of the mean (SEM) 
of each group. (* p<0.05, **p<0,005). A. Representative dot plots of controls and patients indicating naive 
(CD45RA+CCR7+), CM (CD45RA-CCR7+), EM (CD45RA-CCR7-) and EMRA (CD45RA+CCR7-) CD8+ and CD4+ T cell 
subsets. Numbers depict frequency of cell populations. B. and C. The frequency of naive CD4+ T cells (B) and CD8+ 
T cells (C) is reduced in APDS patients and HIV+ patients compared to controls. D. The frequency of CM CD4+ T cells 
is increased in APDS patients and HIV+ patients. The frequency of the different memory CD4+ T cells in controls, 
APDS patients and HIV+ patients is shown. E. The frequency of EM CD8+ T cells is increased in APDS patients and 
HIV+ patients. The different memory CD8+ T cell subpopulations are shown for controls APDS patients and HIV+ 
patients. 
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APDS patients have increased inhibitory receptor expression on CD8+ T cells
Since exhaustion is a gradual process in which cells over time co-express multiple 
inhibitory receptors, we studied both the single expression of PD-1, CD160 and CD244 
and co-expression of these three receptors on CD8+ T cells (Figure 3A-E). As we observed 
with the activation markers, the expression profile of inhibitory receptors within the APDS 
patients is very heterogeneous, with some patients in the range of controls and others 
in the range of HIV+ patients. We observed a significantly higher percentage of CD8+ T 
cells from APDS patients expressing CD160 compared to controls (mean 38%±6.0% and 
21%±4.5%, respectively). This frequency in APDS patients was closer to HIV+ patients 
(mean 50%±6.8%) (Figure 3B). The frequency of CD244-expressing CD8+ T cells within 
APDS patients and HIV+ patients was significantly increased compared to healthy controls 
(Figure 3C). PD-1 was also found increased on CD8+ T cells in APDS patients compared to 
controls (mean 38.8%±6.5% and 23.6%±6.9%, respectively) (Figure 3D). Most importantly, 
we observed a significant increase in the frequency of CD8+ T cells expressing all three 
inhibitory receptors, PD-1, CD244, and CD160 (PD-1+CD160+CD244+), in the APDS patients 
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Figure 2. 
Expression of CD38, HLA-DR and CD57 on CD8+ and CD4+ T cells from controls (black dots), APDS patients (black 
squares) and HIV+ patients (black triangles). Red lines and brackets indicate the mean and standard error of 
the mean (SEM) of each group. (* p<0.05, **p<0,005). A. The frequency of CD38bright cells is increased in APDS 
patients and HIV+ patients compared to controls. The frequencies of CD38bright cells within CD8+ cells are shown 
for healthy controls, APDS and HIV+ patients. B. The frequency of HLA-DR+ cells is increased in APDS patients and 
HIV+ patients compared to controls. Frequencies of HLA-DR+ cells within CD8+ T cells are shown. C. Frequency of 
CD57+ CD8+ T cells is not increase in APDS patients. Frequencies of CD57+ cells within CD8+ cells shown for healthy 
controls, APDS patients and HIV+ patients. D. Frequency of CD38+ CD4+ T cells is comparable in healthy controls, 
APDS patients and HIV+ patients. E. Frequency of HLA-DR+ CD4+ T cells is increased in APDS patients. Frequency 
of HLA-DR+ cells within CD4+ T cells shown for heathy controls, APDS patients and HIV+ patients. F. Frequency of 
CD57+CD4+ T cells is not increased in APDS patients compared to healthy controls. Frequency of CD57-expressing 
cells within CD4+ T cells shown.
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Figure 3. 
Expression of inhibitory receptors on CD8+ cells from controls (black dots), APDS patients (black squares) and 
HIV+ patients (black triangles). Red lines and brackets indicate the mean and standard error of the mean (SEM) 
of each group. (* p<0.05, **p<0,005). A. Representative dotplots of controls and patients indicating populations 
that were considered positive for inhibitory receptors. B. CD160 expression is increased on CD8+ T cells from 
APDS patients and HIV+ patients compared to controls. C. CD244 expression is increased on CD8+ T cells from 
APDS patients and HIV+ patients compared to controls. D. PD-1 expression is increased on CD8+ T cells from APDS 
patients but not HIV+ patients compared to controls. E. The frequency of PD-1+ CD160+ CD244+ CD8+ T cells is 
increased in APDS patients and HIV+ patients compared to controls. F. The frequency of PD-1+ CD160+ CD244+ 
CD8+ T cells is negatively correlated with the frequency of naive CD8+ T cells in controls and APDS patients.
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which was 20%±5.6% compared to 6%±2.3% PD-1+ CD160+ CD244+ CD8+ T cells in healthy 
controls. This frequency of PD-1+CD160+CD244+ CD8+ T cells in APDS patients is compara-
ble to the one observed in HIV+ patients (21%±7.6%). 
We examined whether a history of EBV infection influences the expression of inhibitory 
receptors on CD8+ T cells. From the APDS patients, EBV status information was available 
from 5 individuals, with 3 being EBV-antibody positive and 2 being EBV-antibody negative. 
We compared the expression of inhibitory receptors on CD8+ T cells from these two groups 
to the expression of the inhibitory receptors on the CD8+ T cells in the 9 EBV-positive healthy 
controls. We found that the frequency of CD160+, CD244+, PD-1+ and CD160+CD244+PD-1+ 
CD8+ T cells is highest in the EBV+ APDS patients (CD160+CD8+: 57%±4.9%; CD244+CD8+: 
87%±3.4%; PD-1+CD8+: 61%±8.2%; CD160+CD244+PD-1+CD8+: 36%±5.6%), but lower 
in the EBV- APDS patients and the EBV+ healthy controls (CD160+CD8+: 26%±3.8%, 
22%±4.7%; CD244+CD8+: 43%±5.3%, 48%±5.9%; PD-1+CD8+: 18%±3.0%, 25%±7.6%; 
CD160+CD244+PD-1+CD8+: 5.6%±1.5%, 7.0%±2.5% for EBV- APDS patients and EBV+ healthy 
control, respectively). Thus, EBV antibody positivity is accompanied by increased inhibitory 
receptor expression on CD8+ T cells. 
We next analyzed whether reduced naive CD8+ T cell frequency and PD-1+CD160+CD244+ 
CD8+ T cells correlate in healthy controls and APDS patients. Although a negative correla-
tion was already observed for healthy controls (Figure 3F), the correlation between the 
frequencies of PD-1+CD160+CD244+ CD8+ T cells and naive CD8+ T cells was highly signif-
icant in APDS patients (Figure 3F). For the HIV+ patients, this relationship was not signifi-
cantly correlated. These results indicate that total CD8+ T cells from APDS patients have 
increased co-expression of inhibitory receptors similar to what is observed in HIV+ patients. 
Furthermore the negative correlation of PD-1+CD160+CD244+ CD8+ T cells and naive CD8+ 
T cells indicates that exhaustion in this compartment is associated with the skewed subset 
distribution.
Virus-specific CD8+ T cells from APDS patients exhibit an exhaustion phenotype 
To further compare exhaustion in APDS patients to exhaustion due to HIV infection, 
we analyzed virus-specific CD8+ T cells in both patient groups and healthy controls. HIV-
specific CD8+ T cells from HIV+ patients are highly sensitive to apoptosis, present with a 
skewed memory phenotype, have proliferative defects and show increased expression 
of inhibitory receptors.29, 38, 39 However, in the same HIV+ patients, CMV-specific CD8+ T 
cells are not impaired. Using peptide-loaded HLA-A2 tetramers, virus-specific CD8+ T cells 
were analyzed from three APDS-patients (EBV-specific CD8+ T cells), five HIV+ patients (HIV 
Gag- or Pol-specific CD8+ T cells, CMV-specific CD8+ T cells) and four healthy controls (EBV-
specific CD8+ T cells). Within the three APDS samples, are two different donors with one 
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donor being represented as a child (7 years, red square in Figure 4) and as an adult (25 
years, open square).
The virus-specific CD8+ T cells in all four groups have a predominantly CD45RA-CCR7- 
EM phenotype (Figure 4A) which is lowest in CMV-specific CD8+ T cells from HIV+ patients 
since these cells have the highest frequency of more differentiated EMRA (Figure 4A). No 
clear difference was observed for the frequencies of the chronic activation markers CD38 
and HLA-DR when the four virus-specific CD8+ T cell groups were compared (Figure 4B). 
All virus-specific cells have higher frequencies of CD38+ and HLA-DR+ cells than total CD8+ 
T cells (Figure 2A, B) from the same groups. CD57 expressing cells seem to be more abun-
dant within EBV-specific CD8+ T cells from APDS patients and CMV-specific CD8+ T cells 
from HIV patients than in EBV-specific CD8+ T cells from healthy controls and HIV-specific 
CD8+ T cells from HIV patients. 
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Figure 4. 
Phenotyping and activation marker expression on EBV-specific CD8+ T cells from controls (black dots), EBV-
specific CD8+ T cells from APDS patient 1 at the age of 7 years (red square), at the age of 25 years (open square), 
APDS patient 2 (black square), HIV-specific CD8+ T cells from HIV+ patients (black triangles) and CMV-specific 
CD8+ T cells from HIV+ patients (open triangles). Red lines and brackets indicate the mean and standard error 
of the mean (SEM) of each group. (* p<0.05, **p<0,005). A. Frequency of memory subpopulations (CM, EM and 
EMRA, CCR7+ memory (CD45RA+CCR7+)) within virus-specific CD8+ T cells shown for healthy controls (EBV-specific 
CD8+ T cells), APDS patients (EBV-specific CD8+ T cells) and HIV+ patients (HIV- and CMV specific CD8+ T cells). 
B. Frequency of CD38+ (left), HLA-DR+ (center), and CD57+ (right) cells shown within virus-specific CD8+ T cells.
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Figure 5. 
Inhibitory receptor expression on virus-specific cells from controls and patients. A. Representative dotplots of 
healthy controls and patients indicating identification of virus specific cells and inhibitory receptors positive cells 
within virus specific populations. B. Inhibitory receptor expression on EBV-specific cells from controls (black dots), 
EBV-specific cells from APDS patient 1 at the age of 7 years (red square), at the age of 25 years (open square), 
APDS patient 2 (black square), HIV-specific cells from HIV+ patients (black triangles) and CMV-specific cells from 
HIV+ patients (open triangles). Red lines and brackets indicate the mean and standard error of the mean (SEM) of 
each group.
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To assess exhaustion in the virus-specific CD8+ T cell population, the expression of PD-1, 
CD160 and CD244 was analyzed (Figure 5). The mean percentage of CD244+ CD8+ T cells was 
above 90% in all virus-specific CD8+ T cell groups. Frequency of CD160 expression slightly 
increased on HIV-specific CD8+ T cells compared to the other groups. The frequency of 
PD-1 expressing CD8+ T cells was lowest in CMV-specific CD8+ T cells and EBV-specific CD8+ 
T cells from healthy controls but higher within EBV-specific CD8+ T cells from APDS patients 
and HIV-specific CD8+ T cells from HIV patients. We found that within the HIV-specific CD8+ 
T cells 71%±4.0% express all three inhibitory receptors, and within the EBV-specific CD8+ 
T cells from APDS patients 47%±10.6% express all three inhibitory receptors. EBV-specific 
cells from controls and CMV-specific cells from HIV+ patients have a lower frequency of 
PD-1+ CD160+ CD244+ populations (32%±3.2% and 23%±5.2%, respectively). Compared to 
overall CD8+ T cells, all virus-specific CD8+ T cells show increased expression of inhibitory 
receptors. 
PD-1 blockade can enhance in vitro proliferation of virus-specific cells in APDS and HIV+ 
patients
Although both senescent and exhausted cells do not proliferate, the mechanism lead-
ing to the replicative impairment is different. In senescence, a cell cycle arrest causes the 
inability of cells to replicate whereas in exhaustion receptor-ligand interaction (such as 
between the inhibitory receptor PD-1 and its ligand PD-L1) leads to inhibition of TCR-
signaling and therefore inhibition of proliferation. Thus, blocking the interaction between 
receptor and ligand through checkpoint inhibitors could lead to an increase in proliferation 
of exhausted cells, as shown for HIV-specific CD8+ T cells from HIV+ patients44-46 but not in 
senescent cells. We stimulated PBMC from HIV+ patients and APDS patients with virus-spe-
cific peptide in the presence of blocking anti-PD-L1 or isotype control antibodies for five 
days prior to analysis of proliferation and effector function. As reported previously,44-46 
inhibition of PD-1/PD-L1 interaction increased proliferation of HIV-specific CD8+ T cells in 
2 out of the 4 tested PBMC samples from HIV+ patients by ~2-fold (Figure 6). When PBMC 
from APDS patients were stimulated with EBV-peptides in the presence of anti-PD-L1 anti-
bodies, proliferation was increased in all three samples compared to samples stimulated 
with peptide in the presence of an isotype control. Not only did we observe improved 
proliferation of these cells but also increased effector function as demonstrated by the 
frequency of cytokine producing cells (Figure 6). The patient with the highest proliferative 
and effector cytokine response was also the patient with the highest frequency of PD-1+ 
and PD-1+CD160+CD244+ EBV-specific CD8+ T cells. These findings indicate that PD-1 signal 
inhibition not only increased proliferation but also enabled these cells to release effector 
cytokines including IFNγ and TNFα. These results suggest that exhausted EBV-specific CD8+ 
T cells from APDS patients can be functionally restored through checkpoint inhibitors, 
resulting in increased proliferation and effector functions. 
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DISCUSSION
How T cell defects due to GOF mutations of PI3Kδ contribute to morbidity in APDS 
patients is not fully understood. The goal of this study was to determine whether the GOF 
mutations in PI3Kδ (causing APDS) lead to exhaustion of CD8+ T cells. Furthermore, we 
determined whether virus-specific CD8+ T cells against recurrent or persistent infections 
such as EBV are exhausted in APDS patients and if immune-checkpoint blockade can 
rejuvenate exhausted CD8+ T cells in APDS patients. We compared CD8+ T cells from 
APDS patients to healthy controls and HIV+ patients, which served as a control for antigen 
induced exhaustion of CD8+ T cells. Understanding the effect these mutations have on 
the immune system is central to further treatment strategies to support these patients in 
controlling chronic infections like EBV and CMV to reduce morbidity and mortality.
In line with previous reports,13, 14 we found significantly reduced frequencies of naive 
CD4+ and CD8+ T cells in APDS patients. Loss of naive T cells is thought to be caused by 
hyperactivation of the mTOR pathway induced by PI3Kδ mutations. This leads to increased 
glycolysis, proliferation and differentiation into short lived effector cells.11, 12 The APDS 
patients showed a skewed CD8+ T cell subset distribution, with increased EM CD8+ T 
cells, which we also found in HIV+ patients. Impaired control of viral infection could be an 
Figure 6. 
Proliferation and effector cytokine production in vitro of EBV-specific CD8+ T cells from APDS patients and HIV-
specific CD8+ T cells from HIV+ patients after peptide stimulation in the presence of anti-PD-L1 antibodies or 
isotype controls. A. Representative dot plots showing cytokine-producing and proliferated CD8+ T cells after 5 
day peptide stimulation of PBMC from an APDS patient in the presence of isotype control (upper panel) or anti-
PD-L1 monoclonal antibodies (lower panel). Gates indicate cells positive for IFNγ, TNFα or cells with diluted cell-
trace proliferation dye. B. Anti-PD-L1 antibody treatment resulted in increased proliferation and production of 
TNFα and IFNγ upon peptide stimulation in both APDS and HIV+ patients. Pooled data showing fold change of 
the frequency of either cells undergoing proliferation or cytokine producing cells in the presence of anti-PD-L1 
antibody over isotype control. Cells were stimulated with viral peptide for 5 days in the presence of monoclonal 
antibodies. Red lines and brackets indicate the mean and standard error of the mean (SEM) of each group.
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underlying mechanism causing the increased effector memory pool in HIV+ patients. In 
APDS patients chronic and/or recurrent viral infections such as EBV and CMV on top of the 
GOF mutation is likely to contribute to this phenotype. Interestingly, although the effector 
memory population is also slightly increased in CD4+ T cells, it is the central memory 
population which is significantly higher in both patient groups.
To further examine the effect of PI3Kδ GOF mutations on the total CD4+ and CD8+ T cell 
compartments, we analysed the expression of the chronic activation markers CD38 and 
HLA-DR. Especially HLA-DR was shown before to correlate with immune activation and 
disease progression in HIV infection.61 This is the first time that these chronic activation 
markers are analysed on T cells from APDS patients. HLA-DR expression was significantly 
increased on CD8+ and CD4+ T cells in APDS patients compared to healthy controls and it is 
comparable to what is observed in HIV+ patients. Our findings indicate that a subpopulation 
of CD4+ and CD8+ T cells in APDS patients are chronically activated. However, APDS 
patients show great heterogeneity, with only a small part of T cells expressing the chronic 
activation markers, our findings thus suggest that the mutation alone does not lead to a 
chronic activation of T cells. One exhaustion-inducing factor could perhaps be infection 
with a persistent virus; we therefore analysed the expression of CD38 and HLA-DR on 
CD8+ T cells specific for persistent viruses. We did not find significant differences in the 
expression of activation markers on virus-specific cells between controls, APDS patients 
and HIV+ patients. Thus, we cannot at this moment conclude that infections with persistent 
viruses contribute to the higher frequency of HLA-DR+ T cells in APDS patients. 
Some APDS patients have increased CD57 expression on CD8+ T cells and previously this 
was interpreted as increased senescence.12, 54, 55 The surface marker CD57 is commonly used 
as a senescence marker, but T cells in HIV+ patients also express increased CD57, indicating 
that exhaustion and senescence can co-exist in patients.62-64 In our study cohort, the mean 
CD57+ T cell frequency in APDS patients is only slightly increased compared to healthy 
controls and much lower than that of HIV+ patients. However, the CD57 expression in the 
APDS cohort is very heterogeneous, with some patients comparable to controls and others 
in the range of HIV+ patients. CD57 expression levels were not correlated with age, gender 
or mutation in our patient cohort. Neither was this correlated with clinical characteristics 
like lymphadenopathy, auto-immunity, malignancies, the expression of other markers 
we studied here or with B-cell phenotypes. Our results suggest that senescence and 
exhaustion might not be totally separate processes, but rather two intertwined cellular 
states that can occur together in specific types of disease like APDS.
To further assess exhaustion in APDS patients, we analysed the expression of the 
inhibitory receptors CD160, CD244 and PD-1. We have included PBMC from HIV infected 
patients since it is well established that HIV infection leads to exhaustion of HIV-specific 
CD8+ T cells but not CMV-specific CD8+ T cells in HIV infected patients39, 41 and can therefore 
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serve as a positive control for exhaustion. We found that CD244+, CD160+ and PD-1+ 
CD8+ T cells are significantly increased in APDS patients. CD8+ T cells expressing all three 
inhibitory receptors (PD-1+CD160+CD244+), which would indicate the most exhausted 
state, were also significantly increased in APDS patients and to a similar degree as in HIV-
infected individuals. We did not find any correlates for the PD-1+ CD160+ CD244+ CD8+ T cell 
population in APDS patients when age, gender, type of mutations, B cell phenotype, or any 
other marker we have described were analysed. When we separated the APDS patients in 
EBV-antibody positive and EBV-antibody negative, we found that the highest expression 
of the inhibitory receptors including the concurrent expression of all 3 inhibitory receptors 
was observed in EBV+ APDS patients. However, EBV- APDS patients had a frequency of 
inhibitory receptor expressing CD8+ T cells which was similar to the one from EBV+ healthy 
controls. These findings suggests that chronic EBV infection or antigen stimulation in APDS 
patients contributes to the exhaustion of CD8+ T cells.
Within virus-specific CD8+ T cells, we found increased expression of inhibitory receptors 
in all subpopulations. Overall, the expression of inhibitory receptors on CD8+ T cells from 
APDS patients has more similarities with HIV+ patients, supporting the idea that the PI3Kδ 
GOF mutations may contribute to exhaustion. This was supported by the highly significant 
negative correlation between the frequency of naive and PD-1+CD160+CD244+CD8+ 
T cells, indicating that the hyper-activation leading to reduced naive T cells, may also be 
responsible for the increased expression of inhibitory receptors on T cells. Our findings do 
not imply that signalling mechanisms leading to exhaustion is identical in APDS and HIV 
infection although chronic antigen exposure may play an important role in both APDS and 
HIV patients as has been suggested in mouse studies.59 
Commonly, exhaustion is studied in the context of chronic antigen stimulation due to 
chronic viral infections and cancer. In APDS we see a similar increase of exhausted CD8+ 
T cells especially in patients that are EBV-antibody positive implying that chronic antigen 
stimulation contributes to T cell exhaustion. Chronic TCR stimulation is sufficient to lead to 
CD8+ T cell exhaustion.59 Since PI3Kδ participates in TCR signalling in T cells,58 a cell-intrinsic 
chronic activation due to the hyperactivity of the PI3K-AKT signaling pathway could be a 
factor promoting the exhausted phenotype in the absence of specific chronic antigen in 
APDS. Since not all APDS patients’ T cells show a significant increase in inhibitory receptor 
expression, the PI3Kδ mutations may be necessary but not sufficient for exhaustion. 
One mechanism to lower the threshold for exhaustion in APDS could be PI3K-induced 
epigenetic modifications. Several studies have shown epigenetic alterations in exhausted 
T cells.65, 66 The altered gene expression patterns induced by epigenetic modifications are 
rather stable resulting in permanent exhaustion independent of the level of remaining 
antigen.67, 68 Demethylation of the PD-1 promotor region in exhausted CD8+ T cells allows 
sustained expression of PD-1. That PI3K can indeed alter epigenetic modifications 
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was indicated in a study in mouse embryonic stem cells, suggesting that de novo DNA 
methyltransferases are downregulated due to PI3K-induced AKT, leading to reduced 
DNA methylation of imprinted loci.69 Therefore PI3Kδ GOF mutations could promote the 
demethylation of inhibitory receptors or reduce the threshold for such demethylation, 
thus facilitating the exhaustion in CD8+ T cells.
Over the past years, PD-1 blockade has been a subject of research in both HIV and 
cancer treatment. By blocking inhibitory receptors, exhausted CD8+ T cells can regain 
effectors functions and provide anti-viral or anti-tumor immunity. However, upregulation 
of inhibitory receptors on activated T cells has also a physiological function: they function 
as negative regulators, downregulating the immune response after successful control of 
infections.70, 71 They are important to prevent autoimmunity and pathological responses 
leading to tissue damage. In the absence of inhibitory receptors an increased risk for 
autoimmunity and immunopathology was reported.72-74 Upregulation of inhibitory 
receptors in APDS could be a protective mechanism to prevent damage through an overly 
activated immune system. This hypothesis is supported by a study which showed how PD-1 
signaling can prevent activation of PI3K and AKT phosphorylation, thereby preventing 
proliferation.75 This benefit of preventing autoimmunity or inflammation in APDS comes at 
a cost of impairing immunity to viruses. Indeed, we have seen an increase in proliferation 
and effector cytokine secretion in virus-specific CD8+ T cells from APDS patients in vitro 
in the presence of PD-L1 blocking antibodies. The increase of proliferation and cytokine 
production we have observed in the presence of a PD-L1 blocking antibody is moderate, 
and this raises the question of biological significance. Since we have observed that the 
patient with the highest expression of PD-1 showed the highest increase in proliferation 
and cytokine-producing EBV-specific CD8+ T cells this suggests that the more responsive 
patients to PD-1 blockade will be the highest expressers. To more significantly improve the 
effector functions in all patients a combination of blocking several checkpoint inhibitors 
may be required, as indicated by PD-1/CTLA-4 blocking in cancer studies.76, 77 Furthermore, 
the increase of effector function is similar when EBV-specific CD8+ T cells from APDS 
patients are compared with HIV-specific T cells from HIV-infected patients and within the 
range reported previously for HIV-specific CD8+ T cells.41, 44, 45 Thus, short term treatment of 
patients with checkpoint inhibitors during a re-current EBV- and/or CMV infection could be 
a means to augment efficacy of exhausted virus-specific CD8+ T cells and thus reduce EBV- 
and CMV related morbidity. Because inhibitory receptor upregulation may possibly be 
beneficial in APDS by preventing excessive inflammation or autoimmunity, manipulating 
this pathway has to be done with caution, and ideally it should be combined with long-
term treatment that can reduce the hyperactivation of the pathway, for example selective 
PI3K-inhibition.78
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In summary, we have shown that CD8+ T cells from APDS patients have an exhausted 
phenotype and upregulated expression of inhibitory receptors. This exhaustion of the 
CD8+ T cell compartment contributes to the deficient anti-viral capacities of the CD8+ T cell 
compartment. Blocking the PD1-PD1L interaction could be a target for treatment in these 
patients during recurrent or persistent viral infections.
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GENERAL DISCUSSION 
In this thesis we aimed to study how specific genetic defects influence signaling 
cascades in B-cells and thereby lead to disturbances in B cell development and repertoire 
formation eventually causing antibody deficiencies. To study how mutations and 
disturbances lead to disease, knowledge of normal B cell development and B cell intrinsic 
processes is crucial to embed newly obtained results from patients. We employed different 
techniques including multi-color flow cytometry, next generation sequencing, and in vitro 
stimulation assays to study B-cell differentiation and signaling in the context of healthy 
controls and patients with different causes of antibody deficiency. 
This General Discussion, highlights how the knowledge obtained in our studies can be 
used for further research on for example B cell precursor development (chapter 2.1 and 
2.2). The effect of PI3Kδ gain-of-function mutations on B cell differentiation was studied in 
chapters 4.1 and 4.3 and in that light, other types of mutations than the classical loss-of-
function mutations will we reviewed. Additionally there will be a focus on other etiological 
mechanisms that might cause antibody deficiencies like epigenetics. In in extension to that 
the likelihood of polygenetic causes and how pathway analysis might help to elucidate 
this as a cause for immune deficiency or dysregulation will be discussed. Finally the current 
vision on CD21lo B cells and how they compare to CD21deficient cells (part 3) will be 
reviewed as a well as and how these cells might link to exhaustion (chapter 4.4).
BONE MARROW B-CELL PRECURSOR DEVELOPMENT
Bone marrow studies described in this thesis (part 2) are just the beginning of more 
extended experiments that can shed light on normal and abnormal B-cell development in 
bone marrow. Not only can this data be used in the diagnostic practice of PID, additionally, 
using data from genetically identified cases, clues for diagnosis in unsolved cases can 
be obtained. Furthermore, by employing other techniques next to the flow cytometric 
immunophenotyping and immune repertoire sequencing as described here, more 
knowledge on BCP differentiation can be obtained.
Asynchronous marker development reflects multiple differentiation routes between BCP 
checkpoints
In our BCP differentiation studies in chapter 2.1, we employed a new flow cytometric 
panel developed by the EuroFlow PID consortium to study BCP differentiation in healthy 
bone marrow and we used genetically defined PID cases as a control for absence of 
recombination and (pre-)BR signalling. We found that expression pattern of some surface 
Part 5
206
markers is asynchronous to cyIgµ expression This suggests that marker development 
is partially asynchronous to the process of BR formation. Additionally, we found that 
population based gating is not ideal for analysing this continuous process of differentiation, 
especially in the stages in which marker development is most asynchronous. We 
hypothesize that some cells, deviate from the most common route, because they are 
unable to form a functional B cell receptor, or because they need more time to compose 
a functional allele. V(D)J rearrangement is a stepwise process in which first the D segment 
is linked to the J segment.1-3 This occurs commonly on both alleles, forming incomplete 
rearrangements. V-DJ rearrangements takes place on one allele at a time. When the first 
attempt (on allele one) is successful, the second allele will not be rearranged. However, 
in case rearrangement of the first allele results in an unproductive sequence, or if the 
produced heavy chain cannot pair with the surrogate light chain, the second allele 
needs to be rearranged. Hence, rearranging a functional IGH-allele takes more time. If 
the rearrangement of the second allele fails, the cell will become apoptotic. This means 
that different cells, depending on the speed with which they can produce a functional 
heavy chain, will follow a different molecular route. We hypothesize that this is reflected to 
some extent in phenotypic markers that can be measured by flow cytometry. Some of the 
routes can, at least partially, be explained by molecular processes that are linked to V(D)J 
recombination and (pre-)BR signalling. 
This can be further studied using extended phenotyping techniques like cytometry 
time-of-flight (cyTOF), which enables integration of up-to 40 markers on a single cell.4 We 
have put together a cyTOF panel, that integrates the markers present in our flow-panel, 
with more extended phenotypic markers, apoptosis and proliferation markers and several 
transcription markers (Table 1). This enables more extensive sub-setting of populations 
and prediction of which populations have increased apoptosis and therefore might be part 
of a maturation route that leads to a dead end. We tested the flow cytometry panel and 
the cyTOF panel in parallel on the same samples and found that we could reliably gate the 
same populations with the cyTOF approach as with the flow cytometry approach (Figure 
1). This indicates that the cyTOF approach can be a good extension of our flow cytometry 
studies. The data sets that can be obtained with this panel can be used with advanced 
analysis tools to predict differentiation routes of B cells in bone marrow. Others have used 
the Wanderlust algorithm to model BCP-differentiation.5 This model takes into account 
the continuity of BCP differentiation, circumventing population based gating. However, 
it also assumes a non-branching model of BCP differentiation, which is not in line with 
our observations. Therefore, it is interesting to adapt the Wanderlust algorithm in such a 
way that branching in the form of divergence based on differences in V(D)J-recombination 
and convergence at the BCP-checkpoints can be modelled to integrate the continuous 
differentiation and asynchronous development. 
207
General discussion
5
The single-cell protein expression data that can be obtained by flow cytometry or cyTOF 
should ideally be extended with single cell RNA-expression data and DNA-sequencing of 
IG-loci to understand the link between V(D)J-recombination status, transcriptome and 
protein expression. These type of studies can give more in-depth knowledge on how 
different processes in BCP development are linked and interacting to form a diverse pool 
of functional B cells that provide complete humoral immunity.
Table 1. cyTOF panel for BCP development in human bone marrow
Markers 
in flow 
panel
Phenotyping Apoptosis Proliferation 
and survival
Cell cycle 
regulation
Differentiation 
and migration
CD19 CD34 CD45 CD9 i- Caspase 3 i- PAX5 i-cPARP CXCR5
IgM CD38 CD24 CD44 i- Caspase 7 BCL-6 BCL-6 CXCR4
IgD i-CD79a CD22 CD27 BCL-2 CD135 HLA-DR
CD20 i-Igμ IgKappa i-CD79b Ki-67 CD73
CD10 i-TdT IgLambda
 
i- indicated intracellular markers
Bone marrow studies in PAD; Good syndrome and CVID
In chapter 2.3 bone marrow precursor B cells were studied in patients with Good 
syndrome.6 These patients suffer from thymoma and hypogammaglobulinemia and in most 
cases have a complete absence of B cells in the peripheral blood.7 We found that the bone 
marrow of these patients is highly B-lymphopenic as well, and that the subset distribution 
and the type of arrest is different than in other patients with agammaglobulinemia. 
The arrest in Good syndrome patients seems to occur after the Pro B stage, whereas in 
agammaglobulinemia patients a differentiation arrest occurs after the Pre B-I stage, 
indicating a different disease causing mechanism in the two groups of patients. Good 
A B
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Figure 1. 
Comparison between flow cytometry and cyTOF in parallel on the same human bone marrow sample. A. Dotplots 
showing TdT and CD34 expression of BCP measured by cyTOF and flow cytometry. B. Gating of the main BCP 
populations acquired cyTOF and flow results in approximately the same subset distribution.
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syndrome patients are one group of PAD patients in whom studying the bone marrow can 
help resolve these disease causing mechanisms. But there are other groups of patients with 
PAD in which bone marrow studies can be useful. One of the most frequently diagnosed 
PAD is common variable immunodeficiency (CVID). A highly heterogeneous disease 
in which a defect arises at some point in B-cell differentiation. Driessen et al. proposed 
a model for classification of CVID patients based on the underlying pathophysiological 
mechanism.8 This model uses a combined approach of flow cytometric and molecular 
techniques to identify 5 patterns of CVID-causing defects. In pattern 1, patients have low 
numbers of transitional and memory B cells and an increased number of cell divisions in 
the naive B cells, which likely reflects proliferation to compensate for the reduced bone 
marrow output. In this group of patients a defect that arises already in bone marrow B cell 
development is proposed to cause the disease. Different studies have previously identified 
groups of CVID patients with defects in BCP development. Ochtrop et al. found a partial 
defect in BCP differentiation at the pre-BI to pre-BII stage in CVID patients with low numbers 
of transitional B cells.9 Results from a study by Anzilotti et al. showed that all investigated 
CVID patients had BCP in all major stages of development, consistent with the observation 
that they had peripheral blood B cells, however reduced numbers of pre-BII large and 
immature cells (the last two stages of BCP development) were found in the patients.10 This 
suggests that in a group of CVID patients, a defect in the pre-BI to pre-BII checkpoint is the 
cause of disease. Additionally, a B-cell extrinsic defect, such as in the bone marrow stroma 
or cytokine milieu, might contribute to the disease. Another explanation could be a defect 
that is not B-cell unique, since some patients additionally have T cell abnormalities. The 
most recent study in bone marrow of CVID patients was performed by Lougaris et al.11 and 
confirmed that in one third of CVID patients, a problem arises in the bone marrow, however, 
this study did not show the underlying pathological mechanism. Additional studies in 
CVID studies have indicated that possibly, some patients have problems in DNA-repair.12 
This hypothesis can be further studied using a combined approach of flow cytometry 
and repertoire analysis. Based on these observations, we hypothesized that some CVID 
patients might have reduced efficiency of V(D)J-recombination causing reduced bone 
marrow output of naive B cells. This could be reflected in a reduced diversity of the naive 
repertoire. In chapter 2.2 we studied the naive repertoire of 18 CVID patients. We found 
no qualitative defect in the naive IGH repertoire of CVID patients, and the diversity was not 
reduced in 17 out of 18 patients. However, one of them had a profound reduced diversity 
which was stable over the years. This indicates that repertoire analysis can be a useful tool 
to identify CVID patient that might have a recombination problem. In our studies we so 
far did not study precursor B-cell development in CVID patients using flow cytometry. 
However, our new panel and understanding of BCP can be used to study the etiology of 
disease by linking specific phenotypical patterns that are seen in genetically defined cases 
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to specific pathways. In this way, we might be able to understand which pathways are 
affected in patients with CVID. Of course, while performing such studies, it is crucial to 
recognize and emphasize the heterogeneity within the disease that is called CVID. This 
means that studying the bone marrow is most useful in patients with early defects in 
B cell development and that it is likely that within a group of patients, different causal 
mechanisms can play a role. Moreover, in many patients the interplay between multiple 
mechanisms can cause variability in immune biology. Therefore it is crucial to integrate 
multiple analysis strategies for these types of studies, like flow cytometric phenotyping, 
repertoire analysis, RNAsequencing and analysis of epigenetic regulation in healthy 
controls, genetically defined PID cases and CVID patients. By this approach, we can better 
understand the pathways that lead to disease in CVID.
DISTURBED SIGNALING PATHWAYS CAUSING ANTIBODY DEFICIENCIES
In part 3 of this thesis deficiencies in the CD19 complex and specifically in CD21 have 
been described. In addition, dysregulation of the PI3K-AKT signaling by mutations in PI3K 
and PTEN was studied in part 4. All these pathways are interlinked in the B cell. Here, we 
discuss how disruption of CD19-complex signaling and PI3K signaling lead to antibody 
deficiency. Additionally we will discuss the current view of increased CD21lo B cells, since 
these cells are found in conditions of PI3K-signaling dysbalance.
The connection between B-cell receptor signaling, CD19-complex signaling and PI3K signaling
The goal of each BCP is to recombine and express a functional BR to be able to signal 
antigen once it enters the peripheral blood. The BR can forward a signal via multiple signaling 
cascades (Figure 2). Via tyrosine kinases LYN and SYK, Bruton`s Tyrosine Kinase (BTK) can be 
activated, which can in turn activate Phospholipase C Gamma 2 (PLCγ2) and thus induce 
Mitogen-Activated Protein Kinase (MAPK) and Nuclear Factor Kappa B (NF-κB).13, 14 These 
factors can both translocate to the nucleus to induce transcriptional changes that promote 
B cell survival and differentiation. Furthermore, BR-mediated signaling will enhance release 
of intracellular calcium, also referred to as calcium influx, via PLCγ. Additionally, Via SHP-2, 
a protein tyrosine phosphatase, and by LYN directly, PI3K-AKT signaling can be initiated. 
PI3K signaling again stimulates the increase of intracellular calcium and NFκB. BR-signaling 
upon antigen binding is enhanced by the CD19 complex, consisting of CD19, CD21, CD81 
and CD225. The intracellular domain of CD19 contains multiple tyrosine residues and 
hereby can activate PI3K signaling, enhancing the BR-initiated signaling cascade. This 
effect is rather strong, which is reflected by the observation that CD19 induced signaling 
could rescue BR-deficient naive B cells.15
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CD21 in the CD19 complex
Signaling via the CD19 complex is critically important for B cell development, 
differentiation and maturation.16 The complex functions as a co-stimulatory element to 
amplify antigenic signaling and it bridges innate and adaptive immunity by signaling 
complement17 via CD21, which is complement receptor 2. The complex does not only 
amplify the BR-signal but also prolongs the signal.18 CD19 has a cytoplasmic tail with 
multiple tyrosine kinase residues to induce for example PI3K signaling and CD81 is a 
tetraspanin, which is critically important for the expression of CD19 on the surface. 
Therefore it is no surprise that a deficiency in this complex results in PAD. In this thesis the 
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Linking BR, CD19 complex and PI3K signaling.
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second CD21 deficient patient is described in chapter 3.1. We found that CD21 deficiency 
results in hypogammaglobulinemia with a rather mild phenotype compared to CD19 
deficiency. Since CD19 deficiency and CD81 deficiency as a cause for PAD were described 
before by our group, we were able to compare the differences between the different 
disease modalities in more detail in chapter 3.2. These patients with specific defects in the 
CD19-complex are highly interesting since their disease phenotype can be used to study 
the function of the different proteins in human B cells. 
In our CD21 deficient patient (chapter 3.1), two compound heterozygous mutations 
resulted in complete absence of CD21 protein on the surface of B cells. In his parents, who 
both carried one of the mutations, CD21 expression was reduced by half compared to 
healthy controls. This decreased expression did not result in any clinical or immunobiological 
phenotype. Expression of CD19 was increased in the patient and to lesser extent in his 
parents. Although no CD21 transcripts could be detected at mRNA level, the increased 
plasma membrane expression of CD19 was not reflected at transcript level. The increased 
CD19 surface expression is also found in CD21lo cells in auto-immune diseases19, 20 and 
in Cd21/Cd35 deficient mice.21, 22 Vice versa, in CD19 deficient patients, CD21 surface 
expression is reduced, indicating that CD21 and CD19 expression are interlinked. This was 
previously suggested in mouse studies as well, where it was shown that even though CD21 
and CD19 are closely connected, CD19 function was dominant over CD21 function and 
regulates B cell signal transduction independent of CD21.23 Our data from both human 
CD21 deficiency and human CD19 deficiency indicate that not only function but also 
expression of the two proteins is connected albeit not at transcript level. 
In chapter 3.2 we further investigated the differences and similarities between 
patients with different deficiencies in the CD19 complex. In total 15 patients with PAD due 
to deficiencies in the CD19 complex have been described. All deficiencies were caused 
by either homozygous or compound heterozygous mutations and although all patients 
had an antibody deficiency, the clinical phenotype was different per deficient protein. 
Thus far, 10 patients with CD19 deficiency have been reported24-28 and 1 patient with CD81 
deficiency.29 These patients suffer from (severe) recurrent infections and all of them had 
hypogammaglobulinemia. Many of them additionally had low serum levels of IgA and/
or IgM and reduced responses to vaccination. The four patients with CD21 deficiency 
that have been described in literature, had a less severe phenotype. Although they all 
had hypogammaglobulinemia, the infections that were found in these patients were less 
severe and one of them did not have infectious complications at the time of analysis.30-32 
Calcium influx assays that were performed by us and others indicated that in CD21 
deficiency, B cells can be activated though the BR as long as the signal is strong enough, in 
contrast to CD19 deficient or CD81 deficient B cells that to not respond even to high doses 
of stimulation. Thiel et al. showed that in CD21 deficiency, calcium influx is only impaired 
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in a complement dependent manner.30 Thus, the hypogammaglobulinemia in CD19 and 
CD81 deficiency can at least partially, be explained by defective BR-signaling and therefore 
by an activation problem. In CD21 deficiency, the activation is intact and perhaps even 
compensated for by increased CD19 expression, but our results from in vitro stimulation 
experiments indicate that induction of activation induced deaminase (AID) is delayed. 
AID is a key factor for somatic hypermutation (SHM) and class switch recombination (CSR) 
in B cells. AID is activated, via PI3K-AKT signaling (Figure 2). It could be that because of 
the lack of CD21, the PI3K-AKT signaling pathway is less activated, resulting in a slower 
signal transduction and delayed AID induction. In CD19 and CD81 deficiency however, this 
signaling cascade is not induced at all, resulting in more pronounced absence of SHM and 
CSR.
Overall, CD19 and CD81 deficiency result in a more severe clinical phenotype than 
CD21 deficiency. This can be explained by the interaction of the different proteins and 
their different functions within the CD19-complex.
Activated PI3Kδ syndrome: APDS
Over the past years, multiple series of patients with gain-of-function mutations in PI3Kδ 
have been described.33-37 These patients suffer from Activated PI3Kδ syndrome (APDS) and 
share clinical characteristics such as recurrent respiratory tract infections, bronchiectasis, 
hepatosplenomegaly, generalized lymphadenopathy and antibody deficiency. Immune 
phenotypically an inversed CD4/CD8 ratio and increased transitional B-cells are 
commonly found. The first reports on this disease showed that hyperactivation of the 
PI3K-AKT signaling pathway in T cells resulted in constitutive activation of naive cells, fast 
differentiation into short-lived effector CD8+ T cells and reduced memory formation.33-35 
In chapter 4.1 of this thesis, we report a young girl with APDS, who presented with a 
mediastinal mass. She had recurrent respiratory tract infections, severe pulmonary damage 
and generalized lymphadenopathy with an enlarged spleen and liver. The mediastinal mass 
consisted of lymph adenal tissue with dysplastic germinal centers. She was treated with 
corticosteroids and became prednisone-dependent, which resulted in reduced growth 
in length. After discovery of APDS, a pathogenic mutation in PIK3CD (E525K) was found, 
confirming the diagnosis APDS. She started on rapamycin treatment and prednisone 
could be weaned. Upon follow-up the infectious load reduced dramatically, reducing the 
need for antibiotic treatment and she gained . This case illustrates the importance close 
collaboration between pulmonologists and immunologists. Furthermore, the clinical 
improvement in this girl shows that rapamycin can be a possible treatment for patients 
with APDS. 
APDS is not the only disease in which PI3K-signaling is dysregulated. PTEN (phosphate 
and tensin homologue deleted on chromosome 10) is the antagonist of PI3K (Figure 2). 
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Autosomal dominant germline mutations in PTEN are associated with PTEN deficiency 
resulting in three partly overlapping clinical syndromes which together are referred 
to as PTEN Hamartoma Tumor Syndromes (PHTS). Although in mice PTEN deficiency 
was linked to reduced AID induction and reduced CSR over a decade ago,38 in humans, 
this connection was not made until 2015 when we and other described PHTS patients 
with hypogammaglobulinemia.39, 40 These patients are described in chapter 4.2, where 
we identified three patients with heterozygous PTEN mutations who suffered from 
PTEN deficiency and hypogammaglobulinemia. Not all patients with PHTS develop 
hypogammaglobulinemia and thus, we performed study of the peripheral B-cell 
development of these three patients with hypogammaglobulinemia and of patients 
with PHTS without hypogammaglobulinemia. We demonstrated that patients with PTEN 
deficiency have CSR and SHM deficiency irrespective of hypogammaglobulinemia. This is 
most likely because of PI3K/AKT mediated inhibition of AID, which is present in all patients. 
However, other factors, like the encounter of micro-organisms or perhaps SNPs in other 
genes contributing to B cell development might be different between individual patients 
and thus explain why some develop hypogammaglobulinemia while others do not. This 
clinical heterogeneity is also seen in patients with APDS.
The hypogammaglobulinemia in APDS patients was originally thought to result from 
decreased CD4+ T cell help to B cells. However, the PI3K-AKT signaling pathway is critical 
for B cell development and maturation and therefore, in chapter 4.3 we focused on B cell 
differentiation in APDS patients. We identified 13 patients of whom 3 had new mutations 
in PIK3CD or PIK3R1. We studied the peripheral blood B cell compartment and BCP 
differentiation in BM. P110δ deficient mice show a normal BCP development41 since p85α 
was shown to be able to take over the role of p110δ role in autonomous pre-BR signaling.42 
However, in APDS patients over-active signaling because of constitutive activation of the 
PI3K-AKT pathway in BCP in bone marrow may cause disturbance at the pre-BR check-
point. This might lead to cells routing to alternative maturation pathways because of 
increased proliferation signals and increased tonic signaling at the pre-B I stage might 
cause increased apoptosis. Indeed we found an increase of CD34- TdT+ BCP in our patients, 
which we hypothesize to be the result of alternative maturation pathways. Also, we found 
reduced CD19 expression in a subset of BCP cells, which could reflect early apoptotic cells. 
The increase in transitional B cells in the peripheral blood that we found in APDS patients 
could indicate that cells do not easily pass the phase of antigenic stimulation, which 
might be due to an already hyperactive metabolic state of the cells. This is in line with 
our phospho-flow results, where we found increased constitutive phosphorylation of AKT, 
especially in the naive and natural effector B cells and to lesser extent in memory B cells. 
This increased activation may lead to cell death rather than differentiation, as indicated by 
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the increased apoptosis rate that we found upon in vitro culture and stimulation of APDS 
lymphocytes.
This constitutive activation and apoptosis were also found in the T cells of APDS 
patients by us and others. Continuous activation of T cells can induce senescence and/or 
exhaustion of CD8+ T cells. The increased CD57 expression that was previously described 
in a subgroup of APDS patients was associated with senescence of the CD8+ T cell 
compartment.34 However, the increased apoptosis rate and previous reports of increased 
expression of PD-1 could also indicate a role for exhaustion in causing reduced function 
of the CD8+ T cells in APDS. In chapter 4.4 we therefore investigated the expression of 
activation markers and inhibitory receptors as markers for exhaustion on total CD8+ T 
cells and virus-specific CD8+ T cells in patients with APDS. We compared them to healthy 
controls and patients with HIV, who served as a model for exhaustion. CD8+ T cells 
expressing all three inhibitory receptors (PD-1+ CD160+ CD244+), which would indicate 
the most exhausted state, were significantly increased in APDS patients and to a similar 
degree as in HIV-infected individuals. This increased inhibitory receptor expression was not 
correlated with gender, age, type of mutation, B cell phenotype or with other phenotypic 
markers on T cells that we have investigated. The frequency of PD-1+ CD160+ CD244+ T 
cells was negatively correlated with the amount of naive CD8+ T cells, we suggest that the 
hyper-activation leading to reduced naive T cells, may also be responsible for the increased 
expression of inhibitory receptors on T cells. Overall, the expression of inhibitory receptors 
on CD8+ T cells from APDS patients has more similarities with HIV+ patients, supporting 
the idea that the PI3Kδ GOF mutations may contribute to exhaustion. Blocking inhibitory 
receptors on exhausted CD8+ T cells can restore or improve their function in chronic viral 
infections.43, 44 Inhibitory receptor blockade was introduced into the clinic to re-activate 
exhausted T cells in cancer.45, 46 In our study, we showed that blocking PD-1 signalling can 
increase virus-specific CD8+ T cell proliferation and cytokine production of APDS EBV-
specific CD8+ T cells. However, upregulation of inhibitory receptors on activated T cells has 
a physiological function: they downregulate the immune response after successful control 
of infections47, 48 to prevent autoimmunity and pathological responses leading to tissue 
damage. In APDS, upregulation of inhibitory receptors could be a protective mechanism 
to prevent damage. This hypothesis is supported by a study which showed how PD-1 
signaling can prevent activation of PI3K and AKT phosphorylation, thereby preventing 
proliferation.49 The increase in proliferation and effector cytokine secretion in virus-specific 
CD8+ T cells from APDS patients that we found in vitro was already detectable after 5 
days, indicating that, short term treatment of patients with PD1/PD-L1 blockade might 
work. During a re-current EBV- and/or CMV infection, inhibitory receptor blockade could 
augment efficacy of exhausted virus-specific CD8+ T cells and thus reduce EBV- and CMV 
215
General discussion
5
related morbidity and mortality. However, because of the increased risk of autoimmunity 
and hyper activation, manipulating this pathway has to be done with caution.
Although mutations in PIK3δ and PTEN have only recently been found to cause PAD, 
somatic PI3K and PTEN mutations are found in a variety of solid tumors.50 The vast majority 
of the PI3K mutations arise in PIK3CA, the gene encoding p110α (the catalytic subunit of 
PI3Kα) and are found in carcinoma`s and in some B-cell lymphoma`s PIK3CD mutations 
are found. The most common “hotspots” of oncogenic PIK3CA mutations are H1047R and 
E542K/E545K, which respectively are located in the C-terminal kinase domain and the 
helical domain. Both these and other less common mutations (e.g. N345K and C420R) result 
in activation of PI3Kα through increased lipid binding and/or increased basal activation.51 
P110α and p110δ share ~72% sequence homology. Germline APDS-causing PIK3CD 
mutations are located in the same PI3K domains as somatic oncogenic PIK3CA mutations, 
and in some cases even corresponding amino acids are affected amino acid (Figure 3). 
They result in the same activation of the PI3K-AKT signaling pathway, albeit in different 
cell types. Heurtier et al. recently published two APDS-causing mutations in PIK3CD (E81K 
and G124D) that cause increased PI3K-AKT signaling and the clinical phenotype of APDS.37 
These same two mutations were later found in other patients by Takeda et al, confirming 
the findings of the earlier paper.52 Some of the oncogenic PIK3CA mutations are also found 
as mosaic mutations occurring during development or germline mutations,53 in which 
case they result in the megalencephaly-capillary malformation-polymicrogyria syndrome 
(MCAP).54 This syndrome can also be caused by mutations in PIK3R1 and PIK3R2, as was 
the case in one of our APDS2 patients (PI3KR-1) in chapter 4.3.36 In this boy, one PIK3R1 
mutation caused both APDS and MCAP which underlines the notion that gain-of-function 
mutations in PIK3CD, PIK3CA and PIK3R1 likely share the same activation mechanisms. 
These mechanisms probably are also affected in patients with germline PTEN-mutations, 
whom have been described by us (in chapter 4.2) and others to have PI3K-signaling 
mediated hypogammaglobulinemia next to their PTEN hamartoma tumor syndrome 
C-lobeN-lobeHelicalC2RBDABD
E1021K
 p110δ catalytic subunit
C-lobeN-lobeHelicalC2RBDABD
 p110α catalytic subunit
E542K/E545KN345K
E81K G124D E525K/E525A E1025GN334K C416R R929C
C429R H1047R
APDS1
mutations
oncogenic
mutations
Figure 3. 
Schematic representation of locations of mutations in PIK3CA and PIK3CD. Oncogenic mutations in PIK3CA map to 
the same domains and in some cases to corresponding amino-acids as APDS-causing PIK3CD mutations.
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(PHTS) phenotype.39, 55 Both patients with MCAP and PHTS have neurological abnormalities 
and in some cases they suffer from developmental delay.
Because of the extended knowledge on PI3K in the field of oncology, there are multiple 
possible options for treatment of APDS known; most of these drugs already existed before 
the disease was described (Figure 4). These strategies are now under investigation. We 
have suggested short-term treatment with PD1/PD-L1 blocking agents as a possible 
treatment option in chapter 4.4. Extended studies in vitro are needed to prove our results, 
before these can be applied in the clinics. These treatment strategies are already available 
in cancer treatment and we would recommend trialling them in APDS patients to control 
recurrent viral infections on a short-term basis. Another readily available treatment option 
for patients with APDS is rapamycin (also known as sirolimus). This drug has a long history 
as immune suppressive drug used to treat kidney transplant patients. Over the past years, 
it has been used in both adult and children`s clinics to treat patients hyperactivation of 
mTOR signaling, for example patients with tuberous sclerosis complex.56, 57 Rapamycin 
inhibits mTOR and thereby changes the metabolic state of cells, reducing proliferation. 
Since part of the APDS phenotype was attributed to increased mTOR activity, many APDS 
patients that were prednisone dependent have started to use rapamycin, like the patient 
we described in chapter 4.1 and some of the others described in chapter 4.3 and 4.4. 
The success of this treatment strategy can be evaluated in the next couple of years, when 
more patients have been treated over extended periods of time. Ideally, this should be 
done in trials where this treatment regime is tested against standard treatment to prove 
which treatment is best in which case. A third option, that is currently under investigation 
is treatment with specific PI3Kδ-inhibiting compounds. This was suggested already when 
APDS was discovered as an ideal form of personalized medicine.58 A specific PI3Kδ-inhibitor 
is expected to treat the disease at the level of the hyperactive protein and, because of 
specificity, have fewer side effects. In a recent study, 6 patients were treated with the 
specific PI3Kδ-inhibitor leniolisib.59 The patients in this study all had improvement of their 
clinical symptoms and laboratory parameters and the drug was well tolerated. This study is 
now extended to include more patients and treat them over a longer period to investigate 
long-term outcome. Another option for treatment of APDS could be hematopoietic stem 
cell transplantation (HSCT). One of the patients we described in chapter 4.3 has been 
transplanted years before we found the genetic defect leading to his disease. He was 
diagnosed with a combined immunodeficiency as a child and received a HSCT at a young 
age. He had a good engraftment and infections ceased. However, since APDS has a highly 
heterogeneous phenotype HSCT might not be the treatment of choice in all APDS patients 
given the risks and possible complications of HSCT.
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CD21lo B cells, what are they?
The CD21 protein has been of interest in the field of PAD for decades, because CD21lo 
cells have been suggested to play a role in a subgroup of patients with CVID that have 
increased CD21lo cells. To date, the role and function of these cells in physiology and 
disease etiology has not completely been elucidated, although many studies have been 
performed. In our patients with APDS, which were described in chapter 4.3, and in the 
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Figure 4. 
Possible compounds to treat APDS.
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patients with PTEN mutations described in chapter 4.2, we found increased CD21lo cells 
in a subgroup of patients (unpublished data, Figure 5). For years CD20lo B cells have been 
known to be increased in several auto-immune diseases like SLE20 but also in patients with 
CVID who suffer from auto-immune cytopenias.60 This was linked to the finding that CD21 
can function as a receptor for DNA,61 and thus, down regulation might lead to decreased 
sensitivity of the B cells and reduced auto-antibodies. Recently, patients with Down 
syndrome were shown to have a high frequency of these cells,62-64 but in these patients, 
this finding was linked to increased apoptosis in the lymphocyte compartment. 
Rakhmanov et al. studied CD21lo B cells in CVID patients and concluded that they to 
some extent in vitro resemble innate B cells, or B1 B cells that are found in mice.65 They 
hypothesized that in CVID patients, this subset is abnormally expanded. In HIV patients 
CD21lo B cells are expanded as well.66 This is thought to be a sign of B-cell exhaustion 
occurring during chronic infections. The “exhausted-like” phenotype of CD21lo B cells in 
chronic infection was additionally found in patients infected with hepatitis C,67 where the 
authors found that the CD21lo B cells were hypo proliferative but retained some antibody 
secreting capacity. This hypothesis is supported by the finding that CD21lo B cells in 
CVID express a variety of inhibitory receptors and do not proliferate in vitro in response 
to stimuli.65, 68 A study by Visentini et al, confirmed the reduced replicative potential of 
CD21lo B cells from CVID patients but furthermore showed that telomeres are shortened 
in the B and T cells of their study-cohort.69 This was explained as an increase in replicative 
senescence in the lymphocytes if these patients. However, telomere shortening can also 
be found in patients with HIV and PD-1 blockade increased telomerase activity in HIV 
specific CD8+ T cells,70 indicating that senescence and exhaustion are two mechanisms that 
are not necessarily mutually exclusive. In our study on CD8+ T cell exhaustion in patients 
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Figure 5. 
CD21lo B cells in healthy adults, APDS patients and PTEN patients. Both in the APDS patients and PTEN patients a 
subgroup of patients has increased CD21lo B cells.
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with APDS (chapter 4.4) we concluded that both senescence (as described previously) 
and exhaustion probably play a role in the decreased immune function in these patients. 
This would fit the notion that also the B cell compartment is affected in an exhaustion-like 
manner by PI3K-mutations, resulting in an increase in CD21lo cells. The decreased CD21 
expression was recently linked to high expression of SYK, which presumably results from 
chronic activation in inflammatory environments.71 The idea of this exhausted-B-cell-
hypothesis is, that B cells become less sensitive to stimulation, hence the threshold for 
activation in increased by downregulation of CD21. And this can be a possible mechanism 
to protect the cell (and the immune system) from hyper activation, thus reducing severe 
inflammation or auto-reactivity. In APDS patients, both the intrinsic hyper activation of B 
cells resulting from the mutations and the inflammatory milieu that is caused by recurrent 
infections might cause CD21 down-regulation on B cells. However, this has to be elucidated 
further in more extensive studies.
Many diseases that are associated with increased numbers of CD21lo B cells are also 
associated with dysregulation of PI3K-signaling. Perhaps extended studies of CD21lo B cells 
in patients with APDS or PTEN mutations can reveal a common mechanism for exhaustion 
within the B and T cell compartment, since we have shown that exhaustion is present in the 
CD8+ T cell compartment of APDS patients (chapter 4.4) and they have increased CD21lo 
B cells. Our studies in a CD21 deficient patient (chapter 3.1) showed that the loss of CD21 
per se does not lead to complete unresponsiveness, but rather to an increased threshold 
for activation. However, B cells from a CD21 deficient patient do not represent CD21lo cells 
that are found in other diseases, since the origin of the reduced or absent CD21 expression 
in different.
CAUSES FOR ANTIBODY DEFICIENCY; MONOGENETIC DEFECTS AND BEYOND
In this thesis we have investigated how specific defects disturb signaling and B cell 
differentiation ultimately resulting in an antibody deficiency. But for many patients, we still 
cannot explain why they suffer from antibody deficiencies. In search for disease etiology 
of PAD, many turn to genomics, searching for genetic defects that can explain the disease 
phenotype. And although over the years over 300 monogenetic causes for PID have been 
described,72, 73 in most antibody deficiencies no genetic defects can be found, even when 
the whole genome is sequenced. It is likely that in many PAD patients, disease etiology 
is complex including genetic, epigenetic, regulatory and environmental factors.74 The 
position of genetics and some of the other possible disease modifying mechanisms and 
contributing factors will be discussed here.
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Discovery of new genetic defects, Next-Generation Sequencing and targeted sequencing
The availability of next generation sequencing techniques has massively changed the 
field of genetic PID research in the past few years. Screening for genetic mutations by 
sequencing all coding regions (whole exome sequencing, WES) or even whole genomes 
(WGS) is done in PID patients in whom no clear candidate genes are likely to cause the 
immune deficiency. However, success rates depend highly on the a priori chance that a 
genetic defect is causing the disease. This chance increases in cases with familial history 
of PID or in patients that have a syndrome-like phenotype with multiple specific features 
other than infections due to an antibody deficiency. In some cases, the clinical and 
immunological phenotype clearly indicates a candidate gene. Then, it is faster and more 
effective to Sanger sequence the candidate gene. WES/WGS takes a couple of weeks to 
months, before the results are known. Children with severe immune deficiencies, who need 
treatment fast, cannot always wait for WES/WGS results. Therefore it is vital to combine 
genetic diagnostics with flow cytometric immunophenotyping in an early stage, so that 
severe deficiencies can be recognized fast (i.e within days). A point that should also be 
taken in to account is that with WES or WGS also regions will be sequenced that are not of 
interest for the question, but that can hold variants that predispose for neurodegenerative 
disease or increased risk for certain malignancies. It is therefore important to decide what 
to do with this information before the assay is run, and patients and their parents should 
be carefully counselled by a clinical geneticist before this type of diagnostic testing is done.
In searching for APDS patients (part 4 of this thesis), we have sequenced locations 
of known mutations in PIK3CD and PIK3R1 of a cohort of >100 patients with CVID or 
hyper IgM syndrome (HIGM). In this cohort, we found one APDS patient. When we 
sequenced PAD patients who were selected based on high transitional B cells combined 
with reduced memory B cells and increased CD8+ effector T cells, hepatosplenomegaly 
or lymphadenopathy and clinical symptoms (respiratory tract infections or EBV/CMV 
recurrence) most patients (4 out of 5 sequenced in one cohort) were found to have a 
PIK3CD or PIK3R1 mutation. This indicates that combining clinical phenotype with immune 
phenotyping and targeted sequencing can be a strong method to identify mutations in 
patients. However, this only works if you know what you are looking for.
In the research context, WGS and WES approaches are used to search for new gene 
defects in groups of patients with PID. For example CTLA4-deficiency, APDS and LRBA-
deficiency were discovered to a certain extent because of efforts to sequence cohorts of 
PID patients. As such, it has proven to be an effective tool in discovery of new mutations 
in new candidate genes. However, finding new mutations always requires carefully 
conducted functional testing to link the specific defect to the disease phenotype. And, not 
unimportantly, in the majority of PAD patients that were sequenced in these cohorts, no 
candidate variants were found. In a study by Maffucci et al, 50 (highly pre-selected) CVID 
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patients were subjected to WES.75 In 30% of them, a possible candidate gene was found, 
14% had a TACI variant that possibly was predisposing for CVID and in 56% no variant was 
found that could be linked to disease. Using this approach can also reveal new mutations 
in known genes that lead to a different clinical phenotype, a phenomenon that is referred 
to as phenotypic extension. Therefore, WGS and WES approaches can be useful to discover 
new disease causing genes in PAD if combined with functional testing of newly found 
variants.
Single gene errors: loss of immunity by gain-of-function
Immune deficiency is often related with loss-of-function of a certain immune-element, 
immune-cell or specific gene. New genetic defects in PI3Kδ and STAT3 have shown that 
not only deficiencies but also increased protein function can lead to disease. 
In chapter 4.3 we focused on the effect of gain-of-function PI3Kδ mutations (APDS) on 
the B cells. We found that besides a relative increase in the transitional B cells and reduced 
memory B cells, there is increased apoptosis of the lymphocytes and B cells specifically in 
vitro. It will be interesting to further investigate which mechanisms that induce apoptosis 
are affected by gain-of-function PI3Kδ mutations. Furthermore, in chapter 4.4 we examined 
the expression of inhibitory receptors on CD8+ T cells of APDS patients and controls as a 
measure for exhaustion of the CD8+ T cell compartment. We found that in APDS patients, 
a relatively large proportion of total CD8+ T cells express multiple inhibitory receptors at 
the same time, indicating that this compartment has features of exhaustion. Some of these 
inhibitory receptors signal via the PI3K-AKT signaling pathway, and down regulation could 
be induced via negative feedback to prevent overstimulation and premature cell death in 
the case of these patients. However, not all mutations in PI3Kδ lead to gain-of-function. Thus 
far, one patient has been described to suffer from immune deficiency due to homozygous 
mutations in PIK3R1, that caused a loss-of-function of the p85α regulatory subunit which 
is the abundant form in lymphocytes.76 This patient suffered from colitis and had no B cells 
in the peripheral blood. In bone marrow, a very early block in BCP with normal numbers 
of CD19- pro-B cells was found. After this stage, hardly any CD19+ cells could be detected. 
The patient’s T cells were unaffected. Analysis showed lowered levels of p110δ indicating 
that p85α is needed to stabilize p110δ. This patient did not have abnormalities in other 
organ systems; her disease phenotype was markedly different from APDS. Until now, no 
other patients have been described to have a loss of function of p110δ, which is expected 
to follow a recessive trait, and therefore will be rare. However, p110δ KO mice have been 
generated which showed normal BCP development in bone marrow, normal numbers of 
CD4+ and CD8+ T cells and a reduction of specifically B1 B cells and marginal zone splenic 
B cells.77 The mice had impaired antibody responses and reduced in vitro proliferation 
with increased spontaneous apoptosis. These results indicate that PI3Kδ LOF whether it is 
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through PIK3CD mutations or PIK3R1 mutations is likely to result in a B cell defect either in 
bone marrow or early in peripheral blood. (Figure 6)
Another example of a gene in which both gain-of-function and loss-of-function 
mutations are found in STAT3. In, loss of STAT3 function causes autosomal dominant 
Hyper-IgE syndrome (AD-HIES).78-80 Gain-of-function mutations in STAT3 cause severe 
multi-organ autoimmunity.81-83 These examples illustrate that immunodeficiency is more 
than simply loss of a protein and that in some cases, loss-of-balance because of gain-of-
function should be considered.
Polygenic causes and pathway analysis
In the search for monogenic causes for antibody deficiencies, mutations in TACI84, 85 have 
been described for years. However, some of the variants that were found can also be found 
in healthy relatives of patients.84, 85 This led to the idea that these mutations are disease 
contributing or predisposing factors but solely do not cause disease. It is likely to think that 
in a patients multiple less-favorable variants in the same pathway could eventually cause 
disease. This mechanism is called a polygenetic cause for disease. This disease causing 
mechanism has been postulated for CVID, which is the most common PAD and therefore 
often studied. Orange et al, performed genotyping with >600.000 single nucleotide 
polymorphisms (SNPs) in 360 CVID patients.86 This data was used to perform genome 
wide association analysis which revealed multiple novel susceptibility loci. The authors 
hypothesize that CVIDs are collections of diverse mechanisms leading to complex disease. 
This hypothesis was further underlined by a study performed by Van Schouwenburg et 
al, in which WGS was applied to a cohort of CVID patients. Additionally, they performed 
transcriptomic analysis by means of RNA-sequencing.12 Their results indicate that in some 
PI3Kδ gain-of-functionnormal function
balanced immuneresponse
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with absent B cells
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Figure 6. 
PI3K dysbalance.
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CVID cases, the origin of disease is perhaps polygenic. By bio-informatic analysis, several 
cellular pathways were found that can be linked to B cell differentiation and development 
and as such are likely candidate pathways to be affected by CVID.
One of the pathways that is potentially disrupted in antibody deficiencies is the PI3K-
AKT signaling pathway. As discussed extensively in part 4 of this thesis, this signaling 
cascade is crucial for both T and B cell development and function. Besides mutations in 
PIK3CD and PIK3R1 that are reported to cause the disease called APDS,87, 88 mutations in 
PTEN can also cause disturbed B cell maturation and hypogammaglobulinemia.39, 55 These 
are examples of monogenetic mutations that directly cause a disease phenotype. However, 
it is not unlikely that variants in different components of the pathway exist and that an 
unfavorable combination of variants can cause a comparable disease phenotype. There is 
one variant in PIK3CD that has been found in multiple patients with an APDS-like phenotype 
(unpublished data). It concerns a missense variant c.935C>G (NM_005026.3) resulting in 
an amino acid change p.S312C (NP_005017.3) in PIK3CD. This variant is also found in the 
general population with a minor allele frequency of ~2% (SNP reference: rs61755420)89 
and therefore it is unlikely that it causes disease by itself. However, phospho-flow analysis 
of AKT phosphorylation in a patient carrying this variant revealed that pAKT/AKT ratio is 
increased compared to healthy controls without this SNP (Figure 7)(unpublished data). 
Furthermore, this patient suffers from antibody deficiency and auto-immunity. We studied 
the effect on the CD8+ T cells of this variant together with patients with known disease 
causing mutations in chapter 4.4, and found that the CD8+ T-cell phenotype was alike 
the APDS patients with disease causing mutations and not alike controls. This variant is 
likely disease modifying, like TACI mutations in CVIDs. Extended analysis of patients and 
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pAKT/AKT ratio of a patient with the PI3Kδ S312C variant (PI3K-SNP, red dot) compared to a cohort of healthy 
controls (light grey bar), known APDS-patients (dark grey bar) and an age matched healthy control that was ran 
in the same experiment (day control, black dot).
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controls with this variant could shed light on the clinical relevance of this variant and 
other genetic and epigenetic variants that could together cause disease. Given that PI3K 
signaling is important in many phases of B cell development90-92 (Figure 8) and that PI3K-
PTEN balance is linked to AID-expression,93-96 it is likely that more variants in this pathway 
will be discovered that contribute to or partially cause antibody deficiencies.
Other signaling pathways in B cell differentiation and development can also be 
candidates for more extensive analysis to find new polygenetic, pathways defects, such as 
B cell receptor signaling itself, NFκB or CD19-complex signaling. It is not unlikely to think 
that suboptimal function of two or more kinases that are involved in these pathway might 
result in defective B cell survival or maturation. 
Epigenetics in the context of PAD
Genetic defects are mistakes in the DNA-sequence itself. Those can affect protein 
function directly or affect gene expression by mutations in promotor regions. Moreover, 
premature stop-codons can lead to nonsense mediated RNA-decay,97 heavily influencing 
gene expression. Gene expression can also be influenced by accessibility and structure of 
the DNA , and alterations could potentially also cause disease by altering gene expression. 
This is studied in the field of epigenetics. Epigenetics is the study of heritable traits that 
are not confined within the DNA sequence.98 Commonly, epigenetics refers to changes 
in DNA-structure that affect gene activity and expression, but also microRNA`s, a form of 
small non-coding RNA`s, can influence gene expression.98 These changes are heritable in 
the sense that daughter cells will have the same imprint, but some can also be heritable 
over organisms. Most studied in this field are DNA-methylation and post-translational 
histone-modifications, two mechanisms that together change the ability of nuclear factors 
to access the DNA. This either allows or blocks transcription and expression of genes and 
therefore epigenetics are crucial in immune cell development99-101 and thus could be of 
importance in PID pathogenesis.102, 103 
For the studies on BCP development that are described in this thesis we mainly made 
use of flow cytometry, repertoire analysis and to some extent in vitro stimulation assays. 
The panel for flow cytometry we developed and described in chapter 2.1 and our method 
for repertoire analysis described in chapter 2.2 could be extended with epigenetic studies 
to further elucidate the interplay between genetics, epigenetics and protein expression in 
the developing BCP cells in BM.
DNA methylation occurs at cytosines in CpG dinucleotides, which are known to play 
a regulatory role. CpG dense regions are referred to as CpG islands, which are found 
often in promotor and enhancer regions and are thus hotspots for functionally relevant 
DNA methylation changes.104 Early stages of B cell development have a specific DNA 
demethylation signature, as shown by Lee et al, who studied pre-B-stages in human bone 
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marrow and found demethylation events were often associated with transcription factors 
that are crucial for early B cell development such as EBF1 and PAX5.105 Also in the peripheral 
blood B cell compartment, distinct DNA-methylation profiles were found for naive and 
memory subsets and these correlated with stimulation induced profiles that were found.106 
Moreover, many epigenetic changes mapped to transcription factor binding sites and this 
corresponded with changes in the transcriptome between naive B cells versus stimulated 
B cells, memory B cells and plasma cells. This indicates that epigenetics play an important 
role in the differentiation and maturation of B cells. 
Previously, it was shown that the epigenetic profile of several leukemia types could 
refine patients stratification.107 Since the epigenetic marks reflect both cell intrinsic 
factors (e.g. genetic alterations)99 and cell extrinsic factors,108 DNA methylation profiles 
were used to indicate the cell-origin of for example chronic lymphocytic leukemia.109 
Although not often studied, recent studies by the group of Ballestar in Barcelona, have 
shown that epigenetic profiles are changed in B cells of CVID patients. In a study from 
2015 they compared monozygotic twins discordant for CVID and studied a cohort of CVID 
patients. They showed B-cell specific DNA methylation alterations in genes relevant to 
B-cell function such as, PIK3CD, TCF3, BCL21L1 and RPTOR in sorted B-cell subsets of CVID 
patients.110 However, as noted by them and others,103, 111 this field is still little studied in 
primary immune deficiencies and more studies that combine different high-throughput 
analysis methods are needed to elucidate the role of epigenetics in PAD disease etiology. 
When studying exhaustion of the CD8+ T cells compartment in APDS, our results 
indicated that not all patients showed the same degree of exhaustion and we hypothesized 
that probably having the mutation alone does not induce exhaustion (chapter 4.4). 
It was indicated in a study in mouse embryonic stem cells that PI3K can indeed alter 
epigenetic modifications. The authors showed that de novo DNA methyltransferases 
are downregulated due to PI3K-induced AKT, leading to reduced DNA methylation of 
imprinted loci.112 Demethylation of the PD-1 promotor region in exhausted CD8+ T cells 
allows sustained expression of PD-1. Therefore PI3Kδ GOF mutations could promote the 
demethylation of inhibitory receptors or reduce the threshold for such demethylation, 
thus facilitating the exhaustion in CD8+ T cells. In APDS but also in other forms of PAD, this 
is an interesting field to study disease etiology.
Another method that could be applied in the field of PAD is the Assay for Transposase-
Accessible Chromatin using sequencing (ATAC-seq),113 a technique that can measure 
genome-wide chromatin accessibility and thus define which regulatory elements in 
a given cell are active. In ATAC-seq, probes are used to label “open-chromatin” in such a 
way that these areas can be sequenced and mapped back to total genome. In this way, 
low cell numbers (between 10.000 and 50.00 cells) allow sequencing and bio-informatic 
reconstruction of a chromatin fingerprint of a given cell subset. In this way patients can be 
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compared with controls and subsets within one individual can be compared to each other 
(Figure 9). Rendeiro et al. recently showed the use of this technique in profiling primary 
chronic lymphocytic leukemia samples109 and associated the epigenetic landscape 
to gene regulatory networks. It will be interesting to apply these types of analysis with 
transcriptome analysis in B cell subsets from bone marrow and peripheral blood in both 
healthy individuals and patients with PAD do dissect disease contributing mechanisms 
that lead to defective B cell development and reduced production of antibodies.
B-cell extrinsic factors contributing to PAD
Besides an origin intrinsic to the B cell (be it genetic, polygenetic or epigenetic), 
factors in the external milieu of the developing B cell can also contribute to disturbed 
development of the B cells in antibody deficiencies. As discussed already before in this 
chapter, disturbances in the bone marrow niche or cytokine milieu are hypothesized to 
contribute to CVID development.10 In addition to this, Pott et al. recently raised the question 
whether autoantibodies against BAFF, APRIL or IL21, which are crucial for peripheral B cell 
development) could form an alternative pathogenesis for antibody-deficiencies.114 The 
presence of autoantibodies against cytokines has been recognized for decades, but they 
were usually regarded as an epiphenomenon rather than disease causing. However, more 
recent studies have shown presence of specific disease-causing autoantibodies in pure 
red cell aplasia.115 Additionally, anti-IL6 antibodies were found in a patient with recurrent 
staphylococcal infections116 and anti-IL17A, anti-IL17F and anti-IL22 antibodies were found 
in patients with chronic mucocutaneous candidiasis.117 This indicates that autoantibodies 
can be of specific interest in the field of immune deficiencies. Therefore, the authors 
screened for auto-antibodies against BAFF, APRIL and IL-21 in >200 PAD patients. They 
found presence of these antibodies was more abundant in their patient cohort than in 
peripheral blood
bone marrow
DNA isolation
lymphocytes closed chromatin
open chromatin
Tagmentation
Amplication
and
sequencing
Figure 9. 
Adapted from Rendeiro et al.109 ATAC sequencing. Lymphocytes, total B cells or B cells subsets are isolated from 
peripheral blood or bone marrow. DNA is isolated and the open chromatin is tagmented with Tn5 transposomes. 
After tagmentation, the open chromatin is selectively amplified and sequenced.
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controls. However, they could not show that functionally these autoantibodies inhibit the 
function of BAFF, APRIL or IL21, and thus, their role in disease formation remains uncertain. 
Another recent field of interest in the studies of immune dysregulation is the 
microbiome. The microbiota in the gut contributes to health and disease in the gut. But 
because of the interaction of the microbiota and the immune cells in the intestinal mucosa, 
the microbiome is essential for immune regulation and homeostasis.118 In HIV patients, is 
was shown that impaired immune function can lead to microbial translocation, causing a 
systemic immune activation.119 A similar mechanism has been proposed to play a role in 
the immune deregulatory component of CVID;120 because of impaired immune response, 
microbial translocation can take place and the immune system in turn over responds 
driving dysregulation and associated complications. The association between gut 
microbiome and CVID was reviewed recently by Berbers et al. 121 They conclude that there is 
evidence of increased microbial translocation in CVID patients with immune dysregulation 
complications, and that the composition of the microbiome is likely different in this group 
of patients, although up to now, few studies that specifically addressed these questions in 
antibody deficiencies have been conducted. Therefore, the microbiome may contribute to 
the disease phenotype in antibody deficiencies, but more research is needed to confirm 
the observations that were done previously.
Besides commensal bacteria in the gut, that influence the immune-system, another 
group of micro-organisms that has for years been recognized as immune-cell-influencing 
are the persistent viral infections of which EBV and CMV are two often studied examples. 
EBV is known to play a role in CD8+ T cell exhaustion122, 123 and can be driving factor in certain 
B-cell lymphoma`s.124 Several groups of PAD patients, especially if also T cell function is 
hamered, are known to have trouble to control EBV87, 125 and as such an EBV infection is an 
external factor influencing their risk for lymphoma development. Additionally, recurrent 
or chronic infections with EBV could lead to exhaustion-phenotypes in these patients, 
which in turn could further decrease their control of other infections. We studied this in our 
cohort of APDS patients in chapter 4.4. However, the number of EBV-positive patients was 
too low to draw firm conclusions and more extensive experiments are needed to resolve 
this question. CMV is considered one of the contributors to immunosenescence126 and a 
recent report showed that CMV-infection caused dysregulation in a CVID patient which 
eventually led to development of lymphoid interstitial pneumonia.127 On the other hand, a 
study by Kuntz et al. demonstrated that CVID patients have normally differentiated virus-
specific CD8+ T cells.128 In their study CMV infection however, was associated with advanced 
CD8+ T cell differentiation. Overall, their CVID patients had a more senescent phenotype 
than controls. But they could not conclude from their data that the virus-specific response 
was different in the patient group. They did state that preventive vaccination for persistent 
viral infection might be preferable in CVID patients since this might prevent virus-infection 
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related complications. Taken together, patients with immune deficiencies more often suffer 
from recurrent infections with persistent herpes viruses, and those in turn contribute to 
increased senescence and exhaustion and thus to decreased immune function. This makes 
them an extrinsic factor that plays a role in symptom pathogenesis.
CONCLUDING REMARKS
In this thesis we aimed to study antibody deficiencies and how specific defects disturb 
B cell development. Our studies of BCP differentiation in human bone marrow indicate that 
this is not a single linear route of differentiation, but rather a complex process that requires 
many mechanisms including V(D)J-recombination-driven checkpoints, divergence, parallel 
pathways and convergence to form a unique and functional B cell receptor. Our studies 
indicate that different phenotypes in different CD19-complex deficiencies are related to 
the function of the protein in the complex. PI3K signaling is a connecting element between 
the B cell receptor and CD19-complex signaling and vice versa misbalanced PI3K signaling 
can result in increased CD21lo cells. PI3K/PTEN imbalance additionally results in T cell and B 
cell intrinsic problems, reflected in defective humoral immune responses and an inability 
to control persistent viral infections. This knowledge is not only important for patients 
with antibody deficiencies, but also for our general understanding of B cell biology and 
therefore for other immunological diseases and processes such as malignancies, auto-
immunity, immune dysregulation and regeneration after stem cell transplantation. The 
future of PAD disease etiology research is connecting multiple–omics approaches to 
investigate differentiation pathways and signaling cascades and connect genetic and 
functional defects to immunophenotypical and clinical findings.
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ABBREVIATIONS
AD-HIES autosomal dominant Hyper-IgE-syndrome
AID activation induced deaminase
APDS activated PI3K delta syndrome
APRIL a proliferation inducing ligand
APS automated population separator
ATACseq assay for transposase-accessible chromatin using sequencing
ATM ataxia-telangiectasia mutated
BAFF B cell activating factor
BCP B cell precursor
BLNK B cell linker
BM bone marrow
BR B cell receptor
BTK Brutons tyrosine kinase
CCR C-C chemokine receptor
CDR complementary determining region
CMV cytomegalo virus
CR1/2 complement receptor 1/2
CSR class switch recombination
CVID common variable immune deficiency
cyTOF cytometry time-of-flight
DBS double strand breaks
DC dendritic cell
DNA-PKcs DNA dependent protein kinase catalytic subunit
DS Down syndrome
Ebf1 early B cell factor 1
EBV Epstein-Barr virus
FOXO Forkhead box subgroup O
FR framework region
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GC germinal center
GOF gain-of-function
GS Good syndrome
HD healthy donor
HIGM hyper IgM syndrome
HIV human immunodeficiency virus
HLA human leukocyte antigen
HR heterochromatin
ICOS inducible co-stimulator
IFITM1 interferon induced transmembrane protein 1
IFN-γ interferon gamma
Ig immunoglobulin, antibody
IgH immunoglobulin heavy chain
IgL immunoglobulin light chain
IL interleukin
IVIG intravenous Ig substitution
KO knock-out
LAD lymphocyte adhesion defect
LOF loss-of-function
MALT mucosa associated lymphoid tissue
MAPK mitogen-activated protein kinase
MCAP megalencephaly capillary malformation syndrome
MFI mean fluorescent intensity
mTOR mammalian target of rapamycin
N nucleotide non-templated nucleotide
NEMO nuclear factor-kappaB essential modulator
NFkB nuclear factor kappa-light-chain-enhancer of activated B cells
NGS next generation sequencing
NHEJ non-homologous end-joining
P nucleotides palindromic nucleotide
PAD primary antibody deficiency
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PASLI p110 delta activating mutation causing senescent T cells, 
lymphadenopathy, and immunodeficiency
PAX5 paired box protein 5
PC principle component
PCR polymerase chain reaction
PD-1 programmed cell death protein 1
PHTS PTEN hamartoma tumor syndrome
PI3K phosphatidyl inositol 3-kinase
PID primary immune deficiency
preBR pre-B cell receptor
PTEN phosphate and tensin homologue deleted on chromosome 10
RAG recombination activating genes
RSS recombination signal sequences
SCID severe combined immune deficiency
SCIG subcutaneous Ig substitution
SD standard deviation
SEM standard error or the mean
SHM somatic hypermutation
SLE systemic lupus erythematosous
SNP single nucleotide polymorfism
TACI transmembrane activator and CAML interactor
TdT terminal deoxynucleotidyl transferase
TLR toll like receptor
TNF tumor necrosis factor
TR T cell receptor
WES whole exome sequencing
WGS whole genome sequencing
XLA X linked agammaglobulinemia
XLF XRCC4 like factor
XRCC4 X-ray repair cross-complementing protein 4
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SUMMARY 
The human body is a collection of tissues and organs, which are all composed of cells 
and extracellular matrices that work together to form the total organism. Potential threats 
from both the outside, in form of foreign substances and infectious micro-organisms and 
from inside, like (pre-)malignant cells, are recognized and neutralized by a specialized 
and highly diverse organ system called the immune system. The immune system consists 
of lymphoid organs (e.g. bone marrow, lymph nodes, spleen) and the white blood cells: 
leukocytes. Leucocytes can be divided in the cells of the innate immune system and the 
cells of the adaptive system, the latter are called lymphocytes or T cells and B cells.
B cells arise in bone marrow were they differentiate from hematopoietic stem cells via 
multiple precursor stages into precursor B cells and mature B cells, that enter the peripheral 
blood. In the bone marrow, each individual B cells forms its own unique B cell receptor, via 
the process of V(D)J-recombination. 
To ensure the quality B cell receptors, B cells have to pass checkpoints during which 
their receptor is tested for expression and signaling. B cells that cannot pass the checkpoint 
will become apoptotic. The total pool of different B cell receptors forms the naive B 
cell repertoire. Because of the variety of possible antigens, a broad repertoire of B cell 
receptors is vital for proper humoral immunity. Upon antigen encounter, the naive mature 
B cells differentiate into memory B cells or plasma cells, which can produce antibodies. This 
process takes place in the secondary lymphoid organs, where the naive B cells undergo 
affinity maturation and proliferation with or without help from CD4+ T cells.
When B cells are unable to develop into functioning plasma cells due to an inborn 
defect too few antibodies can be formed, resulting in a primary antibody deficiency 
(PAD). Patients with a PAD suffer from recurrent infections, but additionally can have auto-
immunity, lymphoproliferation or malignancies. Some patients have a defect in the B cell 
precursor stages in the bone marrow due to a defect in an early transcription factor or in 
the pre B-cell receptor or its downstream signaling molecules. Other processes that can 
be disturbed in PAD are B cell survival, antigenic activation, class switch recombination, 
memory formation or even excretion of antibodies from plasma cells. In a part of PAD 
patients causative genetic defects have been described, but in other and the genetic cause 
or etiology are still unknown.
Studying the etiology and immune biology of PAD requires extensive knowledge on B 
cell development. Connecting B cell differentiation to disease causing genetic defects or 
specific clinical phenotypes of PAD leads to new insights into pathophysiology, prognosis 
and even provides new treatment options for patients. Moreover, knowledge that is 
obtained by studying these diseases teaches us about protein function, developmental 
checkpoints and signaling cascades in B cell development.
Addendum
246
The aim of this thesis was to study B cell differentiation in the context of antibody 
deficiencies and how specific deficiencies affect signaling cascades that are crucial for this 
normal development. We followed the line of B cell development, starting in the bone 
marrow until memory and plasma cell formation after antigenic stimulation. Part 1 outlines 
normal B cell development and recent findings regarding this development in the General 
Introduction. Additionally, different genetic defects that cause antibody deficiencies are 
discussed and placed in the context of B cell development. This underlines why it is crucial 
to study B cell development, together with studying antibody deficiencies.
Part 2 of this thesis focuses on developmental processes in bone marrow, studying the 
expression of phenotypic markers by flow cytometry in chapter 2.1. Together with the 
EuroFlow consortium we developed a new flow cytometry panel and a specific analysis 
strategy, that gives insight into how processes that guide B cell precursor development 
are linked to phenotypic expression patterns. Here we found that although the start and 
the end-point of BCP development are defined, the route to get to the end-point can 
be different for individual cells, with asynchronous marker expression while passing the 
checkpoints that are dictated by IgH and IgL rearrangements. In chapter 2.2 we studied 
the naive BR repertoire of controls and patients with common variable immunodeficiency 
(CVID) using Next Generation sequencing of the B cell receptor loci. We found that the 
naive BR repertoire of patients with CVID was comparable to healthy controls. Both the 
diversity of the repertoire and the junction characteristics of the CVID samples were in the 
same range as healthy controls, indicating that although the numbers of B cells might be 
low in CVID patients, the naive cells that are selected for the periphery have a normal BR 
repertoire. 
Naive B cells need to be activated by antigen, and this signal is amplified by the CD19 
complex (described in Part 3). In chapter 3.1 we discuss the function of the CD19 complex 
and described human patients with deficiencies in this complex that have been reported 
in literature. Chapter 3.2 is dedicated to a patient with CD21 deficiency that we described 
and compared to previously described CD19 deficiency. Here we found that depending 
on which protein is affected, the phenotype and disease severity are slightly different, and 
this is related to the function of the protein in the complex. 
A recent discovery in the PAD field are the dysregulations of the PI3K/PTEN-AKT 
signaling pathway. Part 4 focuses on disturbances in this pathway, starting with a case 
report of a young girl with a mediastinal mass who was finally diagnosed with Activated 
PI3Kδ syndrome (APDS) in chapter 4.1. This disease is characterized by recurrent 
infections, progressive airway damage, EBV and CMV viremia and lymphopenia due to 
dysregulation of the PI3K-AKT pathway in T cells and B cells. This report is an example 
of how finding a genetic diagnosis leads to personalized treatment, furthermore it 
underlines the importance of multidisciplinary diagnostics in complicated cases. Chapter 
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4.2 describes patients with heterozygous loss-of function mutations in PTEN, that leads to 
PTEN hamartoma tumor syndrome (PHTS). We found that a subset of these patients suffer 
from hypogammaglobulinemia and that this is partially due to the dysregulation of PI3K/
PTEN AKT signaling in the T and B lymphocytes. This dysregulation was also observed in 
patients who did not show overt hypogammaglobulinemia, but it indicates that immune 
deficiencies should be considered as possible clinical phenotype in patients with PHTS. 
We continued these studies in chapter 4.3, studying patients with APDS. We identified 
PI3KCD and PIKR1 mutations in patients of our PAD cohort and studied their peripheral B 
cell compartment. We found that the B cells of APDS patients display a specific phenotype 
with a high frequencies of transitional B cells and reduced memory B-cells despite relatively 
normal levels of somatic hypermutation. Furthermore, B cells from these patients were 
extremely sensitive to apoptosis, which probably contributes to the clinical phenotype. 
We performed more studies on APDS patients in chapter 4.4, where we found that CD8+ T 
cells of these patients, show an exhausted phenotype rather than a senescent phenotype. 
Additionally, blocking the PD-1 PD-L1 interaction could restore cytokine production and 
proliferation of EBV-specific CD8+ T cells in these patients, suggesting that drugs that 
interfere with this interaction might be useful to treat chronic viral infections in these 
patients. 
Finally in part 5 (chapter 5 General discussion), we highlight interesting findings of our 
studies and additionally shed light on how our findings can lead to better understanding 
of PAD and B cell differentiation. We discuss how PI3K signaling forms a link between the 
B cell receptor and CD19-complex signaling. Furthermore, recent ideas on CD21lo cells 
are discussed and related to CD19-complex deficiencies and APDS. Disease- causing 
mechanisms other than the classical loss-of-function mutations are summarized including 
gain-of-function mutations, polygenic causes and B cell extrinsic factors that contribute to 
disease. Furthermore we suggest new tools such as cyTOF, epigenetic studies and single 
cell analysis will further enhance knowledge on B cell biology and PAD.
And in the end, it is repertoire: the development of B cells via multiple pathways in bone 
marrow and the checkpoint that cells have to pass ensure a competent B cell repertoire, 
which we studied in more detail using NGS. Both in the CD21 deficient patients and in 
the PTEN and APDS patients, we studied the antigen experienced memory and plasma 
cell repertoire, since these mutations affect activation and maturation of the B cells after 
antigenic encounter and are specifically linked to activation of AID in the case of PI3K-PTEN 
dysregulation. Altogether, we studied how specific defects lead to disturbances in B cell 
development and repertoire formation and thereby cause antibody deficiencies.
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SAMENVATTING
Het menselijk lichaam is een verzameling weefsels en organen, die op hun beurt 
allemaal bestaan uit cellen en extra-cellulaire matrixen die samenwerken om het totale 
organisme te vormen. Mogelijke bedreigingen van zowel buitenaf, in de vorm van 
vreemde stoffen of infectieuze micro-organismen én van binnenuit, zoals (pre-) maligne 
cellen, worden herkend en geneutraliseerd door een gespecialiseerd orgaansysteem 
dat het immuunsysteem wordt genoemd. Het immuunsysteem bestaat uit de lymfoïde 
organen (zoals beenmerg, lymfklieren en de milt) en de witte bloedcellen: leukocyten. 
Leukocyten kunnen onderverdeeld worden in de cellen van het aangeboren systeem en 
de cellen van het adaptieve immuunsysteem. Deze laatsten worden lymfocyten genoemd, 
ofwel T cellen en B cellen. 
B cellen ontstaan in het beenmerg, waar ze differentiëren vanuit bloedvormende (ook 
wel hematopoietische) stamcellen. Via meerdere voorloper-stadia ontwikkelen ze zich tot 
voorloper-B cellen en later naïeve B cellen die naar het perifere bloed migreren. In het 
beenmerg vormt iedere individuele B cel zijn eigen, unieke B cel receptor via het V(D)
J-recombinatie proces.
Om een goede kwaliteit van de B cel receptoren te waarborgen moeten de voorloper 
B cellen een aantal checkpoints passeren. Hier wordt getest of de receptoren op de juiste 
wijze tot expressie kunnen worden gebracht op de celmembraan en of ze op de juiste 
manier kunnen signaleren. B cellen die niet slagen voor deze tests worden apoptotisch. De 
totale pool van verschillende B cel receptoren vormt het naïeve B cel repertoire. Een breed 
repertoire aan verschillende B cel receptoren is nodig om te zorgen dat ieder mogelijk 
antigeen herkend kan worden. Bij het signaleren van antigeen differentiëren de naïeve 
B cellen in geheugen B cellen of plasmacellen, die antistoffen kunnen produceren. Dit 
proces vindt plaats in de secundaire lymfoïde organen, waar de naïeve B cellen affiniteits-
maturatie en proliferatie ondergaan, met of zonder hulp van CD4+ T cellen.
Indien de B cellen niet in staat zijn om functionele plasma cellen te vormen door een 
aangeboren defect, kunnen te weinig antistoffen worden gevormd, wat resulteert in 
een primaire antistofdeficiëntie: PAD. Patiënten met PAD krijgen recidiverende infecties, 
maar zij kunnen ook lijden aan auto-immuniteit, lymfo-proliferatieve aandoeningen of 
maligniteiten. Sommige van deze patiënten hebben een blokkade in de voorloper B cellen 
in het beenmerg door een defect in een vroege transcriptiefactor, in de B cel receptor zelf 
of in de signaleringsmoleculen die nodig zijn voor B-cel signalering. Andere processen die 
verstoord kunnen zijn in patiënten met PAD zijn B-cel overleving, activatie door antigenen, 
klasse switch recombinatie, vorming van geheugen cellen of zelf het uitscheiden van de 
antistoffen door de plasma cellen. In een deel van de patiënten met PAD wordt de ziekte 
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veroorzaakt door genetische defecten, fouten in het DNA, maar in veel van hen is nog 
geen genetisch defect gevonden en is soms zelfs de etiologie van de ziekte onbekend.
Het bestuderen van de etiologie en de immuno-biologie van PAD vereist uitgebreide 
kennis over normale B cel ontwikkeling. Het verbinden van B cel differentiatie met 
ziekte-veroorzakende genetische defecten of specifieke klinische fenotypes geeft 
nieuwe inzichten in pathofysiologie, prognose en nieuwe behandelingsopties voor PAD 
patiënten. Verder kan het bestuderen van deze ziekten ons meer leren over eiwit-functie, 
ontwikkelings-checkpoints en signaleringscascades in B cel ontwikkeling.
Het doel van dit proefschrift was het bestuderen van B cel ontwikkeling in de context 
van antistof deficiënties en hoe specifieke defecten signaleringscascades beïnvloeden die 
nodig zijn voor normale ontwikkeling. Dit proefschrift volgt de lijn van B cel ontwikkeling, 
beginnend in het beenmerg tot aan de geheugen B cel en plasma cel formatie na antigene 
activatie.
Deel 1 belicht normale B cel ontwikkeling en recent onderzoek betreffende deze 
ontwikkeling in de Algemene introductie. Verder worden hier verscheidene genetische 
defecten besproken, die leiden tot antistof deficiënties. Deze defecten worden geplaatst 
in de context van de normale B cel ontwikkeling. Dit onderstreept hoe belangrijk het is om 
B cel ontwikkeling samen met antistof deficiënties te bestuderen.
Deel 2 focust op B cel ontwikkeling in het beenmerg, waarbij in hoofdstuk 2.1 
wordt beschreven hoe humane B cel ontwikkeling in het beenmerg met behulp van 
flowcytometrie kan worden onderzocht. In samenwerking met het EuroFlow Consortium 
hebben we een nieuw flowcytometrie panel ontwikkeld met een eigen analyse strategie. 
Samen geeft dit inzicht in hoe de sturende processen in B cel voorloper ontwikkeling 
samenhangen met fenotypische expressie patronen. Hier vonden we dat alhoewel het 
begin en eindpunt bekend zijn, de route tussen deze twee punten verschillend kan zijn 
voor iedere individuele cel, waarbij asynchrone expressie van markers kan bestaan terwijl 
de cellen de checkpoints passeren die worden gevormd door de status van zware- en 
lichte keten rearrangering. In hoofdstuk 2.2 hebben we het naïeve B cel receptor repertoire 
bestudeerd in gezonde controles en patiënten met Common Variable Immunodeficientie 
(CVID). Hiervoor hebben we Next Generation Sequencing technieken gebruikt om de B cel 
receptor loci te sequencen. We vonden dat het naïeve B cel receptor repertoire van onze 
patiënten groep vergelijkbaar was met dat van gezonde controles. Zowel de diversiteit 
als de junctie-karakteristieken van de CVID patiënten bevonden zich in dezelfde range als 
de gezonde controles. Dit indiceert dat hoewel de aantallen B cellen in het perifere bloed 
laag zijn in CVID patiënten, de cellen die geselecteerd worden in het beenmerg een min of 
meer normaal repertoire lijken te vormen.
Naïeve B cellen moeten worden geactiveerd door antigen, dit signaal wordt versterkt 
door het CD19-complex, beschreven in deel 3. In hoofdstuk 3.1 bespreken we de functie 
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van het CD19 complex en beschrijven we de humane patiënten met deficiënties in dit 
complex die tot nu toe in de literatuur beschreven zijn. Hoofdstuk 3.2 is gewijd aan een 
patiënt met CD21-deficiëntie die wij beschreven en vergeleken met de eerder beschreven 
CD19-deficiëntie. Hier vonden we dat afhankelijk van welk eiwit is aangedaan, het 
fenotype en de ernst van de ziekte enigszins kunnen verschillen en dat dit samenhangt 
met de functie van de verschillende eiwitten binnen het complex.
Een recente ontdekking in het PAD-veld vormen de ziekten die veroorzaakt worden 
door disregulatie van de PI3K/PTEN-AKT signaleringsroute. Deel 4 focust op verstoringen 
in deze signaleringsroute, te beginnen met een casusbeschrijving van een jong 
meisje met een massa in het mediastinum, die uiteindelijk werd gediagnosticeerd met 
Activated PI3Kδ Syndrome (APDS) in hoofdstuk 4.1. Deze ziekte wordt gekenmerkt door 
recidiverende infecties, progressieve schade aan de luchtwegen, EBV en CMV viraemie 
en lymfopenie veroorzaakt door disregulatie van de PI3K-AKT signalering in T cellen en B 
cellen. Deze casusbeschrijving is een voorbeeld van hoe het vinden van een genetische 
diagnose kan leiden tot gepersonaliseerde behandeling en daarnaast onderschrijft deze 
casus het belang van multidisciplinaire diagnostiek in gecompliceerde casus. Hoofdstuk 
4.2 beschrijft patiënten met heterozygote loss-of-function mutaties in PTEN, welke 
leiden tot PTEN hamartoma tumor syndroom (PHTS). Wij vonden dat een subgroep van 
deze patiënten lijdt aan een antistofdeficiëntie en dat dit deels veroorzaakt wordt door 
disregulatie in de PI3K/PTEN-AKT signalering in de T en B cellen van deze patiënten. Deze 
disregulatie werd ook gezien in patiënten zonder klinisch evidente antistofdeficiëntie, 
maar het impliceert dat immuundeficiënties mogelijk een onderdeel kunnen vormen van 
het klinisch fenotype van patiënten met PHTS. We zetten onze studies voort in hoofdstuk 
4.3, met het bestuderen van patiënten met APDS. We vonden mutaties in PIK3CD en PIK3R1 
in patiënten in ons PAD cohort en bestudeerden hun B cellen in het perifere bloed. We 
vonden dat de B cellen van patiënten met APDS een specifiek fenotype vertonen met een 
hoge frequentie van transitionele B cellen en verminderde geheugen B cellen, ondanks 
relatief normale frequenties van somatische hypermutaties. Verder waren de B cellen van 
deze patiënten extreem gevoelig voor apoptose, wat waarschijnlijk bijdraagt aan het 
klinisch fenotype van de patiënten. In hoofdstuk 4.4 hebben we nog meer studies gedaan 
bij APDS patiënten, hier vonden we dat CD8+ T cellen van deze patiënten een zogenaamd 
“exhausted” (uitgeput) fenotype vertonen, meer dan een “senescent” (slapend) fenotype. 
Verder vonden we dat het blokkeren van PD-1 PD-L1 interactie het cytokine producerend 
vermogen en prolifererend vermogen van EBV-specifieke T cellen kon herstellen in deze 
patiënten. Dit suggereert dat medicijnen die interfereren met deze PD-1 PD-L1 interactie 
mogelijk van nut kunnen zijn om virale infecties bij deze patiënten te bestrijden.
Tenslotte wordt in hoofdstuk 5, de algemene discussie, aandacht besteed aan de meest 
interessante bevindingen uit dit proefschrift en ook wordt hier beschreven hoe deze 
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bevindingen leiden tot nieuwe inzichten in PAD en B cel ontwikkeling. Er wordt beschreven 
hoe PI3K een verbinding vormt tussen de B cel receptor en het CD19-complex. Verder 
worden recente ideeën omtrent CD21lo cellen beschreven en deze worden gerelateerd 
aan CD19-complex deficiënties en APDS. Ziekte-veroorzakende mechanismen die anders 
zijn dan klassieke loss-of-function mutaties worden beschreven, zoals gain-of-function 
mutaties, polygenetische oorzaken en B-cel extrinsieke factoren die kunnen bijdragen 
aan het ontwikkelen van een antistof deficiëntie. Ook wordt dieper ingegaan op nieuwe 
mogelijkheden zoals cytometrie time-of-flight (cyTOF), epigenetische studies en analyse 
van individuele cellen om meer inzicht te krijgen in B cel biologie en PAD.
En uiteindelijk is het repertoire: het ontwikkeling van B cellen via meerdere routes in 
het beenmerg en de checkpoints die ze moeten passeren om te komen tot een competent 
B cel repertoire, wat we in detail bestudeerden met NGS. Zowel in de CD21 deficiënte 
patiënten als in de APDS en PTEN patiënten hebben we het antigeen-geselecteerde 
repertoire bestudeerd, omdat deze mutaties invloed hebben om activatie en maturatie 
van de B cellen na het herkennen van antigeen, met name in het geval van PI3K/PTEN 
disregulatie, wat is gelinkt aan de activatie van AID. Samengevat hebben we bestudeerd 
hoe specifieke defecten leiden tot verstoringen in B cel ontwikkeling en repertoire formatie, 
waardoor ze antistof deficiënties veroorzaken.
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DANKWOORD
De enige verstandige manier van opvoeden bestaat eruit een voorbeeld te zijn, desnoods 
een waarschuwend voorbeeld - Albert Einstein
Ik begin dit dankwoord met een citaat van Albert Einstein, want promoveren is voor 
een groot deel niet anders dan leren. Leren samenwerken, leren wetenschappelijk te 
denken, leren experimenteren en leren over het onderwerp van de promotie en heel veel 
daarnaast. Leren doen mensen door het volgen van voorbeelden en ik wil op deze plek 
mensen bedanken die in de jaren van mijn promotie en ervoor op een bepaalde manier 
een voorbeeld voor mij zijn geweest.
Mirjam, van jou heb ik ontegenzeggelijk veel geleerd. Van jou heb ik geleerd hoe ik 
een project aan kan pakken, nadenken, hypothese vormen, samenwerken, kortom: hoe je 
wetenschap bedrijft. Maar in de afgelopen jaren heb je me meer geleerd, ook op andere 
vlakken waardoor ik me optimaal kon ontplooien en ontdekken wat ik zelf interessant vind 
en waar ik naartoe wil. Bedankt voor je ondersteuning in dit proces. Ik voelde me altijd als 
wetenschapper én als mens bijzonder door je gewaardeerd en je zal in heel veel opzichten 
altijd een voorbeeld voor me blijven.
Beste Jacques, hartelijk dank dat je mijn promotor bent, ik heb veel geleerd binnen 
afdeling immunologie tijdens de research meetings en tijdens de EuroFlow meetings en 
diners, waar ik aan deel mocht nemen. 
Beste professor Hendriks, beste Rudi, bedankt dat je als secretaris in mijn commissie deel 
wilt nemen. Ik waardeer je aanvullingen tijdens B-cell meetings en andere besprekingen 
altijd ontzettend en je rustige en opbouwende manier van kritiek geven is voor mij een 
voorbeeld.
Beste Arjan, bedankt dat je plaats hebt genomen in mijn kleine commissie. In de 
afgelopen jaren hebben we meerdere keren samengewerkt aan projecten en ik vond de 
samenwerking altijd prettig door de combinatie van enthousiasme en kennis/kunde in het 
onderwerp. Voor mij ben je een voorbeeld van iemand die kliniek en wetenschap op een 
goede en vruchtbare manier combineert.
Dear dr. Shiobhan Burns, thank you very much for your willingness to join the thesis 
committee and for your efforts to judge the thesis manuscript.
Dear Peter, thank you for being part of my thesis committee. I have very much 
appreciated our collaboration on the exhaustion of CD8+ T cells in APDS patients. 
Additionally during my time as member of the PhD-committee we have discussed how the 
department can support the PhD-students by organizing lunches with speakers, how to 
organize journal club and set-up committee-meetings. Thank you for your support going 
back into the clinics, I have landed safely.
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Beste professor Taco Kuijpers, hartelijk dank dat u plaats wilt nemen in mijn 
promotiecommissie. 
Beste Martin, hartelijk dank voor het plaatsnemen in mijn promotiecommissie. 
Al een aantal jaren geleden bespraken we in Budapest dat de groep oudere patiënten 
met een immuundeficiëntie groeiende is, en dat meer expertise in het verouderend 
immuunsysteem waardevol zou kunnen zijn voor zowel de immunologie als de geriatrie. 
Hopelijk kan ik in de toekomst voor beide velden iets gaan betekenen.
Beste Gertjan, wat ontzettend leuk om jouw in mijn commissie te hebben. Hartelijk 
dank voor alle discussies en voor alle mooie APDS-verhalen waarvan jij aan de wieg hebt 
gestaan. Behalve je ontzettend sterke klinische-APDS-voorspellend vermogen ben je voor 
mij een voorbeeld van enthousiasme en motivatie. En door de start van het Down-project 
zullen we elkaar in de toekomst zeker nog spreken en verder kunnen discussiëren. Er zijn 
best veel overeenkomsten tussen kindergeneeskunde en geriatrie. 
Dear Marta, thank you for being part of my committee. I remember us sitting in the 
back seat of a car, crossing the beautiful country side around Prague and discussing 
going back to the clinics after years in the lab. You told me geriatrics was also one of your 
choices of specialization and that you thought I was making the right choice going back 
to the clinics. Thank you for your advice, both the scientific and work-related part and the 
personal advice.
Beste Ingrid, Barbara, Sandra, Erik, Hanna Kok, Hanna IJ, Pauline, Fabian, Christina en 
David, lieve PIDjes, ik kan hier niet alles opnoemen wat ik van jullie heb geleerd, maar 
zonder jullie zou ik geen flow kunnen, niet weten wat ik waar zou moeten vinden, geen 
repertoire data kunnen analyseren, en me geen raad weten als ik patiëntengegevens zou 
moeten achterhalen! Maar behalve dat zijn jullie een ontzettend fijne groep collega`s 
geweest de afgelopen jaren. Lieve Sandra, ontzettend bedankt dat je vandaag naast me 
wilt staan als paranimf. We gingen samen naar Salamanca om “Infinicyt te leren” en wat 
betreft het testen van flow-buizen en alle flow- en niet-flowproblemen kon ik altijd bij je 
terecht, wat dat betreft was je mijn flow-voorbeeld. Ingrid, ontzettend bedankt voor alle 
454-PCRs en andere PCRs die je aan de praat wist te krijgen. Ik vond ik het ontzettend 
gezellig om met je samen te mogen werken. Barbara, sorry voor alle onderbrekingen van 
je werk omdat ik even niet wist hoe ik verder moest en dan bij jou om advies ging vragen. 
Dankjewel voor de rust en het luisterend oor en voor alle lijstjes die je uit databases wist te 
halen en namen bij ID-nummers-uit-je-hoofd. Lieve Hanna en Pauline, bedankt voor alle 
tips en adviezen, niet alleen over sequence data, maar over promoveren in het algemeen. 
Ik vond het erg fijn om met jullie over werk en niet-werk te praten en over hoe het werkt in 
het leven als je 30-en-een-beetje bent.
Beste immu-OIO`s van de laatste jaren. Jullie zijn met te veel om allemaal apart te 
bedanken, maar ik ben blij dat ik deel heb kunnen uitmaken van de club waarmee we 
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gingen barbecueën, eten en op retraite gingen. Vooral die retraites heb ik ontzettend 
gewaardeerd, je kunt er leren van elkaar op een veilige en ongedwongen manier, waarbij 
voor mij de oudere PhD-studenten echt een voorbeeld waren toen ik begon. Liza, je was 
mijn PhD-commissie maatje na ons jaar bij de FC en ik vond het ontzettend leuk om beide 
met jou te doen, we hebben er een ontzettend gezellig retraite van gemaakt, dankjewel.
Lieve roomies van kamer Na-1222k: binnenkort gaat hij op in de kantoortuin, maar ik 
begon met Diana en Anna samen op de kamer. Waarvoor later Martine en Anne kwamen, 
en inmiddels zit Jorn er ook. Bedankt voor alle discussies, nuttig en niet-nuttig, voor de 
orchidee, voor de koffie, voor de gezelligheid, voor de (para-)normale verdeling, voor alle 
grapjes voor ingewijden, voor de Heisse Hugo en de motorverhalen. Het was heerlijk!
Lieve FCCF, lieve Sascha, Christina, Liza en Kim, wat een geweldig FC-jaar hebben wij 
gehad. Het heeft waarschijnlijk heel veel foto`s opgeleverd die rondom mijn promotie 
opnieuw gebruikt zullen worden, maar ach, dat is dan maar zo. Elke maand hebben we 
iets georganiseerd, schaatsen met erwtensoep, borrels, karaoke, eieren zoeken en een 
super leuke labdag in de Beekse Bergen. Tijdens de events, maar ook zeker ervoor in de 
voorbereidingen heb ik genoten van jullie enthousiasme en ontzettend veel plezier gehad. 
En dat was precies waar het om draaide: Girls just wanna have fun!
Beste dames van het secretariaat, waar zou ik zijn zonder jullie? Een heleboel pakketjes 
zouden niet zijn aangekomen, mijn boekje zou niet zo mooi gelay-out zijn als het nu is en 
handtekeningen niet gezet. Bibi, Danielle, Sascha en Erna, dankjulliewel.
Beste Arko, Margot en Eveline, in mijn tijd bij de immunologie heb ik jullie master-
onderzoek mogen begeleiden. Behalve dat ik het heel leuk vond om te doen en het 
de bedoeling was dat jullie iets leerden (wat geloof ik wel gelukt is) heb ik er zelf ook 
ongelooflijk veel van geleerd, niet alleen van hoe het werkt om iemand te begeleiden, 
maar ook van jullie zelf, bedankt daarvoor.
Dear Lucia, you were my Spanish counterpart. Thank you for all the fun we had during 
your stays in Rotterdam, during the EuroFlow meetings and thank you for being my 
personal guide in Madrid. Hope to see you soon again.
Dear Tomas, Ondra and the rest of the CLIP-lab in Prague. Thanks for all the weeks that 
I got to spend fussing with the reindeer, the cyTOF protocol and setting-up experiments 
to barcode samples and analyze bone marrow samples. You guys are my example of how 
approaching a problem from a different way can also solve the issue. Thank you so much 
for everything I have learned from you, I hope to visit again someday. Děkuji!
Dear Martin, Quentin and the rest of the Salamanca lab. Thank you for teaching me how 
to work with Infinicyt and helping me set-up analysis strategies for bone marrow. I am still 
learning and the strategies are still evolving, but I think this will be an ongoing process. I 
have really enjoyed the week I have spent with you in Salamanca, gracias!
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Lieve Studiegroep 8, lieve Sigrid, Nina, Bram, Jeff, Adinda, Jihan, Joris, Sophie, Koen 
en Shukri. Inmiddels zijn we de collegebanken ontgroeit en werken we verder aan onze 
medische carrières. We hebben al een hele rits promoties mogen vieren met z`n allen, 
maar wat ben ik blij dat we dat nog steeds mogen vieren. Lieve Nina en Sigrid, behalve 
studiegroep genootjes zijn jullie echt mijn vriendinnen geworden. Ik ben super blij om 
twee zulke stoere, onafhankelijke, lieve en oprechte vrouwen tot mijn vriendinnen te 
mogen rekenen. 
Lieve Kelly, Anuradha en Atija oftwel Kel, An en Tik, jullie zijn al jaren mijn vriendinnen 
en ik ben dankbaar voor alle jaren vriendschap die we inmiddels hebben. An, technisch 
gezien ken ik jou van dit groepje het kortst, maar inmiddels al meer dan mijn halve leven! 
Dankjewel voor alle gezelligheid en vriendschap over alle jaren. Kel, dankjewel voor 
je nuchtere kijk op dingen, je steun, voor de etentjes, de logeerpartijen, de sauna`s, je 
bezoekje aan mij in Praag, dankjewel voor je vriendschap. 
Lieve Tik, mijn oudste vriendinnetje, mijn getuige en nu mijn paranimf. Je bent er 
altijd, al 25 jaar. Dankjewel voor alle steun, liefde, gezelligheid, voor het luisterend oor, ook 
zonder woorden, je weet het… dankjewel voor alles.
Lieve “de V + aanhang”, lieve actiegroep, in alfabetische volgorde, lieve A&B, Des, Fleur, 
Fons, Fre, Jaap, Jap, Jasper, JK, Kaar, Liek, Naat, Peet, Rein, Steef, Strid, Taco en Tijn, wat 
heerlijk dat in dit rijtje geen enkele volledige naam staat! Dankjewel voor jullie interesse in 
iets wat jullie helemaal niet begrepen, maar omdat ik het deed waren jullie geïnteresseerd, 
en dat is werkelijk geweldige support.
Lieve Rien en Olga, hartelijk dank voor alle liefdevolle steun. Jullie staan altijd klaar om 
ons te helpen om op te passen of op een andere manier, en dat waardeer ik enorm.
Lieve Lex, je bent mijn kleine grote broertje en ook al vrees ik dat we zo veel verschillen 
dat we nooit een nier aan elkaar kunnen doneren, ik kan altijd op je rekenen in geval van 
nood, dankjewel.
Lieve papa en mama, jullie hebben me altijd gestimuleerd om mezelf te ontwikkelen. 
Bij nacht en ontij staan jullie klaar, ontelbare keren hebben jullie me ergens gebracht 
of opgehaald, bijvoorbeeld toen ik zo nodig gekke diensten moest werken in het 
Havenziekenhuis terwijl ik nog geen rijbewijs had. Jullie verzetten afspraken om ons te 
helpen met de opvang van de kinderen en zo zijn er ontelbaar veel dingen. Jullie hebben 
het echt voor mij mogelijk gemaakt om dit proefschrift af te maken en te verdedigen en 
jullie inzet voor mij motiveert me enorm om mijn best te doen. Mam, je bent mijn grootste 
voorbeeld.
Lieve Lars en Ise, jullie zijn mijn grootste experiment in het leven. Wat wonderbaarlijk 
om jullie te mogen zien opgroeien. Ik leer elke dag van jullie, dankjulliewel.
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Lieve Dave, de laatste woorden zijn voor jou. Dankzij jou lukt het allemaal. Je bent mijn 
stabiele basis, mijn rots, mijn rustpunt, mijn fundament. Dankjewel voor de liefde, met jou 
kan ik de wereld aan.
- Bij twijfel: doe het allebei - D.A. de Man
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CURRICULUM VITAE
Marjolein Wentink was born in Puttershoek on the 30th of March 1987. In 2005 she 
graduated from St. Monfort College Rotterdam, after completing VWO-gymnasium, 
profile: “Natuur en gezondheid” (science and health). She studied medicine at Erasmus MC, 
Rotterdam and in parallel did a research master Molecular Medicine at the same institute. 
In 2009 she obtained her doctoraal diploma in Medicine after completing an internship 
entitled: Expression of Splice-Variants of the Testis-Specific Protein of the Y-Chromosome in 
Carcinoma in Situ of the Testis Compared to Normal Testis in the lab of prof. L. Looijenga, 
Experimental Pathology, Erasmus MC. Subsequently she studied Tuberous sclerosis 
complex under supervision of dr. M. Nellist and dr. J.A. Kievit at the department of Clinical 
genetics, Erasmus MC, Roterdam. She defended her master thesis “Functional analysis 
of TSC2 variants associated with Tuberous sclerosis complex” in 2010 to obtain her master 
degree in Molecular Medicine. From 2011 until 2013 she completed medical internships in 
different hospitals to finish her MD degree, which she obtained in April 2013. In April 2013 
she started her PhD-project entitled: “Immune repertoire in the picture” under supervision 
of dr. M. van der Burg and Prof. dr. J.J.M. van Dongen at the department of Immunology, 
Erasmus MC, Rotterdam. After completion of her PhD project she resumed clinical work as 
an MD and she is currently working at the Amphia Hospital in Breda as a resident in Clinical 
Geriatrics.
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PHD PORTFOLIO
Name PhD student: Marjolein Wentink
Erasmus MC department: Immunology
Research school: Molecular Medicine
PhD-period:  April 2013-October 2017
Promotor: Prof. dr. J.J.M. van Dongen
Co-promotor: Dr. M. van der Burg
PhD training
Courses
2013 NGS data analysis, MGC, University Medical Center Utrecht
2014 Advanced Immunology Course, MolMed, Erasmus MC
2016 Biomedical English writing, Erasmus MC
2016 Course on R, MolMed, Erasmus MC
Workshops
2014 MS Excel Basic and MS Excel Advanced , MolMed
2014 Photoshop and Illustrator workshop, MolMed
2014 Research integrity, Erasmus MC
Traject deel-BKO, Desiderius School, Erasmus MC (finished)
2016 Teach the teacher I
2014 workshop “individuele begeleiding”
2017 workshop “feedback geven”
Seminars and symposia
2013-2017 seminars and mini-symposia at the department of Immunology
2013-2017 weekly journal club at the department of Immunology
2013 EuroFlow PID juniors, visit to CLIP, Prague, Czech republic
2014 EuroFlow Infinicyt Workshop, Salamanca, Spain
2016 Symposium Medical Immunology, De Doelen, Rotterdam
2017 ESID juniors Spring School, Sv. Jan Pod Skalou, Czech Republic
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National conferences
2013 Dutch Society for Immunology (NVVI) annual meeting
Poster: CD21 deficiency and CD19 deficiency: two defects in the same complex   
 lead to different disease modalities
2013 Werkgroep Immuundeficienties (WID)
 Oral presentation: CD21 deficientie
2014 Dutch Society for Immunology (NVVI) annual meeting
Poster: CD21 deficiency and CD19 deficiency: two defects in the same complex 
lead to different disease modalities
2015 Molecular Medicine Day, Rotterdam
Oral presentation: CD21 deficiency and CD19 deficiency: two defects in the same 
complex lead to different disease modalities
2015 Dutch Society for Immunology (NVVI) annual meeting
Poster: Genetic defects in PI3Kδ affect B-cell differentiation and maturation via 
multiple AKT-dependent pathways
2016 Molecular Medicine Day, Rotterdam
Poster: Genetic defects in PI3Kδ affect B-cell differentiation and maturation via 
multiple AKT-dependent pathways
2017 Werkgroep Immuundeficienties (WID)
 Oral presentation: Immunological aspects of APDS
International conferences
2015 European Congress of immunology, Vienna, Austria
Oral presentation: CD21 deficiency and CD19 deficiency: two defects in the same 
complex lead to different disease modalities
2015 IPIC conference, Budapest, Hungary
2016 Keystone, Systems Immunology, Big Sky, Montana, United Stated
Poster: Genetic defects in PI3Kδ affect B-cell differentiation and maturation via 
multiple AKT-dependent pathways
2016 European Society for Immune Deficiencies (ESID) Biennial Meeting, Barcelona,  
 Spain
Poster: Using geneticaly defined PID cases to unravel normal precursor B-cell dif-
ferentiation in bone marrow
EuroFlow PID meetings
2013 Rotterdam, The Netherlands, oral presentation: Precursor B-cell labelings, 
EuroFlow
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2014 Milan, Italy, oral presentation: 10-12 color flow cytometry for Precursor B cells in 
Bone Marrow
2015 Madrid, oral presentation: Precursor B-cell labelings BM EuroFlow PID 
Workpackage
2015 Zurich, Swiss, oral presentation: Using genetically defined PID cases to unravel 
normal precursor B-cell differentiation in bone marrow
2016 Rome, Italy, oral presentation: PI3K project introduction and hypothesis
2016 Leiden, The Netherlands no presentation
2016 Prague, Czech Republic, oral presentation Using genetically defined PID cases 
to unravel normal precursor B-cell differentiation in bone marrow
2017 The Hague, The Netherlands, oral presentation: Flowcytometric immunophe-
notyping of normal bone marrow and PID cases, the EuroFlow approach
Memberships
2013-2017 Junior member of the European Society for Immunodeficiencies
2013-17 Member of the Dutch Society of Immunology
Teaching activities
2013-2017 Histology practicals, 1st and 2nd year medical students, and Clinical Technology
2015+2016 Keuze onderwijs Primaire immuundeficienties, 2nd year medical students, 
 Lecture: PI3K signalering defecten 
 Lecture: B cell development
2017 Keuze onderwijs Primaire immuundeficienties, 2nd year medical students,
 Practical: PID cases
2016+2017 Minor Biomedical research in practise
 Lecture: PI3K signaling defects
2017 Summer course Master Infection and Immunity, 
 Lecture: CVID and APDS
2014-2016 supervision of 2nd year medical students for systematic review writing
2014 supervision 2 week lab-rotation minor students
2014 supervision internship master Life Science and Technology Arko Boogert
 Title: Activity of AKT in CVID
2015 supervision internship master Molecular Medicine, Margot Bongenaar
 Title: Dysregulation of Phosphoinositide 3-kinase/AKT signaling in common 
variable immune deficiency
2016 supervision internship master Medicine, Eveline de Leeuw
 Title: BACH2 overexpression could lead to disharmonic B-cell development
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Funds
2015 European Federation of Immunological Societies, ECI travel grant to attend 
European Conference of Immunology
2015 Dutch Society for Immunology (NVVI) travel grant, to support 1 week 
working visit to University of Salamanca, Spain (project: B cell precursor 
development)
2016 Erasmus Trustfonds travel grant to attend Keystone symposium: Systems 
Immunology
2017 European Federation of Immunological Societies, short-term fellowship 
to support 8 weeks to visit lab of dr. Tomas Kalina, Prague Czech Republic 
(project: cyTOF to study B cell differentiation in bone marrow)
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